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1. INTRODUCTION 
GAS, commonly known as Group A Streptococcus (GAS), is a bacterial pathogen that 
infects the throat and skin and is able to cause a wide range of diseases in humans [1]. This 
ranges from pharyngitis (strep throat) and impetigo to more serious and fatal diseases such 
as acute post streptococcal glomerulonephritis, rheumatic heart disease and invasive 
diseases. Acute rheumatic fever (RF) is an autoimmune sequela of GAS infection which 
occurs in approximately 0.3- 3% of GAS infected patients aged between 5 and 15 years of 
all streptococcal sore throats [2]. GAS is a major global pathogen with a variety of clinical 
manifestations. Over 7 million visit pediatricians each year in the United States alone for 
complaints of “sore throat” and almost a fourth of these visits are due to streptococcal 
pharyngitis [3]. Acute rheumatic fever and rheumatic heart disease, which are well 
recognized non-suppurative sequelae of infection by this organism, have devastating public 
health implications worldwide. An apparent resurgence of acute rheumatic fever in the mid 
1980s  in the US [4, 5] with ongoing new cases [6] and estimated 10,000 cases of invasive 
streptococcal disease reported annually in the US [7] confirm that an improved standard of 
living and use of antibiotic have not adequately reduced  the impact of GAS infections. 
Thus, there is need for a safe, efficacious and cost effective vaccine against GAS infection. 
 Chronic rheumatic heart disease (RHD) affects mainly the valves of the heart, which 
become highly deteriorated and surgical valve replacement is warranted [8-11] . The global 
burden of GAS has a prevalence of 1.78 million new cases of severe GAS disease each year 
[12] . Rheumatic heart disease has a prevalence of 15.6 million cases, with 2, 82,000 new 
cases and 2, 33,000 death each year [12] . The incidence is more common in developing 
countries [13] [14, 15]. Shresha and Padmavathi in 1979 found a very high prevalence of 
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rheumatic fever and rheumatic heart disease, which is 11/1000 among 40,000 school 
children in Delhi [16] . The long term surveillance study by Grace Koshi (1975-78) among 
the school children in South India indicated the high prevalence of RF/RHD as 4.9/1000 
[17] . GAS infection of the pharynx is usually the precipitating cause of rheumatic fever and 
pyoderma is usually the precipitating cause for acute glomerulonephritis (AGN) [18]. In 
India the prevalence of RF/RHD ranges from 0.3 to 5.4 per 1000 children [19] [20, 21]. Oral 
penicillin V has been used for many years for treatment of RF without change in 
susceptibility [22-24]. In case of penicillin allergy, erythromycin is the drug of choice. The 
major challenge for prevention of RF is the development of an effective vaccine [23]. 
M protein is the major virulence factor of GAS [25].Streptococcal surface proteins exhibit a 
high degree of antigenic diversity [26, 27]. Analysis of the clonal relationship between 
clinical isolates from patients by various typing methods is a practical approach to elucidate 
the epidemiology of the disease [28]. Various methods of phenotyping and genotyping have 
been described for GAS. Among these methods, M serotyping has been considered the “gold 
standard” for their characterization [29] [30]. However application of M serotyping is 
restricted due to lack of a comprehensive set of antisera in most laboratories and the high 
proportion of non-typeable isolates. The M serotyping has been replaced by sequencing of 
the 5
' 
coding region of the emm gene [31] [32]. This method has been used worldwide as an 
epidemiological tool to characterize GAS isolates [33]. Currently there are more than 170 
emm types and 750 emm subtypes known. Though emm types are good predictors of clonal 
types within a geographical location, there is considerable genetic diversity within certain 
emm types. Vir-typing and pulse field gel electrophoresis (PFGE) are the other two powerful 
sub-typing methods for epidemiologic investigation of GAS [30].  
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DNA-based typing methods are increasingly important for characterization of bacteria, it 
enables the monitoring of the occurrence, differences and similarities between different 
groups of bacteria [34]. Data provided from such analyses improves our understanding of 
bacterial species, genera and populations and provides information for epidemiological and 
public health interventions [35, 36]. 
In recent times, epidemiological studies on GAS infection have been carried out using gene 
sequencing methods. Nucleotide sequence-based methods of GAS allow rapid and global 
comparison between results from different laboratories. The recent development of multi 
locus sequence typing (MLST) schemes has provided a new approach to molecular 
epidemiology that can identify and track the global spread of virulent or antibiotic resistant 
isolates of bacterial pathogens using the internet [37] [38]. The slow accumulation of 
variation within housekeeping loci provides framework for long term global studies and 
reveals information concerning evolutionary relationships [37]. The relatedness among 
isolates of a bacterial population or species is generally represented as a dendrogram. 
Similar genotypes generating clusters in the dendrogram displays the evolutionary events 
very poorly. There are many online softwares for constructing phylogenetic trees but they 
are inappropriate for exploring the evolutionary relationship among same bacterial species 
where recombination is frequent [39]. The eBurst algorithm clearly explains and focuses on 
closely related isolates within a bacterial population [40, 41], which share recent ancestor 
(clonal complex) [42]. The demonstration of a random association between the alleles at 
different loci within a bacterial population (linkage equilibrium) strongly suggests a high 
rate of recombination within the population and departures from linkage equilibrium i.e. 
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significant levels of linkage disequilibrium [43] [44]between the alleles at different loci are 
often taken to imply a low rate of recombination. 
A thorough documentation of existing GAS clones will lay the ground for gaining a better 
understanding of the epidemiological trends underlying GAS disease and aid in deciphering 
the molecular basis for biological diversity within this species [45].Epidemiological data 
from developing countries for GAS disease is very limited [12] especially from India ,so a 
thorough documentation of GAS epidemiology based on emm typing and multi locus 
sequence typing will allow one to the monitor the occurrence, differences and similarities 
between different emm types of GAS which will aid in designing vaccines and understand 
the population genetic structure of GAS. 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 
 
Hypothesis 
Infections due to GAS and their sequelae continue to be an endemic problem in India. 
Earlier studies from our Laboratory have shown extreme heterogeneity among GAS 
isolates circulating in our community. This is supported by our preliminary observation 
that 33 emm types were identified among 100 strains isolated from school children 
during a rural school survey (community strains).  
Based on this, we hypothesize that large scale mutation, genetic recombination and 
natural selection among the vast pool of GAS circulating in the community is 
responsible for the high heterogeneity. We also hypothesize that allelic variations among 
certain housekeeping genes of GAS causing infections are responsible for the extreme 
heterogeneity. To prove this, we plan to use multi locus sequence typing on 
representative emm types identified among rural school children and compare their 
phylogeny with phylogeny based on emm types.  
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2. AIMS AND OBJECTIVES 
 
2.1. Overall aim 
To study the clonal evolution of common emm types of GAS causing human infections 
in a South Indian community using Multi Locus Sequence Typing. 
2.2. Specific Objectives 
1. To standardize Multi Locus Sequence Typing (MLST) for GAS using seven 
housekeeping loci for enzymes that performs vital functions. 
2. To determine Sequence Types (ST) and their alleles, of GAS causing human 
infections in South Indian community using MLST. 
3. To determine the clonal diversity of common emm types of GAS causing 
pharyngitis, impetigo and clinically invasive disease in South Indian patients by 
comparing the association of allelic profile of the ST with the diverse emm types. 
4. To study the linkage disequilibrium within the GAS population by studying the 
index of association between ST and emm types. 
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3. REVIEW OF LITERATURE 
3.1. History of Group A Streptococcus (GAS) 
GAS was first described by Billroth in 1874 [46] in patients with wound infections and 
coined the term „streptococcus‟ to describe the bacteria. In 1883, Fehleisen [47] isolated 
chain-forming organisms in pure culture from perierysipelas lesions. Rosenbach named the 
organism GAS in 1884 [48]. Studies by Schotmuller in 1903 [49] determined that 
Streptococci produced various kinds of hemolysis on blood agar plates. In 1919 J.H. Brown 
[50] led to knowledge of different patterns of hemolysis described as alpha, beta, and 
gamma hemolysis. 
 A later development in this field was the Lancefield classification of beta-hemolytic 
streptococci by Rebecca Lancefield and later categorized GAS as specific types based on 
serotyping of M-protein, this study resulted in the demonstration of serological differences 
between several of the epidemic strains of GAS [51] . Lancefield established the critical role 
of M protein in disease causation. At about the same time Griffith differentiated GAS (GAS) 
into types with slide agglutination test based on T antigens. 
 In 1920s, Dochez, George, and Dick [52] identified that scarlet fever was caused by 
hemolytic streptococcal infection. In 1932 Todd [53] developed a test for measuring 
antibodies to streptolysin O, The epidemiological studies of the mid 1900s helped establish a 
relationship of GAS infection with acute rheumatic fever (ARF) and acute 
glomerulonephritis [54]. 
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3.2. Taxonomy and Genus definition 
GAS belongs to the family Streptococcaceae [55]. These organisms are gram – positive, 
catalase – negative, spherical or ovoid cells that tend to grow in pairs and chains, non-
motile, non-sporing, fail to reduce nitrate, facultatively anaerobic and requires enriched 
medium containing blood to grow [56]. The G+C content of DNA is 36-46 % [57].  GAS 
genome has single circular chromosome in size from 1.85-1.9 Mb [58].The detection of 
cytochrome enzymes with the catalase test distinguishes members of the family 
Micrococcaceae (catalase-positive) from the members of the family Streptococcaceae 
(catalase-negative). 
Rebecca Lancefield established the Lancefield grouping system for the beta hemolytic 
streptococci based on cell wall carbohydrate [51] .These carbohydrate antigens detected on 
cell wall is composed of repeating units of N-acteyl glucosamine and N-acetylmuramic acid. 
The Group A polysaccharide is a polymer of N-acteyl glucosamine and rhamnose. This 
polysaccharide is also known as “C substance or group carbohydrate antigen”[59]. 
In 1937, Sherman proposed a scheme for placing the streptococci into four categories. These 
categories were organized by hemolytic reaction, group carbohydrate antigens, and 
phenotypic tests (primarily fermentation and tolerance test) [60]. Sherman‟s four divisions 
were the pyogenic division, the viridians division, the lactic division and the enterococci. 
The pyogenic division included the β- hemolytic strains with defined group antigens (A, B, 
C, E, F and G).The nomenclature and taxonomy of streptococci profoundly changed with 
application of genetic techniques. These include DNA-DNA hybridization, DNA- ribosomal 
(rRNA) hybridization and small subunit (16S) rRNA hybridization. In 1991, Bentley and 
coworkers applied partial 16SrRNA sequencing to the streptococcal species to determine the 
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intrgeneric relationship among them [61]. Kawmura and associates in 1995 extended these 
studies with some of the newly identified viridians streptococci [62]. Currently GAS is 
placed in the pyogenic group of streptococcus .The pyogenic group consists of Group A, B, 
C and G streptococci clustered together phylogenitically, while viridians streptococci fell 
into several phylogenetic groups. 
3.3. Morphology and Cultural characteristics 
Streptococci are spherical cells that are arranged in pairs or in chains of up to 50 cells or 
more. Individual cells are typically 0.5-1.0µm × 1.0-2.0µm.Growth occurs by elongation on 
the axis parallel to the chain. Cross walls form at right angles to the chain and after division 
and appearance of pairing may remain. The length varies within wide limits and is 
influenced by the nature of the culture medium. Chain formation is most pronounced in 
broth media than solid media. In liquid media, such as glucose, serum broth, Pike‟s media 
[63] and Todd-Hewitt broth growth occurs as granular turbidity with a powdery deposit. No 
pellicles are formed in liquid media. 
GAS is a facultative anaerobe growing best at 37°C. It is catalase negative, oxidase negative, 
non- motile, non-sporing [64]. The minimal nutrition requirements of the streptococci are 
complex because of the organism‟s inability to synthesize its required amino acids, purines, 
pyrimidines and vitamins. GAS is fastidious in their nutritional requirement. For primary 
isolation of GAS from clinical materials, media enriched with blood is preferred [65]. The 
optimal pH for growth is 7.4 to 7.6 at 37°C [66]. An enhancement of growth of GAS can be 
obtained by culture at reduced oxygen tension or an increased level of CO2. Most GAS is 
beta hemolytic on sheep blood agar, the presence of small amounts of fermentable 
carbohydrate (0.05% of glucose) decreases the hemolytic reaction around the surface 
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colonies. Since hemolysis is enhanced under anaerobic conditions, the agar plates are 
slashed with the loop at the primary site of inoculation to ensure subsurface growth. 
GAS colonies are circular in shape with a diameter range from 0.5 to 2mm. GAS appears in 
three forms: mucoid, matt and glossy [67]. Mucoid colonies are large and glistening with the 
appearance of droplets of water. They are viscous in nature and form confluent growth. 
They are formed by GAS isolates producing large amount of hyaluronic acid capsule. Matt 
colonies, also known as post-mucoid colonies, are flat with rough surface. These matt 
colonies are also produced as a result of drying of mucoid colonies. Glossy colonies are 
smaller than the other forms [68]. They are domed with a shiny surface and are formed by 
strains that do not produce capsule during growth. The size of the hemolytic zone around 
surface colonies of GAS is usually 2-4 times the diameter of the colony. In some strains the 
hemolytic zone is much wider, while in others only a narrow ring is present. 
GAS has been reported to occur as nutritional variants (NV) and grow insufficiently or does 
not grow on the surface of blood agar incubated aerobically [69]. The growth of nutritionally 
variant Group A Streptococci (NVGAS) can be promoted by incubating in presence of 
increased CO2 or addition of special supplementation of the media. The NVGAS grows on 
blood agar as satellites around normal flora of bacterial colonies [70]. 
Based on the principle of Pike‟s medium [71] which incorporates Crystal violet (CV) to 
inhibit the growth of commensals and increase recovery
 
of GAS from clinical samples, 
blood agar containing crystal violet has been used for isolation of GAS strains. This is 
known as crystal violet blood agar. Crystal violet is added in the concentration of 
1:1000000(1µg/ml) to 500ml aliquots of blood agar. Crystal violet, a bacteriostatic dye, is 
used in the preparation of culture
 
media for selective isolation of GAS. This is used in 
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situation where cultures are overgrown with staphylococci from skin lesions, pharyngeal and 
nasal cultures. This is a selective agar media for isolation of GAS. Other selective agar 
media used in isolation of GAS from cultures are Columbia agar with colistin & nalidixic 
acid and sulfamethaxole- trimethoprim blood agar. Columbia 5% blood agar with colistin 
(10µg/ml) and nalidixic acid [72] (15µg/ml) inhibits the growth of gram negative bacilli 
which over grow GAS. A better alternative media for isolation of GAS is Columbia agar 
with colistin (10µg/ml) and oxolinic acid (5µg/ml) [73]. This inhibits the growth of 
staphylococci, coryneform and gram negative bacilli. Sulfamethaxole-trimethoprim blood 
agar is composed of trypticase soy agar with 5% sheep blood supplemented with 
sulfamethaxole (23.75µg/ml) and trimethoprim (1.25µg/ml). This has been used as the 
primary blood agar plate which increases the yields of GAS [74, 75]. 
Specimen collection and processing is the most crucial step
 
in the isolation of ß-hemolytic 
streptococci (BHS).
 
Various methods, such as transport media (Amies and Stuart),
 
filter 
paper strips [76] and silica gel desiccated swabs [77], have been used
 
to improve the survival 
of BHS [78], especially GAS,
 
and prevent growth of commensals. Filter paper strips 
measuring 2 x 6 cm impregnated
 
with crystal violet used in the transport helps in the 
recovery of GAS from clinical samples. This is a good technique for isolation of GAS the 
epidemiological
 
study of streptococcal pyoderma [79]. GAS isolates can be preserved by 
lyophilisation, sand desiccation method and Robertson cooked meat medium [80]. 
3.4. Structure, Antigenic composition and Virulence factors of GAS 
The cell surface of GAS accounts for many virulence factors those concerned with 
colonization and evasion of phagocytosis and the host immune response [81] . The outer 
most layer is the capsule consisting of hyaluronic acid [82] . The cell wall surface is covered 
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with hair like protrusions (made up of M, T and R protein antigen), fibronectin binding 
proteins, cell bound streptokinase and lipoteichoic acid [83]. The cell wall consists of 
peptidoglycan made up of repeated units of N-acetylglucosamine and N-acetylmuramic acid 
cross linked by a short peptide [84, 85]. GAS produces a number of toxin and enzymes. 
Among these are superantigen streptococcal pyrogenic exotoxins (erythrogenic toxins A, B, 
C), Streptolysin S & O and other extracellular antigens such as deoxyribonuclease B (DNase 
B), hyaluronidase, streptokinase and nicotinamide adenine dinucleotidase (NADase) [86]. 
The mechanisms by which GAS initiates invasive infections are currently a focus for 
numerous research groups world-wide. Several virulence determinants which aid the 
pathogen in evading the immune system, adhering to the host epithelial cells and invading 
the host tissue have been identified. The advent of molecular techniques has revealed much 
about the organism‟s virulence and the genomes of several GAS types have been deciphered 
[87]. Surface structures of GAS including a family of M-proteins, the hyaluronic acid 
capsule and fibronectin–binding proteins, allow the organism to adhere, colonise and invade 
tissues [88, 89]. M protein binds to complement control factors and other host proteins to 
prevent activation of alternate complement pathway and thus evade phagocytosis and killing 
by polymorphonuclear leucocytes [90]. Extracellular toxins, including superantigenic 
streptococcal pyrogenic exotoxin contribute to tissue invasion [1]. 
3.4.1. Hyaluronic acid capsule 
The GAS capsule is composed of hyaluronic acid, a high molecular- weight polymer [91] . 
The hyaluronic acid capsule is required for resistance to phagocytosis [92, 93]. The 
production of hyaluronic acid is controlled by an operon composed of three different genes 
hasA, hasB and hasC which are transcriptionally regulated. hasA encodes hyaluronate 
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synthase , hasB  encodes for UDP – glucose dehydrogenase and hasC  encodes UDP-
glucose pyrophosphorylase [94]. The inactivation of hasC does not affect the production of 
capsule [95]. GAS strains rich in M protein and capsules are extremely mucoid and are 
highly virulent. GAS capsular hyaluronate is very similar chemically to the connective tissue 
of human [96]. GAS hyaluronic acid capsule is a poor immunogen, so there is insignificant 
antibody production in humans [97, 98].  
These mucoid strains with capsules have been found associated with virulence has been 
supported by the observation that the capsule is formed by 3% of isolates from patients with 
uncomplicated pharyngitis, 21% of isolates from severe streptococcal infections and 42% 
from acute rheumatic fever which indicates the importance of capsule in invasiveness [99]. 
Among the frequently isolated serotype M1 the prevalence of capsule production is even 
higher (6, 22 and 80% respectively). Capsule producing strains are highly virulent in animal 
models. 
3.4.2. Cell wall 
The cell wall consists of peptidoglycan back bone with integral lipoteichoic components. 
The main function of these components is structural stability of GAS [100-102] . 
Lipoteichoic acid (LTA) facilitates the adherence of GAS to pharyngeal epithelial cells [103, 
104]. Peptidoglycan, like endotoxin of gram negative bacteria, is capable of activating the 
alternative complement pathway [105-107]. Lipoteichoic acid serves by hydrophobic 
interactions as a first step adhesin, bringing the organisms into close contact with host cells 
and allowing other adhesions to promote high affinity binding [89]. 
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GAS surface proteins that bind fibronectin have been studied extensively and are important 
in adherence to both throat and skin [108-110]. These include protein F1 also known as SfbI 
(streptococcal fibronectin binding protein I) [111]. Other proteins which are found in 
relation to SfbI are SfbII, FBP54 (fibronectin-binding protein), protein F2 and PFBP 
(Streptococcus pyogenes fibronectin-binding protein) [112]. Protein SfbI facilitates adherence to 
pharynogeal epithelial cells[113]. Mouse challenged with lethal dose of virulent GAS was 
found to be protected when vaccinated with intranasal vaccination of protein SfbI [114-116]. 
3.4.3. M protein 
The ability of GAS to persist in infected tissues is due primarily to the cell surface protein 
exposed M protein [90] , a molecule which confers GAS ability to resist phagocytosis by 
polymorphonuclear leucocytes in the absence of specific antibody. Antibodies to M protein 
are associated with type specific immunity.  Resistance to infections by GAS appears to be 
related to presence of antibodies in secretion and sera to the M protein molecule [117]. M 
protein is one of the main virulence factors. Under the Lancefield classification scheme 
there are, nearly 80 antigenic M protein serotypes. 
Structural studies of the streptococcal M protein began in the late 1970s and early 1980s by 
Beachey and colleagues [118] and Manjula, Fischetti, and colleagues [119] when the protein 
chemistry was used to obtain the amino acid sequence of peptide fragments of the M 
protein. The structural basis of the biological properties of M protein was elucidated using 
M type 24, 5 and 6 [118, 120, 121]. M protein is composed of two polypeptide chains 
complexed in an alpha helical coil configuration anchored in the cell membrane, traversing 
the cell wall and appearing as fibrils on the cell surface [122] . The C terminus of the coiled 
M protein acts as a membrane anchor. From the membrane anchor region towards the amino 
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(NH2) terminus, the M protein is composed of proline/ glycine – rich region embedded in 
the cell wall followed by repeated regions of repeating amino acids designated A-D. The 
amino acid sequences of regions B-D are highly conserved among different M proteins. The 
A repeat region and the N (amino) terminal portion of the molecule extends into the 
environment and concludes in a series of approximately 11 amino acids.  This short 
sequence and the region A constitute the hypervariable region of M protein. Antigenic 
variation in the hypervariable region constitutes the basis for the Lancefield serological 
classification of GAS [123]. 
Cloning of the M protein gene has expanded the M typing. The M protein gene (emm gene) 
added more emm types to the collection which was not possible by sero-typing. Currently 
there are more than 125 M protein types [124] and 175 emm types with 750 emm subtypes 
[125]. 
Cross-protection between M serotypes was first reported in 1939 by Hirst and Lancefield, 
who immunized mice with crude acid extracts of M protein [126, 127]. Cross reaction 
among M types were correlated with the presence of common peptide fragment which 
suggested a certain degree of structural similarity among cross reactive serotypes of M 
protein. Cross reaction to such shared determinants may also account for the limited degree 
of heterologous protection reported by Wittner and Fox [128] who immunized mice with a 
trivalent vaccine that contained acid extracts of type 1, 3 and 12 M proteins. In addition to 
protection against vaccine serotypes, the immunized animals were also protected against 
challenge infections with M type 6 and 14.  
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M proteins have been divided into two classes, class I and class II molecules based on their 
reaction with antibodies against the C repeat region of M protein. Class I M protein is 
reported to contain a surface exposed epitope on the whole GAS that reacts with the 
antibodies against the C repeat region [129]. GAS containing class II M protein does not 
react with antibodies and do not contain class I epitope. The class I M protein serotypes have 
serum opacity factor while class II M protein do not [130]. In some studies, there was strong 
correlation between serotypes known to produce rheumatic fever and the presence of class I 
epitope [131]. 
Immunity to M protein has shown to be protective against GAS infections and paved a way 
for vaccine studies based on M protein [132]. The immune response to M protein is 
protective (by production of protective antibodies which promote phagocytosis) and 
destructive (antibodies react to the host tissues) [133]. 
Genes related to M protein gene are called the M (emm) gene superfamily [134]. They 
include immunoglobulin binding proteins, M- related proteins and M proteins. According to 
Hollingshead and colleagues more than 20 genes have been identified in the emm gene 
superfamily [134] in which genes shared more than 70% DNA sequence identity at their 
5‟end [135]. The genes in the emm family are located in a cluster occupying 3-6 kb between 
the regulatory genes mga and scpA gene encoding C5a peptidase within the vir regulon on 
the chromosome of GAS [136]. Five major emm chromosomal patterns of the emm 
subfamily genes were identified based on the number and arrangement of emm subfamily 
genesc[137] . These subfamily arrangement were designated A to E. 
17 
 
The immunoglobulin binding proteins identified for GAS are encoded by emm or emm 
related genes. They are immunoglobulin binding proteins which have structural similarity to 
M related proteins and interact with immunoglobulins outside their antigen combining site 
in the Fc region of the immunoglobulin molecule [138]. Heath and Cleary cloned and 
sequenced the first immunoglobulin binding protein gene, the fcrA gene. Genetic studies 
have suggested that a common ancestral gene has undergone gene duplication to produce the 
diversified family of immunoglobulin binding proteins [135, 139-144]. The genes encoding 
the immunoglobulin binding proteins are controlled by multiple gene regulators (mga) of 
GAS, a positive transcriptional regulator also controlling expressions of M protein. 
Antigenic heterogeneity of M protein is the consequence of highly polymorphic 5'ends of 
emm family genes that encodes amino acids distal to the cell surface capable of provoking a 
protective immune response during infection. The 5'end is composed of repeats that 
participate in intragenic recombination resulting in size variation of the M protein. 
3.4.4. Serum opacity factor 
Top and Wannamaker demonstrated that production of opacity factor is closely related to M 
types [145]. Approximately half of GAS strains are capable of opacifying mammalian 
serum, a unique phenotype attributable to the presence of serum opacity factor (SOF) 
encoded by the sof gene [146, 147]. SOF is a 110-kDa protein with an LP(X)SG cell wall 
anchor motif expressed in both membrane bound and extracellular forms [148-150]. SOF is 
a bifunctional protein comprised of an N-terminal opacification domain, and C-terminal 
domain of highly conserved tandem repeat sequences capable of binding the host 
extracellular matrix components fibronectin and fibrinogen[150-152] .Once thought to be a 
lipoproteinase, SOF has recently been shown to bind apoA-I and apoA-II, causing release of 
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HDL lipid cargo, which in turn coalesces to form lipid droplets, resulting in serum 
opacification [153].Studies with SOF-coated latex beads indicate the protein can promote 
adherence to human HEp-2 pharyngeal epithelial cells including fibronectin-specific 
interactions [154]. A role in GAS virulence has been attributed to SOF, since insertional 
inactivation of the sof gene in a serotype 2 GAS isolate reduced mortality in a mouse 
intraperitoneal infection model [148]. SOF also triggers host production of opsonic 
antibodies that protect against infection by SOF (+) strains of GAS, suggesting it may 
represent a useful vaccine antigen [130] . 
The sof gene is recently recognized to be a member of a two gene operon, invariably 
cotranscribed with a gene encoding a second surface anchored protein, sfbX [155]. SfbX 
possesses a C-terminal domain of tandem repeat sequences very highly homologous to the 
fibronectin-binding domain of SOF, but a unique N-terminal domain. SfbX is capable of 
binding fibronectin, but the function of its N-terminal sequences has yet to be elucidated 
[155]. Given previous insertional mutagenesis studies targeting sof were performed before 
the operon structure was recognized, polar effects on sfbX would be anticipated, and the 
precise contribution of each individual gene is therefore uncertain.  
3.4.5. C5a peptidase (SCPA) 
C5a peptidase is a proteolytic enzyme (endopeptidase) found on the surface of GAS [156] . 
It is highly specific 130kDa serine peptidase that is anchored to the streptococcal cell wall 
[157].The SCPA gene is encoded by a gene which is regulated by mga in concert with M 
protein [158]. Its role as major virulence factor has been established. The enzyme SCPA is 
produced by group A, B and G streptococci [1] . SCPA cleaves the complement–derived 
chemotaxin, C5a at the His
67
-Lys
68
 bond, thus removing the leucocyte-binding site of C5a 
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[156]. As a result SCPA inhibits chemotaxis, delaying infiltration of phagocytosis, thus 
promoting the infection of GAS by establishing at the site of infection [159, 160]. Animal 
studies using SCPA as an immunogen has been done to check for protection rendered by 
SCPA against GAS infection. Intranasal immunization of mice with recombinant SCPA 
induced strong humoral and mucosal response and reduced nasopharyngeal colonization 
after challenged with M types suggesting cross protection [161]. Antibody against SCPA 
was found in detectable levels against uninfected adults rather than children who are healthy 
[162] .  
3.4.6. Streptokinase 
Streptokinase is a 46 kDa single chain, 414 amino acid protein, secreted by group A, C and 
G streptococci[163] . Crystal structure studies of the activator complex of streptokinase with 
microplasmin (the catalytic domain of plasmin) indicate that streptokinase contains three 
domains (α, β and γ) which bind to the catalytic domain of plasmin. The streptokinase gene 
is highly conserved [164]. 
Streptokinase interacts with plasminogen to form streptokinase - plasminogen complex with 
proteolytic activity capable of converting other plasminogen molecules to plasmin. The 
breakdown of tissue barriers by plasmin facilitate bacterial spread and also supply 
oligopeptides and amino acids to be used by the pathogen [165] . Attention towards 
streptokinase has been offered due to clinical use as a thrombolytic agent [166] . More 
interest in streptokinase has been seen because of its association with acute post-
streptococcal glomerulonephritis [99] . 
The complete nucleotide sequence of the streptokinase gene has been reported earlier for 
GAS M type 49[167] and M type1[168]. Sequence comparison analysis of streptokinase 
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proteins from different strains of streptococci revealed marked differences in the degree of 
similarity .Streptokinase from GAS M type 1 and group C and G formed one cluster and 
GAS M type 12 and 49 made up another variant [169, 170] . The nucleotide identity 
between nephritis and non-nephritis GAS isolate is 90% and 85 % at amino acid level. The 
non-identical amino acids are located in two major variable regions V1 and V2 
corresponding to amino acid residues 174-244 and 270-290 respectively .The V1 regions of 
nephritis associated with ska allele show more than  95% homology with each other at 
nucleotide level but less than 60% homology with the non-nephritis ska allele [171, 172] . 
Synthesis of the plasminogen activator streptokinase (SK) by
 
GAS has shown to be subject
 
to control by two two-component regulators, covRS (or csrRS)
 
and fasBCA [173]. In 
independent studies, response regulator CovR
 
proved to act as the repressor, whereas FasA 
was found to act
 
indirectly as the activator by controlling the expression of
 
a stimulatory 
RNA, fasX. 
3.4.7. Streptolysin O and S 
Streptolysin O is a protein of approximately 60 kDa. It belongs to a family of oxygen labile; 
thiol activated cytolysins and causes the broad zone of beta hemolysis surrounding colonies 
of GAS with cut on blood agar plates [174]. Thiol activated cytolysins bind to cholesterol on 
cell membranes, creating toxin-cholesterol aggregates that contribute to cell lysis via a 
colloid –osmotic mechanism. Cholesterol inhibits both toxicity in isolated myocytes and 
hemolysis of red blood cells in vitro. In conditions, where serum cholesterol is high 
(nephritic syndrome), falsely elevated ASO titers may occur because both cholesterol and 
anti-ASO antibody will neutralize streptolysin O. They are antigenically related, although 
the similarities are not evident from sequence comparison of the respective genes encoding 
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these toxins. Striking amino acid homology exists between streptolysin O and thiol activated 
cytolysins from other gram- positive bacteria. Intra venous injection of streptolysin O into 
mice, rabbits, guinea pig causes death within seconds [175]. Death is the result of an acute 
toxic action on the heart. Serum antibodies to streptolysin O can be demonstrated, the 
highest titers are found in patients with rheumatic fever [176]. Streptolysin S is a cell 
associated hemolysin that does not diffuse into the agar media. It is produced by GAS in the 
presence of serum albumin, alpha-lipoprotein, and ribonucleic acids. Its hemolytic activity is 
inhibited by serum lipoprotein and other phospholipids. It is not antigenic. Unlike SLO it is 
not inactivated by oxygen. It is thermo labile. Synthetic peptides containing aminoacid 
residues of the SLS molecule evoke toxin neutralizing antibodies [177].  
3.4.8. Streptococcal pyrogenic exotoxin (Spe)  
 Pyrogenic toxins are a group of acid-stable single-chain proteins ranging in molecular 
weight from 20,000 to 40,000. This group includes the staphylococcal enterotoxin serotypes 
A to E (SEA to SEE), the staphylococcal pyrogenic exotoxins A and B, toxic shock 
syndrome toxin type 1(TSST-1) [178], and the streptococcal pyrogenic exotoxin types A to 
C (SPE A to SPE C). These toxins are characterized by their similar biological activities: 
they induce fever, are nonspecific T-cell mitogens, enhance host susceptibility to endotoxin, 
suppress B-lymphocyte function, and cause a scarlet fever-like rash. Some members of the 
group, such as SPE A, staphylococcal enterotoxin SEB, and staphylococcal enterotoxin 
SEC, share significant sequence similarity [179]. 
 The SPEs, formerly called the scarlet fever toxins, have been shown to be important in the 
development of scarlet fever. The speA and speC genes are encoded by bacteriophage [180-
183]while the SpeB is chromosomal [184-186]. SpeB is a cysteine protease which degrades 
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vitronectin, fibronectin and IL-1 precursor [187, 188]. Other pyrogenic exotoxins include 
mitogenic factor (SpeF), streotococcal super antigen (SSA), streptococcal mitogenic 
exotoxin Z (SMEZ), speG, speH, speJ and speK  [189, 190].  
spe genes – speA, speB, speC, speF, speG, speH, speJ, speK,ssa, and smeZ encode a family 
of high mitogenic proteins secreted by GAS [191]. Most of the genes exhibit high 
superantigenic activity. Among the spe genes, speB is exceptional because its mitogenic 
activity is less compared to the other genes because it is a cysteine protease. SMEZ was 
distict from other known mitogenic exotoxins and anti –SMEZ antisera did not cross react 
with SpeA, SpeB and SpeC in neutralization tests of mitogenic activity. 
The nucleotide sequence of speA   gene was found expressed among GAS isolated from 
streptococcal toxic shock syndrome and it accounted to 85% of the isolates. Nucleotide 
sequencing of streptococcal pyrogenic exotoxin A gene from outbrakes revealed four alleles 
of speA (speA1, speA2, speA3 and speA4). speA1, speA2 and speA3 differ from each other 
by single amino acid while, speA4 encodes toxin which differs by 9% divergent from the 
three and speA4 has 26 amino acid substitutions [192]. The allele speA3 is highly mitogenic 
and has more affinity for the HLA DQ molecule. Inflammatory response triggered by the 
streptococcal pyrogenic exotoxins or superantigen lead to autoimmune responses and 
manifestations[193]. 
3.4.9. Cysteine protease (SpeB) 
Streptococcal proteinase (SpeB) is an extracellular cysteine proteinase which is a 40 kDa 
zymogen which is cleaved into 28kDa mature enzyme under reducing conditions [185, 194, 
195]. Increased antibody production is seen in cases of pharyngitis, rheumatic fever and 
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invasive cases against SpeB, while low levels of antibodies are seen in fatal invasive disease 
of GAS [196]. 
SpeB has been shown interact with many host proteins. It cleaves several proteins such as 
fibrenectin and vitronectin and facilitating bacterial dissemination, colonization and invasion 
[187]. Several in vitro studies to analyse the biological importance of SpeB secretion in 
GAS disease has been carried out. SpeB has been detected in vitro during the stationary 
phase of growth in GAS and its production has been inhibited in a nutrient rich environment 
[197].Thus SpeB secretion has been illustrated as an adaptive mechanism of the pathogen in 
a nutrient deficient environment. SpeB is also known to degrade streptokinase in vitro in late 
stationary phase of GAS growth. The addition of cysteine protease inhibitor prevented the 
degradation by M 53 type strain [198]. Proteomic analysis of the culture supernatants of an 
M1 type GAS isolated from invasive GAS disease has shown that SpeB is capable of 
degrading most of the GAS secreted proteins including M protein and streptokinase [199]. 
This degradation has also been associated with decrease in mitogenic activity of 
lymphocytes in vitro. The in vitro studies of M1 GAS strain cultured in human saliva have 
shown high density colony forming units in the stationary phase. The ability of strain to 
maintain such a growth pattern has been attributed to number of virulence factors including 
SpeB. This study helps in gaining an insight into the molecular process that enhances 
colonization in the upper respiratory tract.  
Transcription of speB has shown to be controlled by the gene oppA, which is a part of 
polycistronic operon. The isogenic mutant of oppA has been shown to decrease transcription 
of speB and cause less mortality and tissue damage in mouse model [200] 
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3.5. Clinical manifestations 
 
GAS is the etiologic agent of streptococcal pharyngitis and streptococcal impetigo, which 
result in serious disease sequelae such as acute rheumatic fever (ARF), rheumatic heart 
disease (RHD) and acute post streptococcal glomerulonephritis (APSGN). It is also 
responsible for invasive disease such as streptococcal toxic shock syndrome (STSS), 
necrotizing fasciitis (NF), myositis and bacteremia [1, 201]. 
3.5.1. Non-invasive streptococcal disease 
3.5.1.1. Pharyngitis 
The most common infection due to GAS is streptococcal sore throat. GAS adheres to the 
pharyngeal epithelium by means of lipoteichoic acid covered surface pili. The glycoprotein 
fibronectin on epithelial cells serves as lipoteichoic acid ligand. It primarily affects the 
school children aged 5-15 years [202].  Clinical signs such as abrupt onset of sore throat, 
malaise, and headache generally develop 2-4 days after exposure. The posterior pharynx is 
usually reddened, with enlarged tonsils. The local inflammation results in swelling of 
cervical lymph nodes. Occasionally tonsilar abcess develop which may spread to 
neighbouring regions and to the bloodstream. 
Pharyngitis caused by certain pyrogenic exotoxin of GAS may be associated with diffuse 
erythematous rash of the skin and mucous membrane. This condition is known as scarlet 
fever [203]. The rash develops within 1-2 days after first symptoms of pharyngitis and 
initially appears on the chest, then spreading to the extremities. The tongue becomes red and 
denuded (strawberry tongue). 
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3.5.1.2. Impetigo 
GAS causes several skin infections, sometimes in association with Staphylococcus aureus. 
The superficial and localized skin infection known as impetigo or pyoderma occurs mainly 
in children. It primarily affects exposed area on face, arms or legs. The skin becomes 
colonized after contact with infected person and the bacteria enter through small defects 
[204]. Initially, clear vesicles develop, which within few days become pus filled. Secondary 
spread is often as a result of scratching. 
More severe acute infection is the acute skin infection erysipelas, which occurs in the 
superficial layers of the skin (cellulitis) and involves lymphatics[204]. The infection is 
characterized by diffuse redness of the skin, and patient‟s experience local pain, enlargement 
of regional lymph nodes and fever. Untreated, the infection may spread to the blood stream. 
3.5.2. Invasive soft tissue infection 
GAS invasive infections are severe and life threatening [205]. The most severe forms of 
invasive infections are necrotizing fasciitis (NF), streptococcal toxic shock syndrome and 
puerperal fever [206], all of which are associated with bacteraemia. Once in the blood GAS 
multiplies with incredible speed and the mortality rate reaches 40%.The potential 
complication include acute endocarditis leading to heart failure. 
3.5.2.1. Necrotizing fasciitis (NF) 
Necrotizing fasciitis (NF) disease is a deep seated infection of the subcutaneous tissue that 
results in the progressive destruction of fascia and fat. This was previously known as 
streptococcal gangrene [207, 208].GAS gain entry to these tissues through trauma .Systemic 
shock and general deterioration occur very rapidly. The clinical diagnosis may be difficult 
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because Staphylococcus aureus and anaerobes such as Clostridium perfrigens can produce 
similar clinical picture. GAS can be identified from the blood, blister fluid and cultures of 
infected area. 
Predisposing factors for the development of NF due to GAS include varicella, penetrating 
injuries, minor cuts, burns, splinters, surgical procedures, child birth, blunt trauma and 
muscle strain [209]. The first cutaneous clue to streptococcal necrotizing fasciitis is diffuse 
swelling of arm or leg followed by the appearance of bullae filled with clear fluid which 
rapidly takes on a maroon or violaceous colour. Unless appropriate intervention is 
undertaken, there are chances for cutaneous gangrene, with myonecrosis and an extension of 
the inflammatory process along fascial planes. There are marked systemic symptoms, which 
may include shock and organ failure [209]. 
 
3.5.2.2. Streptococcal toxic shock syndrome 
The early onset of shock and isolation of GAS from a normally sterile site are the defining 
characters of Streptococcal toxic shock syndrome[210]. Patients with invasive and 
bacteraemic GAS infections and in particular necrotizing fasciitis may develop 
Streptococcal toxic shock syndrome. The disease, which was first described in the late 
1980s, is the result of streptococcal toxins to the bloodstream. The early symptoms of 
streptococcal shock syndrome include myalgia, malaise, chills, fever, vomiting and diarrhea. 
Without treatment, the disease progress to shock and organ failure. 
3.5.3. Non -suppurative sequelae 
Two serious diseases develop as sequelae of GAS infection. They are rheumatic fever (RF) 
and acute post streptococcal glomerulonephritis (APSGN). Both are caused by immune 
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reaction induced by streptococcal infection. The first clinical sign appears 1-5 week after the 
infection and at the time the bacteria have been eradicated by the immune system or as a 
result of antibiotic therapy. 
3.5.3.1. Rheumatic fever (RF) 
Rheumatic fever manifest as an inflammation of joints (arthritis), heart (carditis), central 
nervous system (chorea), skin (erythema marginatum) and subcutaneous nodules. Acute RF 
is an inflammatory disease of childhood that occurs following untreated GAS pharyngitis 
infection. Rheumatic fever is diagnosed by physician based on the presence of criteria found 
in the revised Jones criteria [211]. 
Rheumatic fever is a major cause of acquired heart disease in young people throughout the 
world. The incidence of Rheumatic heart disease worldwide ranges from 0.5 to 11 per 1000 
of the population [212]. Rheumatic fever is autoimmune in nature and results from the 
production of auto reactive antibodies and T lymphocytes induced by cross reactive 
components of the bacteria and host tissues (molecular mimicry) [1]. The medical 
importance of rheumatic fever is serious cardiac involvement, with myocarditis or valvulitis 
leading to death or valve replacement. 
The strongest evidence supporting the hypothesis that rheumatic fever is a result of GAS 
infection is that rheumatic fever (RF) parallels the occurrence of streptococcal infection. In 
addition, elevated antistreptococcal antibodies accompany rheumatic fever, such as rise in 
ASO and anti-DNASe B antibody titers. Rheumatic fever has marked tendency to be 
reactivated by recurrent streptococcal infections, whereas APSGN does not. 
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3.5.3.2. Acute post streptococcal glomerulonephritis (APSGN)  
Acute glomerulonephritis is most often seen in children may be associated with acute onset 
of edema, oliguria, hypertension and hematuria. Various mechanisms involved in the 
development of APSGN are immune complex deposition of GAS, reaction of antibodies 
cross reactive with streptococcal glomerular antigens, direct toxic effect on glomerulus, and 
alteration of glomerular tissues by streptococcal toxins such as proteinase or streptokinase, 
direct complement activation by streptococcal complements deposited in the glomeruli. 
Kefalides and colleagues demonstrated that sera from patients with APSGN contained 
antibodies against lamnin, collagen and other macromolecules found in the glomerular 
basement membrane. It was also found that the epitope recognized in collagen resides in the 
70s domain of the type IV collagen [213]. 
The typical clinical feature of APSGN includes edema and smoky dusty urine. Patients also 
exhibit pallor and may contain lethargy, malaise, weakness, anorexia, headache, and dull 
back pain. Fever is not prominent. Facial and periorbital edema are usually present but also 
involves foot, leg, scrotum and sacrum. Another manifestation of fluid overload is 
circulatory congestion, which may give rise to dyspnea, orthopnea, rales at the lung bases, 
distended neck veins and even pulmonary edema. 
3.6. Laboratory diagnosis 
In acute infections, diagnosis is established by culture, while in the non suppurative 
complication the diagnosis is mainly based on the demonstration of antibodies. A 
microbiological diagnosis is essential for throat culture because all the sore throats are not 
caused by GAS, it could be viral. If the sore throat is caused by GAS it is essential to 
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administer penicillin in prevention of primary attacks and recurrences of rheumatic fever. 
This has been demonstrated by Wannamaker et.al., Siege et.al. and Wood et.al. 
3.6.1. Collection of specimen 
The diagnosis of GAS infection is established by demonstrating the pathogen in throat or 
skin swabs, pus, blood cultures, CSF, expectorates or urine according to the site of infection.  
3.6.2. Cultivation and identification 
The specimen collected in aseptic precaution is plated on agar containing 7% sheep blood 
and incubated at 37°C anaerobically or 5-10% CO2. The hemolysis develops better under 
this condition. Slicing the innoculum into the blood agar has similar effects. The colonies 
are about 1mm in diameter and form large zones of hemolysis. 
 Presumptive information may be obtained on Gram stain from specimens. The presence of 
gram positive cocci in chains is indicative of GAS infection. However smears are of no 
value in infections of throat or genitalia, where streptococci may form resident flora. 
 
3.6.3. Bacitracin susceptibility 
Bacitracin susceptibility test is the method of choice to identify GAS. This is a disc diffusion 
method using bacitracin discs with concentration 0.04 to 0.05 international units. Zone of 
inhibition greater than 14 mm in diameter are given by GAS. This test has a sensitivity of 
>95%, is only a presumptive test and is not recommended since group G and C streptococci 
can give false positive results [214]. Batch to batch variation may occur in the commercial 
discs and therefore it is essential to test each batch for quality control with known GAS 
strains. If this is done regularly, one can resort to GAS identification by this method.  
 
30 
 
3.6.4. Group carbohydrate identification 
The recommended method of GAS identification is by testing β -hemolytic colonies on BA 
for group A specific carbohydrate antigen (ACHO) [215]. Numerous methods are available 
in the laboratory for this, of which the time tested Lancefield's hot-acid extraction technique 
and Fuller's formamide extraction method are the most widely used.   
The micro-nitrous acid extraction procedure of El Kholy is a rapid method. 
When performed together with the co agglutination reagents, this technique can identify a 
GAS strain from a BA plate in about 30-45 minutes [216]. 
Twenty microliter of 2M sodium nitrite solution was taken in a test tube. Three to four 
colonies of β -hemolytic streptococci (BHS) was inoculated into this. Three l of glacial 
acetic acid was added to the suspension and left at room temperature for 15 minutes. Sixteen 
to twenty four g of sodium bicarbonate was added for neutralization, after which 60 l of 
distilled water was added. This is the antigen extract.  
The reagent is composed of suspension of Staphylococcus aureus (Cowan I strain) which 
has cell wall associated protein A that can bind to Fc portion of IgG molecules leaving the 
Fab portion free for binding. Using a micro pipette, one drop of well mixed antigen extract 
was added into ring of a ceramic slide. One drop of Group A co agglutination reagent 
(Staphylococcal suspension sensitized with group A antiserum) was added to this. 
The slide was rotated for 3 minutes to mix the suspension well. Agglutination was observed 
against diffuse light. Development of clumping and clearing confirmed the test strain as 
GAS. If agglutination was weak (1+), the co agglutination was repeated with a 6 hour old 
culture of the test strain in THB. 
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3.6.5. Rapid antigen detection test (RADTs) 
Rapid antigen detection test have a basis of extracting carbohydrate antigen from BHS and 
identify them by immunological methods. Despite their higher cost, they can provide a result 
within a few hours even when done directly on throat cultures [22] .This enhances the 
patient compliance to treatment and has been shown to significantly increase the number of 
patients appropriately treated for GAS pharyngitis [217]. Although tests such as latex 
agglutination, co-agglutination, enzyme immunoassays, liposomal and optical 
immunoassays have been employed for this purpose, most of them have sensitivity between 
70% and 90%, but with a specificity of >95% with culture as a gold standard [22]. Therefore 
a negative RADT should always be confirmed with a throat culture. Though molecular 
techniques have been standardized recently with improved sensitivity, factors such as cost 
and feasibility has hindered their use in smaller laboratories.  
3.6.6. Serological Diagnosis 
 Determination of anti-streptolysin O antibodies (ASO) had been the mainstay of confirming 
a diagnosis of GAS pharyngitis as well as RF [218]. Demonstration of a significant or four-
fold rise in titer on paired serum samples taken at an interval of 7 to 14 days apart will 
indicate an ongoing or an acute infection. On the other hand, presence of GAS in throat in 
the absence of a significant rise in antibodies indicates a carrier state and no GAS infection. 
Practical difficulties in getting two serum samples from children and the time taken to 
demonstrate a four-fold rise in titer make this unfeasible on a routine basis. Alternately, titer 
obtained with a single serum sample can be interpreted based on a cut-off value defined as 
the upper limit of normal (ULN). ULN represents the highest level of antibodies that can be 
observed in 20% of normal individuals who have demonstrable antibodies in them. It is to 
be emphasized that ULN titers should be determined in different geographical areas because 
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such titers are distinctly higher in endemic regions as compared to non-endemic areas. Any 
ASO titer above these cut-off values will indicate a GAS infection. This method is generally 
convenient and reliable although an antibody response from an earlier GAS infection may 
confuse the final interpretation of the current ASO titer. 
 One major disadvantage of ASO test is its inability to demonstrate an antibody response in 
many cases of impetigo. In such cases, determination of anti-deoxyribonuclease B antibody 
(ADNB) is a valuable method of diagnosing GAS infection [219]. The ADNB test is more 
sensitive and the magnitude of antibody response is higher than that of ASO both in cases 
pharyngitis and impetigo as well as the non suppurative sequelae. 
 Determinination of ASO and ADNB titers by the conventional micro-titer technique using 
SLO and DNase B enzyme produced and standardized in our laboratory [220]. These tests 
are labor intensive, cumbersome and time consuming. Therefore, nephelometric titration 
(Nephlometer), which is an automated, simple and rapid method which does not require 
much technical expertise, is in use. Many commercial latex agglutination-based ASO kits 
are available for diagnostic purpose [21]. 
3.6.7. Antibiotic Susceptibility Testing 
Antibiotic susceptibility may be performed by either dilution or diffusion methods. The 
choice of method is often based on the ease of performance, availability of materials and 
flexibility of method. While disc diffusion is simpler method, it provides only qualitative 
results.  
Penicillin remains the drug of choice for the treatment of GAS infections and their sequelae 
with macrolides recommended for patients allergic to beta-lactams. However, since the first 
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description of erythromycin-resistant GAS in 1955, many countries have reported varying 
frequencies of erythromycin resistance, with a significant global increase in the incidence of 
resistance in recent years .This increase in resistance is mediated either through target 
modification caused by methylase activity encoded by two classes of methylase genes, 
ermAM and ermTR, or by an active drug-efflux pump encoded by the mefA gene .The 
increased use of macrolides for the treatment of upper respiratory tract infections has 
contributed greatly towards the development of resistance [221]. Continuous surveillance of 
the susceptibility patterns of GAS should therefore be performed in order to recommend 
appropriate guidelines for antibiotic prescription. 
Despite reported penicillin tolerance, GAS continues to be exquisitely susceptible to 
penicillin which therefore is the drug of choice to treat the infections caused by them. Thus 
in practice it is not necessary to test their susceptibility on a routine basis; however it is 
imperative to look for emergence of resistance to penicillin, locally. More importantly, 
resistance to other antibiotics such as macrolides [222] is on the increase which can be 
monitored only by regular testing of GAS strains to such antibiotics. Antibiotic 
susceptibility is performed on Muller Hinton blood agar for GAS. 
3.7. Epidemiology 
Severe invasive infections caused by GAS have been reported with increased frequency in 
United States and from other parts of the world. This increase in the incidence of GAS 
infections has frequently been associated with specific clones, suggesting the possibility that 
the rise of particular virulent clones is responsible for the reemergence. The identification of 
GAS clones in the surveillance and epidemiological studies has frequently relied on 
serotyping using two variable surface antigens, the T antigen (T typing) and the M protein 
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(M serotyping). Serology based typing methods have their own limitations. Typing methods 
are the major tools for the characterization of bacterial pathogen allowing the determination 
of the clonal relationship between isolates. Recent technological advances have resulted in a 
shift from classical phenotyping typing methods such as serotyping, biotyping and antibiotic 
resistant typing to molecular methods such as restriction fragment length polymorphism, 
pulse field gel electrophoresis, PCR based methods, PCR serotyping, sequence based typing 
methods and microarray. 
Clonally related isolates share characteristics by which they can be differentiated from 
unrelated strains. In epidemiological terms, clonally related organisms are members of the 
same species that share virulence factors, biological traits and genomic characteristics. This 
ability to discriminate between genome is essential to several disciplines of microbiology 
including taxonomy, studies of evolutionary mechanisms, phylogenetic relationships and 
population genetics of organisms. There are many typing techniques which provide good 
molecular differentiation and which can be tailored to suit the needs or the nature of the 
clinical study. However, each of these methods has technical and target dependent 
limitations that should be considered before the choice of a typing technique is made. 
Several criteria are proposed for evaluating the performance of typing system, they are 
typeability, reproducibility, stability, discriminatory power and epidemiological 
concordance. The following criteria can be considered for convenience; flexibility, rapidity, 
accessibility and ease of use based on factors like the scale of epidemiological investigation, 
the time when the information is required, the financial aid and technical resources. 
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3.7.1. Typing Methods 
3.7.1.2. emm typing 
The first classification for streptococci was based on the hemolytic activity of isolates. 
Subsequently, the Lancefield classification scheme of serologic typing distinguished the 
streptococci based on the group A carbohydrate present in the cell wall. GAS was further 
classified into different M serotypes based on M surface protein. More than 80 different M 
protein serotypes have been identified using this method where the surface protein can be 
extracted from the bacteria with boiling hydrochloric acid. Serotyping faced several 
problems, to avoid these problems; a molecular approach for the identification of emm genes 
encoding the M protein in GAS was used. Currently there are more than 170 emm types and 
750 emm subtypes known from GAS.  
Approximately 40% of GAS isolates are capable of opacifying sera due to the expression of 
the serum opacity factor gene (sof).Reported literature of Beall based on emm sequence and 
sof gene sequence variation highlighted that within an emm type with same specific M type 
had differing genetic background based on sof gene and T agglutination patterns. Beall also 
reported that within same emm type there were different sof types. They are emm 4 (sof4 and 
sof2920), emm 25(sof25, sof4958, sof75), emm68 (sof68, sof4470, sof4438), emm81 (sof81, 
sof1658, sof1965), emm88 (sof88 and sof1482), emm89 (sof89, sof4835), st4935 (sof4935, 
sof1881, sof27G) and st448 (sof448 and sof3894). Beall also reported that within different 
emm type there are same sof types. They are sof2967 (st2967 and st1160), sof 90(emm 90 
and st833), sof8 (emm 8 and st3018) and sof27G (emm 27G and st4935). This relationship 
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between different sof types and same emm type and vice versa indicates inter strain 
recombination [223].  
A study from Italy highlighted that the most prevalent emm type in throat population were 
emm12, emm 22, emm 4, emm 1, emm 89 and emm 5 [224]. These emm types were found to 
be macrolide resistant and carried speC gene, while the speA restricted emm types emm1 and 
emm3 were found to be macrolide sensitive  [225]. Antibiotic resistance to invasive strains 
was mostly related to emm 89 [226]. The different incidence of exotoxin and antibiotic 
resistance genes among population did not appear to have intrinsic clinical significance, but 
may reflect the propensity of these traits to be associated with certain emm types 
independent of the source from which the strains were isolated [227]. 
emm typing has served as an epidemiological tool and the knowledge gained from various 
studies provided the impetus for exploring emm based genotyping system. The 
epidemiological studies from United States, Europe and the Caribbean reported  emm types 
associated with pharyngitis, they are M1, M3, M5, M12, M18, M19 and M24. These M 
types are rarely found in impetigo lesions. These finding led to widely recognized concept 
that there are distinct GAS population of “skin types” and “throat types” [228].  
In 1992, the distribution of GAS M types among strain isolated during 1988 to 1990 from 
patients with severe systemic infection from all regions of the United States were compared 
with the distribution of community GAS isolates. The study indicated that M1 and M3 were 
significantly more frequently associated with invasive GAS infections than with 
uncomplicated pharyngeal infections [99]. Another epidemiology study from United States 
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during the period 1995-1999 has also found emm types 1, 28, 12, 3 and 11. This accounted 
for 49.2% of isolates [229]. 
In accordance with other studies M1, M3, M12 and M28 isolates were most frequently 
present [229, 230]. Interestingly, the different manifestations of invasive GAS disease 
(meningitis, arthritis, necrotizing fasciitis and puerperal sepsis) were found to be associated 
with certain M types. M2 was found exclusively in puerperal sepsis, M6 was associated with 
meningitis and M12 was associated with arthritis. M1 was found equally distributed among 
different manifestation of invasive GAS disease [231]. M1, M3, M6, M18 and M24 are 
considered rheumatogenic, while M1, M12, M55 and M57 are nephritogenic  [1](REF).A 
Study from North India has shown that out of 94 GAS isolate analyzed thirty seven emm 
types were identified and there was no significant association found between emm type and 
the source of isolation [232].   
Few reports examining emm type diversity has been reported, however most report support 
the presence of predominant emm types. A community study in Korea found that emm78 and 
emm23 accounted for 69% of GAS isolates in one region, whereas in another region M5, 
M12, M3 and M23 accounted for 52% of isolates [233].  M1, M3 and M6 accounted for 
67% of isolates among circulating emm types from Mexico among patients with pharyngitis 
[234]. Nguyen et al. found that M1 and M2 clones represented 70% of GAS isolates 
collected in a survey of 52 patients with pharyngitis [235]. By contrast studies with isolates 
collected from Northen Teritory of Australia revealed much greater diversity of GAS strains 
[236] . Study from North India revealed 33 emm types out of 59 GAS isolates, few were new 
types and no predominant clone was found [124].The factors that influence the 
epidemiological distribution of particular emm types are unknown. 
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Certain studies have pointed to an association between particular emm types and severe GAS 
infection [237, 238]. A number of studies have also suggested that serious GAS disease is 
associated with emergence of highly virulent GAS clones [239, 240]  whereas others have 
found no evidence of this association [241-243]. The concept of M types with increased 
virulence capacity therefore remains controversial [244]. 
3.7.1.2. emm pattern typing 
Another approach known as emm patterning is a method of classification that recognizes 
differences in the number, arrangement and subfamily content of emm gene in the GAS 
chromosome [137]. Five patterns designated A to E are currently in use. An emm-pattern A-
C gene arrangement is generally considered to be associated with isolates from throat 
infections, while those from emm pattern D are related to skin infections. Isolates containing 
the emm pattern E arrangements of emm genes display an affinity for both tissues [137]. A 
large number of isolates from many geographic locations have been related to these 
associations [245]. 
The emm pattern is a genetic marker that distinguishes many throat and skin strains of GAS 
[245]. The emm pattern is defined by the chromosomal arrangements of emm subfamily 
genes. Plasminogen binding M protein encoded by emm gene is found to be uniquely 
associated with emm pattern D [246]. A study from Ethiopia has shown that there is strong 
association between strains isolated from throat and emm pattern A-C, but failed to show the 
association for the strains isolated from skin [247]. 
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3.7.1.3. Vir- typing 
Vir typing, another molecular typing method based on the restriction fragment length 
polymorphism (RFLP) of a PCR based amplified region of the 4-7 kb Vir regulon of GAS 
[248]. This locus encodes M and M related proteins and their positive regulator (the mga 
product)[249]. This method has been found to be discriminatory and is applicable to all 
isolates from diverse geographic origins [236].This method came into use, when there was 
more M non-typeable GAS isolates were identified from Northern Teritory of Australia. 
In a comparative study involving Vir typing, multi locus enzyme electrophoresis (MLEE), 
random amplification of polymorphic DNA (RAPD) and serological techniques, Vir typing 
was found to produce unambiquous and easily scorable restriction fragment length 
polymorphism (RFLP) patterns, easier to perform and interpret than other molecular typing 
techniques.Some VTs containisolates from more than one M type. Of the 15 isolates which 
belong to VT16, five were serotyped as M1, nine were serotyped as M55 and one was 
serotyped as M80 [250].  
 Multiple typing methods have been used in the characterization including M and T 
serotyping, antibiotic resistance typing, ribotyping, random amplification of polymorphic 
DNA, pulse field gel electrophoresis, restriction fragment length polymorphism, vir typing, 
emm sequence typing and multi locus sequence typing. Although all these methods have 
proven useful for the characterization of GAS isolates, phenotyping methods have declined 
in popularity and the mainstream methods are now emm sequence typing, pulse field gel 
electrophoresis and multi locus sequence typing.  
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3.7.1.4. Multi locus sequence typing 
Multi locus sequence typing (MLST) is a nucleotide based method that is well suited 
towards characterization of genetic relationship between the organisms of a bacterial 
species. Housekeeping genes are chosen for analysis because they are present in every 
organism and mutations within them are very neutral. Clones, defined as isolates that are 
descendants of a recent common ancestor, can be identified as having shared alleles at each 
of the housekeeping loci [251]. 
For MLST of GAS seven housekeeping loci‟s are used. MLST is a tool that can be used to 
study the molecular epidemiology and population genetic structure of microorganisms. 
MLST of 212 GAS isolates with 78 different emm types identified hundred unique 
combinations of allelic profiles [38]. 
Studies from Australia has revealed , most of the emm types observed among GAS isolates 
from an aboriginal island community were found in other parts of world, and few emm types 
were recovered within island community. The multi locus genotypes of isolates of the same 
emm type from different regions were different .This findings has implications for attempts 
to make global associations between emm type and certain disease manifestations [252]. 
Population genetic structure and phylogenetics are powerful tools. The site specific 
mutagenesis at codon under diversifying selection provides a rational approach for studying 
the effect of each adaptive change on the in vitro functional activity and immunogenicity of 
streptokinase. Isogenic mutants, generated by direct allelic replacement of the parental ska 
gene with an ska allele of another lineage can be used to measure biological properties of 
GAS [246]. 
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Two hundred and twelve GAS strains collected from 34 countries was used to characterize 
MRGAS (Macrolide Resistant Group A Streptococci). Twenty two MRGAS clonal 
complexes were recovered from more than one continent; intercontinental strain represented 
80% of the MRGAS of the study. The findings suggest that horizontal transfer of macrolide 
resistant clones and their descendants are both major components of the macrolide resistance 
problem found within species [36]. 
MLST for GAS has been reported from other parts of the world (Australia [252], United 
States [38], London [253], Germany [254], Nepal [125], and Norway[255]), but there are no 
reports from India, studying the population genetic structure of GAS. 
3.8. Treatment 
 
Empirical treatment of clinical pharyngitis using penicillins is a common in general practice. 
In case of penicillin allergy erythromycin or cephalexin is the drug of choice. Penicillin 
cannot be recommended in highly endemic situations, for several reasons. Firstly, oral 
antibiotics do not give as much coverage as benzathine penicillin, to patients who may later 
go on to develop RF/RHD due to lack of adequate antibiotic protection. Secondly, misuse of 
penicillin may pave way to increased penicillin tolerance. Thus scientifically, it is better to 
institute the treatment after confirming a GAS etiology which would reduce the unnecessary 
use of antibiotics for treatment of pharyngitis[256]. 
Erythromycin resistance has been reported as high as 70% GAS isolates in Japan and nearly 
50% of pharyngeal isolates in Finland. In Southern India during 1986-2002 the overall 
erythromycin resistance was 2.7%. All isolates were susceptible to penicillin[221]. 
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Treatment of rheumatic fever has three goals: eliminating any residual streptococcal 
infection; reducing inflammation, particularly in the joints and heart, and thus relieving 
symptoms; and limiting physical activity that might aggravate the inflamed structures. IN 
India the following guidelines are recommended for the management of rheumatic fever and 
rheumatic heart disease, they are as follows, (1) Streptococcal eradication with appropriate 
antibiotics (Benzathine penicillin single dose or penicillin V oral or azithromycin). (2) 
Diagnosis of rheumatic fever based on Jones criteria. (3) Control inflammatory process with 
aspirin with or without steroids (total duration of treatment of 12 weeks). (4) Treatment of 
chorea according to severity (therapy to continue for 2-3 weeks after clinical improvement). 
(5) Protocol for managing cardiac complication like valvular heart disease, congestive heart 
failure and atrial fibrillation. (6) Secondary prophylaxis with benzathine penicillin and 
management of anaphylaxis . 
3.9. Vaccines 
Research towards development of safe and efficacious vaccine against GAS infection is an 
ongoing and would be of major importance, especially in developing countries where the 
prevalence of rheumatic fever and post streptococcal glomerulonephritis are high causing a 
significant impact on public health. Different vaccine approaches include the M protein, 
C5apeptidase, cysteine protease, 26- multivalent vaccine, conserved C terminal region of M 
protein, putative proteins and surface markers such as fibronectin binding protein, group A 
carbohydrate protein antigen. They have been associated with reduced colonization and in 
some cases evoked protective immune response when tested in animal models. 
Most GAS vaccine strategies have focused on the surface M protein, a major virulence 
factor of GAS. Antibodies to the amino terminus of the M protein have been shown to be 
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opsonic and provide protection against challenge from homologous organisms, which 
indicate they are specific. Some of the M protein based vaccines are PepM24 vaccine, 
recombinant M5 protein fragment, passive administration of M protein-specific IgA 
antibody, conserved epitopes found in the carboxy terminal region of M protein, conserved 
region[257], protein peptides conjucated to cholera toxin B subunit[258], carboxy terminal 
region of M protein [259] in vaccinia virus and carboxy terminal region of M protein in 
Streptococcus gordoni [260]. 
 However, vaccine based on the M proteins face major problems. Since streptococcal 
sequelae are autoimmune type of disorders, molecular mimicry may play an important role 
in their pathogenesis, safety issues are major consideration in development of GAS vaccine. 
There are various drawbacks of the M protein based vaccines [261], namely, the amino 
terminus of the M protein is highly antigenically variable, there are more than 100 reference 
GAS emm types and an increasing number of which are not M serotypeable, large number of 
different M types circulating and by the dynamics in the epidemiology at a given geographic 
area, cross reaction with human tissues resulting in antibody response that cross react with 
human myosin. Moreover proper animal models and large scale clinical trials involving 
thousands of participants including children will be needed to assess both the safety and 
efficacy of GAS vaccines. 
The emm types of GAS, which causes invasive disease in the United States, is promising in 
terms of use of the 26-valent vaccine but there may be limitations with regard to global 
administration of this vaccine [262]. There is need for a GAS vaccine in both the developing 
and developed country, but the needs for the region differs. Understanding these needs and 
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difference in the epidemiology, as well as the molecular basis of GAS virulence, should 
promote further development. 
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4. SCOPE AND PLAN OF WORK 
As submitted to the university along with the application for the PhD programme, 
shown here as a university requirement in the thesis. 
4.1. Study Design 
Phase I: emm typing of GAS isolated from the community (school survey) and from 
clinical     cases (hospital isolates). 
Phase II: MLST of GAS from the community and clinical samples. 
Phase III: Determination of phylogeny of GAS isolates by comparing dendrograms based 
on emm types and STs 
 Phase IV: Clonality and allelic variations among GAS isolates by eBURST analysis  
Phase V: Determination of linkage disequilibrium among GAS isolates based on their STs.  
4.2. Research Questions 
 Do emm types of different groups of community GAS isolates differ from the clinical 
isolates in their distribution? 
 What are the MLST profiles of GAS isolates causing human infections and 
circulating in the community? 
 Do such patterns differ among community isolates and those causing invasive 
diseases? 
 Can the genetic heterogeneity of GAS isolates be better studied by genetic variations 
of the seven housekeeping genes? 
 Can MLST explain the variations seen among the GAS isolates circulating in an 
endemic community?  
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5. MATERIALS AND METHOD 
5.1. Sample collection 
GAS (GAS) isolates selected for this study included two groups:  
a) Those recovered from rural school children aged 5-11 years during an ongoing 
epidemiological project funded by Indian Council of Medical Research. These will be 
referred to as community isolates. 
b) Those recovered from patients seen in the outpatient departments of a tertiary care 
hospital of the Christian Medical College (CMCH). These will be referred to as clinical 
isolates 
5.1.1 Community isolates 
These were recovered from school children aged 5 to 11 years and attending a rural school 
situated 12 Kms from Vellore town. The GAS isolates included those recovered from 
children with clinical pharyngitis (Community Pharyngitis Isolates), those colonizing throat 
of normal healthy children (Normal Throat Isolates), those recovered from clinical impetigo 
(Impetigo Skin Isolates) and those colonizing normal skin (Skin Isolates). The isolates were 
identified as GAS by micro-nitrous acid extraction method, a co-agglutination technique 
standardized in our laboratory and using in-house prepared antisera. The GAS isolates were 
preserved by lyophilization and stored at +4
o
C until testing.   
5.1.2 Clinical isolates  
These included GAS isolates consisted of two groups.  
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a) Those recovered from throat cultures of patients with acute upper respiratory tract 
infections (Hospital Pharyngitis Isolates), seen at CMCH during  January 2002- 
October 2004  
b) Those recovered from patients with invasive GAS disease seen at CMCH. (Invasive 
isolates). Invasive isolates were defined as those isolates recovered from normally 
sterile body fluids and were isolated in our laboratory from January 2000- July 2007. 
All isolates were preserved in lyophilized vials and stored at +4
o
C until testing.  The 
clinical details of patients with invasive disease and acute pharyngitis were collected 
from their hospital charts. Their emm types were already available for comparison. 
 
5.2. emm typing of GAS isolates 
This was carried out by the technique devised by the Centers for Disease Control and Prevention 
(CDC), Atlanta, Georgia, USA and standardized in our Laboratory [32]. The method was as follows:   
5.2.1. DNA Extraction  
 With a loop fair amount of fresh growth was picked up, emulsified in 300 µl of 0.85% 
Sodium chloride and heated at 70°C for 15 minutes.  
 The samples were spun at 13,000 rpm for 2 minutes. 
 The pellet was re-suspended in 50 µl TE (10mM Tris, 1mM EDTA, pH8) containing 
300U/ml mutanolysin and 30µg/ml hyaluronidase (Sigma-Aldrich, Bangalore)  
 Incubated 37°C for 30 minutes and heated at 100°C for 10 minutes. 
 The lysates were Stored at -20°C until use.  
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5.2.2. DNA Amplification 
     The extracted DNA was amplified by PCR as follows. 
A 20µl of master mix was prepared as follows (TAQ PCR CORE KIT, Qiagen, Hilden, Germany) 
 
 Primer(forward)   -   0.4 µl (TATT (C/G) GCTTAGAAAATTAA) (Sigma-Aldrich, Bangalore) 
 Primer(reverse)    -   0.4 µl (GCAAGTTCTTCAGCTTGTTT) 
 10X buffer           -   2 µl containing 1.5mM MgCl2 
 d NTP                  -   0.4 µl 
 Taq polymerase   -  0.06 µl 
 Water (milliQ)     -  16.74µl 
0.5µl of template was added to 19.5µl of master mix. 
The  thermal cycler  conditions included initial denaturation  at 94°C for 1minute followed 
by 94°C for 15 seconds, 46.5°C for 30 seconds and  72°C for 1 minute 15 seconds repeated 
for 10 cycles and followed by the same conditions but with 10 seconds increment for 72°C 
for each of the subsequent  19 cycles. The amplicon was maintained at + 4°C. 
The emm amplicon was visualised by electrophoresis on a 1% agarose gel. Electrophoresis 
was carried out at 100 V for 50 minutes with an appropriate base pair marker. The quality 
and quantity of the amplified product was checked by visualization of the gels stained with 
10µg/ml ethidium bromide in a gel documentation system (BIO-RAD, California USA). The 
single band in range of 700 to 1200 base pairs shows that the amplified product is specific 
and pure. 
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5.2.3. emm amplicon sequencing 
5.2.3.1. Pres-sequencing clean up 
The emm amplicons were subjected to pre-purification by Millipore filtration technique 
(Millipore Corporation, Bedford, MA, USA) to remove unused dNTPs and primers. The following 
steps were followed. 
 The amplified product was made upto 100 µl using sterile distilled water. 
 The solution was then transferred to Millipore micrtiter plate and attached to the 
Millipore vacum manifold. 
 Vacum pressures was applied for approximately 10 minutes or until the well was 
dried. 
 One hundred microliters of sterile distilled water was added and the same process 
was repeated. 
 Twenty micrliters of sterile distilled water was added to the wells, mixed 25 times 
and the contents transferred back to PCR tubes. 
 Electrophoresis was done with 1% agarose gel in 0.5X Tris-borate buffer with EDTA 
(TBE buffer) for pre-purified product to confirm purity of emm amplicon. 
5.2.3.2. Sequencing Reaction 
Prepare 10 µl reaction mix as follows, 
 RR mix    -  2µl  
 Buffer -  2µl 
 Primer   - 1.6µl (TAT TCG CTT AGA AAA TTA AAA ACAG) 
 Template     - 2µl 
 Distilled water  - 2.4µl     
  The PCR parameters were as follows: 
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 96 °C for 15 seconds 
 96 °C for 20 seconds 
 50 °C for 20 seconds 
 60 °C for 4 minutes 
 72°C for 10 minutes    
5.2.3.3. Post-sequencing clean up 
The sequencing PCR products were then purified by membrane filtration technique kit 
(Millipore Corporation, Bedford, MA, USA).The following steps were carried out for post cycle- 
sequencing clean up procedure. 
 The total volume of the amplicon was made up to 40 µl with injection solution and 
transferred to the Millipore micro titer plates in the vacuum manifold. 
 Vacuum pressure was applied to the plates until the plates are dry. 
 Forty micro liters of injection solution was added to the wells and the vacum 
process was repeated. 
 Thirty micro liter injection solution was added, the contents were mixed well by 
pipetting 25 times and transferred to tubes for sequencing. 
The sequencing was done with the Big Dye terminator Kit in an ABI PRISM 310 automated 
sequencer (Applied Biosystems, Warrington, UK).  
5.2.4. Assigning emm types 
The chromatogram and the text sequences obtained were edited and the sequences were 
blasted to assign a type and subtype and the type specific database with at least the first 240 
bases obtained with primer emmseq2 (www.cdc.gov/ncidod/biotech/strep/strepblast.html). 
24 Cycles 
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More than 95% homology with type specific 150 bases of the standard reference sequence 
gives the designated emm type of the test strain. If homology is not 95%, it was compared 
with most similar emm types and if new, the sequence traces were submitted for 
confirmation. New types were identified by the curator of this site, Dr. Bernard Beall, at 
Centers for Disease Control and Prevention (CDC), Atlanta (bbeall@cdc.gov) on the basis of 
sharing less than 92% sequence identity over the first 90 bases encoding the deduced 
processed M protein of the emm type reference strain.  
For the subtype assignment, database of trimmed 180 base entries corresponded to the first 
50 residues of the mature M protein and the adjacent 10 C terminal residues of the signal 
sequence. If a perfect 180/180 match was obtained to an entry from the type-specific 
BLAST option, the subtype was reported to be correctly identified. If a perfect match to 
bases 31-180 is combined with 3 or fewer mismatches to bases 1-30 was found, this also 
indicated identification of the specific subtype. If there was any mutation in the DNA 
sequence corresponding to the first 50 residues of the mature M protein, it was considered as 
a new subtype. 
5.3. Multi Locus Sequence Typing Protocol 
Multi locus sequence typing is a nucleotide sequence method where in seven housekeeping 
loci are chosen for characterization of GAS [38]. They are internal fragments of the 
following enzymes whose primers (Sigma-Aldrich, Bangalore) are also given below. 
1. Glucose kinase (gki) 
 gki-up  GGCATTGGAATGGGATCACC 
 gki-dn    TCTCCTGCTGCTGACAC 
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2. Glutamine transporter protein (gtr) 
 gtr-up  GAGGTTGTGGTGATTATTGG 
 gtr-dn  GCAAAGCCCATTTCATGAGTC 
3. Glutamate racemase (murI) 
 murI-up TGCTGACTCAAAATGTTAAAATGATTG 
 murI-dn GATGATAATTCACCGTTAATGTCAAAATAG 
4. DNA mismatch repair protein (mutS) 
 mutS-up GAAGAGTCATCTAGTTTAGAATACGAT 
 mutS-dn AGAGAGTTGTCACTTGCGCGTTTGATTGCT 
5. Transketolase (recP) 
 recP-up GCAAATTCTGGACACCCAGG 
 recP-dn CTTTCACAAGGATATGTTGCC 
6. Xanthine phosphoribosyl transferase (xpt) 
 xpt-up  TTACTTGAAGAACGCATCTTA 
 xpt-dn  ATGAGGTCACTTCAATGCCC 
7. Acetyl-coA acetyl transferase  (Yqil)   
 yiqL-up TGCAACAGTATGGACTGACCAGAGAACAAGATGC 
 yiqL-dn CAAGGTCTCGTGAAACCGCTAAAGCCTGAG 
 
5.3.1. DNA Extraction for MLST GAS isolates :( QIAamp DNA BLOOD mini kit, Qiagen, Hilden 
Germany) 
This was done using a commercial kit (QIAamp DNA BLOOD mini kit, Qiagen, Hilden Germany) 
and was briefly as follows:   
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 Inoculated the test GAS strain into 8 ml Todd-Hewitt broth in a 15 ml tube and 
incubated overnight at 37°C. 
 Pelleted the broth culture by centrifugation 
 20mg/ml lysozyme was added to the enzymatic lysis buffer.  
 Re-suspended the pellet in 180 µl of enzymatic lysis buffer and incubated for 60 
minutes at 37°C  
 Added 25 µl of proteinase K, 200 µl of buffer AL and vortexed for 5 seconds.  
 Incubated at 70°C for 30 minutes.  
 Added 200 µl of ethanol (95%) and vortexed for 5 seconds.  
 Pipetted the mixture into a column provided in the kit (QIAamp spin columns) and 
centrifuged for 2 minutes at 10,000rpm; centrifugation was repeated to remove the 
liquid  completely form the column. 
 Discard the collection tube with the flow through.  
 Place the column in a new collection tube; add 500 µl of buffer AW1 and       
centrifuged for 1minute at 10,000rpm and discarded the collection tube.  
 Placed column in a new collection tube, added 500 µl of buffer AW2 and centrifuged 
for 3 minutes at 13,000 rpm.  
 Discarded the collection tube.  
 Placed the column in a 1.5ml micro-centrifuge tube, added 200 µl of buffer AE, 
waited for 1 minute and centrifuged for 1 minute at 10,000 rpm.  
 Repeated the previous step and discarded the column.  
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5.3.2. DNA Amplification 
The extracted DNA was amplified by PCR as given below. 
50 µl of master mix was prepared using a commercial kit (TAQ PCR CORE KIT, Qiagen, 
Germany, Hilden) . 
 Primer(forward)  - 1 µl  
 Primer(reverse)  - 1 µl 
 10X buffer  - 5 µl  
 dNTP   - 5 µl 
 Mgcl2   - 5 µl  
 Taq polymerase  - 0.46 µl 
  Water (milliQ)  - 32 µl  
To 49 µl of master mix added 1 µl of template. 
The PCR parameters were as follows 
 95°C for 5minutes 
 95°C for 1minute 
 55°C for 1minute 
 72°C for 1minute     
 72°C for 5minute 
The PCR products were checked for amplification by electrophoresis on 1% agarose gel. 
Electrophoresis was carried out at 100 V for 45 minutes. The quality and quantity of the 
amplified products were checked by visualization of the 10µg/ml ethidium bromide stained 
bands in a gel documentation system (BIO-RAD, California, USA). 
28  
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The amplified products were pre-purified and checked for purity by gel electrophoresis. The 
sequence of each fragment was obtained using the respective primers used in the initial 
amplification. 
 
5.3.3. Assigning Sequence types (ST) 
The forward and reverse sequences generated were compared aligned, analyzed, edited, and 
trimmed exactly to the respective allele. The size of the amplicon for different loci used for 
assigning alleles for Glucose kinase (gki), Glutamine transporter protein (gtr), Glutamate 
racemase (murI), DNA mismatch repair protein (mutS), Transketolase (recP), Xanthine 
phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase (Yqil) are 498, 450 ,438 405, 
459, 450 and 434 base pairs respectively. 
The single locus query or multiple locus options at http://spyogenes.mlst.net determines an 
allele number for each sequence trimmed and pasted for all seven loci of a test strain into the 
corresponding boxes. The software checks for correct length of sequence for respective 
locus. The sequence of each fragments are compared with all the previously identified 
sequences (alleles) at that locus. If the sequence corresponds to the known allele, an allele 
number is given to the sequence. If the sequence is a new allele it should be compared with 
the most similar allele for that locus to check for nucleotide differences and if new, the 
sequence traces (forward and reverse) should be submitted to the database curator Mr Daniel 
Godoy, (d.godoy@imperial.ac.uk) Research Technician, Division of Epidemiology, Public 
Health and Primary Care, Imperial College, London. The curator will check the sequence 
trace, provide a new allele number and add the new allele to the database. The combination 
of the seven allele number forms the allelic profile of the strain and each different allelic 
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profile is assigned as a sequence type (ST).The MLST databases are hosted on two web 
servers located at Imperial College London (http://www.mlst.net) and Oxford University 
(http://pubmlst.org). 
5.4. eBURST (Based upon related sequence types)  Analysis 
BURST was devised and developed by Ed Feil [263], to determine the relationship between 
closely related isolates of a bacterial species or population. BURST explains the 
evolutionary relationship among closely related genotypes in a simple manner and predicts 
the founding genotype of each group. It displays a radial diagram with the predicted founder 
centered. eBURST was developed to analyse the multi locus sequence typing data and 
integrated in the MLST website by David Aanensen. The MLST data used by eBURST are 
the STs and their associated allelic profiles. 
 The assignment of clonal complexes and clonal variants from the allelic profile can be 
carried out using an algorithm called BURST (Based upon related sequence types) 
(http://eburst.mlst.net/). eBURST uses the sequence types (STs) and their associated allelic 
profiles as input data. To identify groups of related STs, the most conservative definition 
where all members assigned the same group share identical alleles at ≥ 6 of the 7 loci with at 
least one another member of the group. A group is used as a neutral term for the collection 
of sequence types that are clubbed together by eBURST. A clonal complex is a set of STs 
that are descended from the same founding genotype (6/7 shared alleles) and differ from the 
founding genotype or predicted founder by a single loci. This approach results in non-
overlapping groups that is no ST can be assigned to more than one group. The predicted 
primary founder of the group is defined as the ST that differs from the other STs by only a 
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single locus. If they differ from one another by single loci, they are single locus variant 
(SLV) and if they differ by two locus they are known as double locus variant 
(DLV).BURST does not make any inference about the relationship between distantly related 
genotypes that belong to different groups. 
eBURST uses statistical support and bootstrapping procedure to provide the level of 
confidence in the assignment of primary founder in each group. The bootstrap values are 
only available using the stringent group definition where all members assigned the same 
group share identical alleles at ≥ 6 of the 7 loci. The bootstrap value shown for each ST is 
the percentage of times the ST was predicted to be the primary founder of the group. The 
bootstrap values for a ST may differ when one of the ST is used, compared to when all 
isolates are included, since the STs represented in each re-sampling will be influenced by the 
frequencies of the STs in the database. The population snapshot (whole MLST data) can be 
acquired by relaxing the definition from 6/7 to 0/7.This will arrange the whole input data 
into a single eBURST group and will display all the clusters of STs and unlinked individual 
STs as a single BURST diagram, this display is called “Population snapshot”. The linked 
clusters within this population snap shot represents clonal complexes and the primary 
founders and the sub founders of these linked clusters are colored blue and yellow dots 
respectively. Each black dot represents an ST and the size of the dot reflects the number of 
GAS isolates in each ST. 
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5.5. Construction of phylogenetic tree based on emm types 
The Phylogenetic tree was constructed by using MEGA-4  [264]. The evolutionary distances 
were computed using the Maximum Composite Likelihood method. 500 base pairs of 
representative 49 emm types subjected to multi locus sequence typing from the community 
and the hospital GAS isolates were used to construct the phylogenetic tree. 
5.6. Construction of phylogenetic tree based on Sequence Types (ST).  
 Phylogenic tree based on the STs of MLST was constructed using the concatenated 
sequence of the ST. Concatenated sequence was obtained by fusing all the seven loci‟s from 
the allelic profile. The concatenated sequences formed were of 3,314 base pairs. The 
evolutionary history was inferred using the Neighbor-Joining method. The evolutionary 
distances were computed using the Maximum Composite Likelihood method and are in the 
units of the number .The tree was constructed by using MEGA4 [264, 265].  
5.7. Linkage disequilibrium 
The detection of significant level of linkage disequilibrium may indicate that recombination 
has not been sufficiently frequent to randomize the association between alleles. The level of 
linkage disequilibrium can be calculated from the distribution of allelic mismatches between 
all GAS isolates (the number of difference in the allelic profile).The observed variation in 
the mismatches of alleles, Vo is compared with the expected variance VE. A useful measure is 
the index of association (IA) 
IA = (VO / VE) -1 
Observed variance (VO) 
Expected variance (V E) 
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Index of association will not be significantly different from zero since VO and VE should be 
approximately the same in a population with linkage equilibrium.  
The Linkage disequilibrium program (http://linux.mlst.net/link_dis/index.htm) analyses 
whether the alleles at different loci within a population of bacteria are randomly associated 
(in linkage equilibrium), or whether there is a significant association between the alleles at 
different loci (linkage disequilibrium) [266]. The sequence types of each strain and the 
allelic profiles is cut and pasted into the window provided. The observed variance in the 
distribution of allelic mismatches in all pair-wise comparisons of the allelic profiles is 
computed and is compared to that expected in a freely recombining population (linkage 
equilibrium). This is implemented by computing the maximum variance obtained using 20, 
100 or 1000 randomizations of the data set.  Significant linkage disequilibrium is established 
if the observed variance, obtained with the real data set, is greater than the maximum 
variance observed with any of the randomized data sets with p values of 0.05, 0.01 or 0.001 
when the observed variance is greater than that found in any of 20, 100 or 1000 randomized 
data sets, respectively.  If the observed variance is less than that obtained with the 
randomized data sets there is no evidence of a departure from linkage equilibrium. 
 
5.8. Maximum nucleotide sequence identity 
Maximum nucleotide sequence identity among allelic variants of diverse STs having the 
same emm type(s) were carried out by clustal W   (http://www.ebi.ac.uk/Tools/clustalw/) 
[267].Sequence alignment is a way of arranging the sequences of DNA to identify regions of 
similarity that may be a consequence of functional, structural, or evolutionary relationships 
between the sequences. Aligned sequences of nucleotide or amino acid residues are typically 
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represented as rows within a matrix. Gaps are inserted between the residues so that identical 
or similar characters are aligned in successive columns. 
If two sequences in an alignment share a common ancestor, mismatches can be interpreted 
as point mutations and gaps insertion or deletion mutations introduced in one or both 
lineages in the time since they diverged from one another.  
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RESULTS 
6.1. Selection of GAS isolates for emm typing 
6.1.1. Community isolates 
A total of 319 GAS isolates recovered from cases of pharyngitis (n = 101), impetigo (n = 
65), throat cultures of normal healthy children (n = 113) and skin cultures of normal healthy 
children (n = 40) were selected for emm typing. These were recovered from rural school 
children during an epidemiological study conducted from 2000 – 2002.  
6.1.2. Clinical isolates 
Ninety Nine GAS isolates from clinical sources were subjected to emm typing. These 
included isolates from hospital diagnosed acute pharyngitis (n=41) and invasive isolates 
(n=58) that includes isolates from blood (n=35), peritoneal fluid (n=7), CSF (n=5), pleural 
fluid (n=5), fluid from necrotizing fasciitis (n=2) and cellulitis (n=1), bile, synovial fluid 
and fluid from retained placenta (n=1) each.  
6.2. Distribution of emm type among community GAS strains 
Three hundred and nineteen GAS isolates from the school survey were subjected to emm 
typing (Table.1). A total of 73 emm types were identified among them, of which 17 were 
sequence types and two were hitherto unrecognized types. Sixteen types accounted for 166 
GAS isolates (52%) and these included 112, 11, 82, 100, 63, 93, 85, 105, 108, 49.4, 110, 
113, 1, 44, 66 and 111. 
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The most predominant emm type was emm type 112 which accounted for 29 (9 %) of the 
GAS isolates and was found predominantly in normal throat (n=18) and impetigo skin (n= 
8)  
 6.2.1. Distribution of emm types among Community associated Pharyngitis GAS isolates  
Forty five emm types were identified among 101 community pharyngitis GAS isolates (Fig 
1). Twelve emm types namely 11, 110, 108, 63, 85,1,55,58,74,18 and 92 accounted for 53 
(52.4%) of the 101 isolates. Type 11 was the most predominant (n=9) followed by type 110 
(n=8) which was found only among pharyngitis isolates. Type 112, the most predominant 
type among all community GAS isolates, accounted only for 0.9% from the community 
associated pharyngitis. Types 1 and 3, the commonest invasive types accounted for only 4 
isolates (3.96%).  
6.2.2. Distribution of emm types among normal throat carriers 
Among 113 GAS isolates from normal throat, 47 emm types were identified (Fig. 2).  
Predominant types including 112 (n=18), 66, 105(n=5 each) and   11, 49.4, 82, 113 and 
111(n=4 each) accounted for 48 (42%) of the 113 Isolates. Type 112 (n=18) was the most 
predominant emm type while two new types, stKNB3 (n=2) and stKNB8 (n=1) are two new 
emm types accounted for 2.6% of GAS isolates. 
6.2.3. Distribution of emm types among GAS isolates causing impetigo  
Among 65 GAS isolates causing impetigo, there were 35 emm types out of which, three 
types namely 112, 100, 93 and 44 accounted for 21 (32.3%) of 65 isolates (Fig. 3) . Type 
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112 was the most predominant type accounting for 12% of the GAS isolates while type 1 
accounted only for 1.5%. 
6.2.4. Distribution of emm type among normal skin 
Twenty five emm types were identified among forty GAS isolates.The predominant emm 
types colonizing skin included 93 (n=4), 36 and 44 (n=3 each) which together accounted for 
25% of the 40 isolates (Fig. 4).   
6.3. Distribution of emm types among Hospital GAS isolates 
Ninety nine non repetitive GAS isolates from diverse clinical specimens were subjected to 
emm typing. These included isolates from cases of acute pharyngitis (n=41) and invasive 
isolates (n=58). Invasive GAS isolates were recovered from cases of sepsis (n=13), 
meningitis (n=9), peritonitis (n=8) ,cellulitis (n=5) , pneumonia (n=5), necrotizing fasciitis 
(n=3) and umbilical infection(n=3), arthritis(n=2) ,puerperal sepsis(n=1) ,retained 
placenta(n=1) ,empyema (n=1) ,endocarditis(n=1),gangrene(n=1) ,pleural effusion(n=1), 
septic arthritis(n=1) ,urogenital(n=1 ). 
 6.3.1. Distribution of emm types among GAS causing acute pharyngitis in patients seen 
in the hospital (Hospital Pharyngitis) 
Thirty emm types were identified among 41 GAS isolates from cases of hospital pharyngitis. 
Types 75 (n=4), 77 and 55 (n=3each) accounted for 10 (24.3%) of 41 isolates (Fig. 5). 
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6.3.2. Distribution of emm types among invasive GAS isolates 
A total of 37 emm types were identified among 58 invasive GAS isolates (Fig 6).  Five 
types, namely, 110 (n=4), 63, 74, 85 and st854.1 (n=3each) accounted for 16 (27.5%) of 58 
isolates Two new emm types, stKNB6 and stKNB9 (n = 1 each) were identified from 
invasive GAS isolates. Types 1and 3 were conspicuously absent.  
6.3.3. Comparison of emm types associated with community and Hospital pharyngitis 
Table 2 gives the distribution of 12 most predominant emm types of 101 community 
pharyngitis GAS isolates among hospital pharyngitis GAS isolates. Five types namely, 11, 
63, 85, 1 and 55 were identified among 41 hospital pharyngitis isolates, accounting for 7 
(17.1%) of the isolates.  Type 55 was the only type that was seen among both groups as a 
predominant type.  
6.3.4. Distribution of Invasive emm types among Community and Hospital Pharyngeal 
GAS isolates 
The distribution of predominant emm types associated with invasive diseases among 
community and hospital pharyngitis GAS isolates is given in Table 3. The 15 emm types 
that accounted for 62% of the invasive isolates, 9 types were found among community 
isolates while only 3 types were found among hospital isolates. Types 63, 85 and 93were 
identified among all three groups.  
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6.4. Multi locus sequence typing (MLST) of GAS isolates. 
A total of one hundred and forty three GAS isolates were subjected to multi locus sequence 
typing. Out of the 143 GAS isolates, seventy three GAS isolates were selected from the 
dominant emm types from the community which includes cases of pharyngitis, normal 
throat, impetigo and normal skin. The rest of the seventy GAS isolates selected for multi 
locus sequence typing were identified and isolated from hospital. This included twenty GAS 
isolates from hospital pharyngitis and fifty GAS isolates from invasive cases and sterile 
body fluids.  
6.4.1. Community Pharyngitis GAS isolates selected for MLST 
Seventy three GAS isolates representing 23 predominant emm types identified among 319 
GAS isolates were subjected to MLST (Table 4). These included pharyngeal isolates (n = 
21), normal throat isolates (n = 22), impetigo isolates (n = 18) and normal skin isolates (n = 
12). These 23 types accounted for 214 (67.1%) of the 319 isolates.   
6.4.2. Hospital Pharyngitis GAS isolates selected for MLST 
A total of 20 pharyngeal GAS isolates representing 18 predominant emm types seen among 
20 pharyngeal isolates were selected for MLST.  
 
6.4.3. Invasive GAS isolates for MLST 
Fifty invasive GAS isolates including those blood (n = 32) and fluids (n=18) were subjected 
to MLST. The latter included CSF (n=5), Peritoneal fluid (n=6), Pleural fluid (n= 4), 
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Synovial fluid (n=1), Bile (n=1) and aspirate from necrotizing fasciitis (n = 1).   These 
isolates accounted for 31 emm types.  
6.5. Distribution of Sequence Types (STs) among GAS isolates 
Table 5 gives the distribution of STs among 143 GAS isolates that were subjected to MLST. 
The sequence types are arranged chronologically. A total 93 STs were identified among 
them; of thes25 were known sequence types and 68 (73.1%) were new sequence types 
(Table 6). The new alleles and allelic profiles were submitted to the Curator Mr Daniel 
Godoy, (d.godoy@imperial.ac.uk) Research Technician, Division of Epidemiology, Public 
Health and Primary Care, Imperial College, London who designated them as new types. 
6.5.1. Distribution of STs among Community Pharyngeal GAS Isolates            
Twenty STs were identified among 21 pharyngeal GAS isolates (Table. 7); fifteen of these 
sequence types were new types. ST 499 was seen in two isolates of emm type 113.  
6.5.2. Distribution of STs among Community Normal Throat Isolates 
Twenty two STs were identified among 22 GAS isolates indicating that all isolates were 
genetically different (Table.8). Fourteen of the 20 types were new types.         
6.5.3. Genetic relatedness and diversity among emm types of GAS isolates from cases of 
pharyngitis and normal throat from the community 
Seven emm types identified among pharyngitis and normal throat GAS isolates had the same 
MLST sequences (Table .9); however 8 same emm types found in the two groups had 
different ST (Table .10).  
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6.5.4 Distribution of STs among Impetigo Isolates 
Seventeen STs were identified among 18 GAS isolates from impetigo. Only one type, ST 
100, was identified in two different emm types, ie.55 and 92. (Table.11). Seven types were 
new types. 
 
6.5.5 Genetic relatedness and diversity among emm types of GAS isolates from cases of 
Impetigo and normal throat 
Seven emm types found in both groups had the same ST while 8 types seen in both groups 
had different STs. (Tables 12 & 13). 
6.5.6. Distribution of STs among Normal Skin Isolates 
All 12 GAS isolates from normal skin belonged to 12 different STs (Table.14). Eight of 
them were new sequence types. Four emm types had the same ST as that identified in 
impetigo isolates while 5 had different STs.  
6.6. Distribution of Sequence types for Hospital Pharyngitis GAS isolates  
A total of 19 STs were identified among 20 GAS isolates (Table 15). Two emm types, 1 and 
12 had the same ST 36.  Eight new allelic profiles were identified which were assigned new 
sequence types, 471,479,482,483,485,501,508,510.  
6.8. Distribution of STs among Invasive GAS Isolates 
Forty-five ST types were identified among 50 invasive GAS isolates (Tables 16 & 17).  
There were 31 STs among 32 blood isolates representing 25 emm types (Table 16). Two 
blood isolates with emm type 85 had the same ST 484. On the other hand, three blood 
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isolates of emm type 110 had three different STs namely 522, 493 and 494. Similarly two 
blood isolates of emm type 74 had two different STs, 480 and 520. Thus, multiple isolates of 
emm types 74, 85, 86, 100, 110, and st6735   had all different STs.  
Among isolates from other various body fluids, 17 STs were identified from as many emm 
types (Table 17). Nine of them were new types. Two peritoneal fluid isolates with the same 
emm type, st854.1 had the same ST, 224.  Moreover, one CSF isolate with emm type 74 had 
a ST 480 while one peritoneal fluid isolate with the same emm type also had the ST.                
 
6.7. Comparison of ST’s of same emm types identified among community and hospital 
pharyngitis GAS isolates 
Of 26 emm types from hospital and community pharyngitis GAS isolates only few had the 
same sequence types. These were emm types 55, 77, 93, stNS554 and 63 with sequence 
types 100, 482, 10,510and 338 respectively (Table.18).  
6.8. Distribution of different emm types with same ST 
Of the ninety three STs identified in this study, four were shared by more than one emm type 
(Table.19). Such STs are known as emm variable sequence types. There was no association 
between the STs and the sites from where the GAS was isolated (Table 20).                
Pair wise comparison of emm types sharing the same STs were done using clustal W 
(http://www.ebi.ac.uk/Tools/clustalw/). The maximum nucleotide identity was identified as 
follows,( ST 36) emm type 1 and 12 had a percentage identity of 50.47%, (ST100) emm55 
and 92 had percentage identity of 53.42%, (ST 357) had % identity of 56.73% and (ST477) 
emm 44and 113 had percentage identity of 62.96%.                
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Twenty five of the 49 emm types subjected to MLST had more than one identifiable STs 
(Table 21) .Thirteen of them had >2 identifiable STs; of these, emm type 110 and 49.4 had 
five ST‟s identified among them. No association was found between the emm types and their 
STs with their site of isolation (Table.21). 
6.10 Allelic variations of different sequence types within same emm type 
6.10.1. Allelic variations in emm type 1 
Type 1 with four ST‟s showed allelic variations with respect to all seven housekeeping 
genes (Table 22).  All were multi locus variants.  
6.10.2. Allelic variations in emm type 12 
emm type 12 had three different allelic profiles (Table.23) , they are ST 28,36,472. ST 36 
which was found in emm type 1was also found in emm type 12.ST 28‟s allelic profile was 
entirely different from ST 36 and 472. The allelic profile ST 472 and 36 differs at the loci 
gki and mutS. 
6.10.3. Allelic variations in emm type 18 
Type 18 with four ST‟s showed both single locus variant (SLV) and double locus variant 
(DLV). The STs 523, 526 and 535 were all SLV‟s with respect to gtr or gki while ST 120 
showed variations with respect to five loci (Table 24).    
6.10.4. Allelic variations in emm type 44 
ST 178,351,476and 477 were the sequence types of emm type 44 (Table.25) .The allelic 
profile of ST 477 showed variation with rest of the STs at all the loci except  xpt.  The 
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allelic profiles of ST 178 and 351 differed at gki, while the allelic profile of ST 178 and 476 
differed only at Yqil.  
6.10.5. Allelic variations in emm type 49.4 
This type had five ST‟s identified among the various isolates from six different sources 
(Table 26). ST 228 and 478 were single locus variants with respect to gtr; STs 529, 531 and 
534 were also single locus variants between them, with respect to gtr; but they were double 
locus variant with STs 228 and 478 with respect to gtr and muts.  
 
6.10.6. Allelic variations in emm type 85 
The allelic profile of STs of emm type 85 (Table.27) showed variation at the loci gki, gtr 
and yqil. The STs 484,514 and 525 in comparison with ST 109 are single locus variant. ST 
484 differs from allelic profile of ST 109 at the locus gtr. The other two STs 514 and 525 
differ from ST 109 at the locus yqil and gki respectively. 
6.10.7. Allelic variations in emm type 92 
emm type 92 (Table.28) has three different STs , they are ST 100, ST485 and ST 524. ST 
100 has an entirely different allelic profile compared to ST 485 and ST 524. ST 485 has an 
allelic variation at gki and mutS when compared with the allelic profile of ST 524.   
   
6.10.8. Allelic variations in emm type 100 
The STs of emm type 100 (Table.29) differs at the loci gtr, recp and gki. ST 486 and 487 are 
single locus variants of ST100 and differ at the loci gki. The ST 488 differs from ST 100 at 
the loci gki and recp, ST 488 is a double locus variant (DLV) of ST 100. 
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6.10.9. Allelic variations in emm type 105 
emm type 105 (Table.30) had four allelic profiles which varied from one another at the loci 
gki, gtr and xpt . ST 151 differs from ST 490, ST 491 and ST 492 at the locus gtr ,xpt and 
gki respectively. ST 490,491 and 492 were single locus variants (SLV) of ST 151.   
6.10.10. Allelic variations in emm type 108 
ST 357,527and 533 were the STs found among emm type 108 (Table.31) .The  allelic 
profile of ST 357 differed from other STs at all loci, Whereas the ST 527 and 533 showed 
variation at murI and mutS.  
6.10.11. Allelic variations in emm type 110 
The allelic profiles of different sequence types within the same emm type were analyzed to 
determine the extent of variations in the loci with respect to their source of isolation (Table 
32). The emm type 110 isolated from blood showed single locus variations (SLV). Type 110 
with ST 493 and 494, both isolated from blood cultures, was different only with respect to 
one locus, ie. gtr. Thus these two were SLV‟s. The third blood culture isolate with ST 522 
was also a SLV with respect to the other two blood culture isolates, but with respect to the 
locus, yqil.  Type 110 from community pharyngitis with ST 495, and the bile isolate with ST 
515 were also SLVs with respect to gtr, but a double locus variant with respect to the blood 
culture isolates.   
 
6.10.12 Allelic variations in emm type 113 
emm type 113 had three sequence types ,they were ST 477,499 and 500 (Table.33) . ST477 
and 499 had allelic variation at the locus yqil, while ST 500 differs from ST 477at the loci 
recp. 
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6.11. Maximum nucleotide identity of same emm types with different allelic profiles 
The different allelic profiles within same emm type were checked for Maximum nucleotide 
identity using Clustal W(http://www.ebi.ac.uk/Tools/clustalw/). The emm types having more 
than one sequence type were emm1 (ST15, ST36, ST469, ST530), emm12 (ST28, ST36, 
ST472), emm18 (ST120, ST523, ST526, ST535), emm44 (ST178, ST351, ST476, ST477), 
emm49.4 (ST228, ST478, ST529, ST531, ST534), emm85 (ST109, ST484, ST514, ST525), 
emm92 (ST100, ST485, ST524), emm100 (ST119, ST486, ST487, ST488), emm105 (ST151, 
ST490, ST491, ST492), emm108 (ST357, ST527, ST533), emm110 (ST493, ST494, ST515, 
ST522), emm113 (ST477, ST499, ST500). All the emm types showed a maximum 
nucleotide identity of 99% (Table 34 – 45) within their sequence types except emm108 
which showed 98%. emm 108 showed 98% (Table 43) nucleotide identity with ST527 & 
ST533 with respect to ST357 whereas ST527 & ST533 had nucleotide identity of 99%. The 
sequence types within the emm types which showed 99% similarity varied from each other 
by 5 – 9 nucleotides. Figure 7 shows the multiple sequence alignment of the different 
sequence types of emm1.  
6.12. Population snapshot by eBURST of GAS isolates 
The BURST (Based Upon Related Sequence Types) identifies mutually exclusive groups of 
related genotypes in the population and identifies the founding genotype of each group. 
Figure 8 gives the eBURST population snap shot of 93 sequence types from 143 GAS 
isolates, for which MLST was carried out. The most stringent definition of an eBURST 
group is that all ST‟s assigned in the same group must share alleles at least six of the seven 
house- keeping loci with at least one other in ST in the group. This identified clusters of 
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closely related genotypes that are considered to have descended from the same founder and 
are defined as a clonal complex. Based on this definition, there were 19 groups with eight 
groups having predicted founders and the remaining groups did not have predicted founders. 
There were 41 singletons. In the figure 8 „the groups‟ are represented by black lines 
connecting the sequence types within groups. Out of the eight groups two groups had 
multiple sequence type as predicted founder within the group while the other six groups had 
single predicted founder, they are 534, 109, 120, 477, 119 and 535. The snap shot of 
BURST shows two clonal complexes with predicted founder ST 109 and ST 534 as the 
founder supported by bootstrap value showing more than 60% and is highlighted in blue 
dots. 
 
Group 1 clonal complex had ST 534 (fig.9a) as predicted founder with a bootstrap value of 
70% represented as a blue dot. The clonal complex consisted of ST 534 ST 228, ST517, 
ST531, ST529 and ST478. ST 534 had 4 single locus variant (SLV) and 1 double locus 
variant (DLV).The SLVs are represented as a pink line and DLVs are represented as blue 
line in the figure 9a.The four SLVs were ST 228, ST517, ST531 and ST529. ST 478 was 
the DLV of ST 534. In group 1 ST 534 the predicted founder had 4SLVs, while ST228, 
ST517, ST531, ST529 and ST478 had 3, 2, 2,2and 1SLVs respectively within the group. 
The STs of Group 1 clonal complex belongs to emm type 49.4 except ST 517 which belongs 
to stKNB6 which is a newly identified emm type.  
Group 2 clonal complex (fig.9b) had ST 109 as predicted founder with bootstrap value 
61%.The clonal complex was made up of five sequence types, they were ST 109, ST525, 
ST484, ST514 and ST528.ST 109 had three SLV and one DLV. The SLVs of ST 109 were 
ST 525, ST484 and ST514. In group 2 the ST 109 had 3SLV, ST525-2SLV, ST484, 514,528 
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had one SLV each. The STs in clonal complex with predicted founder 109 belongs to emm 
type 85 except ST528 which belongs to emm 55. 
The group 3 clonal complex had multiple candidates as predicted founder and had bootstrap 
value 33%. The complex consisted of ST151, ST491, ST492 and ST490. The STs in this 
complex belongs to emm type 105. The rest of the groups had bootstrap value less than 
50%.Group 4 clonal complex had ST120 as predicted founder with ST480 and ST520. The 
STs in this group belongs to emm 74 except ST120 which belongs to emm 18.               
  
ST477, ST499and ST500 forms group 5 clonal complex with ST 477 as predicted founder 
.ST 477 falls under emm type 44 while ST499 and ST 500 belongs to emm 113.The  sixth 
clonal group comprised of ST119, ST487 and ST486 and belong to emm 100 with predicted 
founder as 119. The seventh group of clonal complex had ST 535,526 and ST523 with the 
predicted founder ST535and belong to emm 18.The group eight had three sequence types 
and has multiple predicted founder.ST494, ST493 and ST522 forms the clonal complex of 
group 8 and belong to emm 110. All of these STs within group 8 differ from each other by 
SLV. 
Figure 10 describes the single locus variants (SLV) found among the 93 sequence types of 
143 GAS isolates. The SLVs are found only in the 19 groups created using the standard 
eBurst definition. SLVs are those which differ at one locus. The pink line indicates the SLVs 
found within the 19 groups. All the STs present in the 19 groups are SLV.  There are 
singletons, which do not form the clonal groups in which the SLVs are absent.  
Figure 11 depicts the double locus variant in the population snapshot of 143 GAS isolates 
with 93 sequence types. The sequence types which differ at two loci‟s are known as double 
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locus variant (DLV), they are represented as blue line in the eBURST population snap shot. 
The DLVs are found only in few groups. All the sequence types found in the groups do not 
differ from each other by double loci. DLVs were also found in singletons which don‟t form 
clonal complexes. The DLVs can be found between two singletons, between singleton and 
group and between groups. ST 503 and ST518 were singletons which differ from each other 
by DLV.ST 503 and ST518 belongs to emm 86.2. ST493, 494,522 which forms group 8 has 
DLVs with group 12 (which does not have bootstrap value) comprising ST515 and 495. 
Both these group belongs to emm 110. ST119 found in group6 has DLVs with singleton 
ST488 and also with ST532 which was found in group 19. ST119 and ST488 belongs to 
emm 100 while ST532 belongs to emm 11. 
Sixty one sequence types were obtained out of seventy hospital GAS isolates (Figure 12). 
With the standard definition of an eBURST group, all ST‟s assigned in the same group must 
share alleles at least six of the seven house- keeping loci with at least one other in ST in the 
group. This identifies clusters of closely related genotypes that are considered to have 
descended from the same founder and are defined as a clonal complex. Based on this 
definition, there were 11 groups which had predicted founders for three groups which had 
low bootstrap values and 36 singletons. The rest of the groups did not have predicted 
founders. Group 1 clonal complex comprised of ST109, ST484 and ST514 where ST 109 
was the predicted founder with bootstrap value 33%.The ST in this group belonged to emm 
85. ST109 had 2SLV, ST484 and 514 had one SLV and one DLV each. 
Group 2 comprised of ST228, 517and 478. ST228 was the predicted founder. This clonal 
complex was found between STs which belong to emm 49.4 (ST228 and478) and stKNB6 
(ST517) which is a new type.ST 228 has only 2SLVs while ST517 and 478 had one DLV 
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and one SLV. Group 3 clonal complex comprised of ST494, 493and 522 has multiple 
candidate for predicted founder. 
The 73 GAS isolates from the Community had 46 sequence types (Figure 13) .Based on 
eBURST definition, there were six groups with 4 predicted founder ST 477,525,491 and 
534.Singletons accounted for 30 numbers. ST477 was the predicted founder with bootstrap 
31% for group 1 which had ST477, ST499 and ST500. ST477 had only 2SLVs while ST499 
and 500 had one SLV and one DLV each. Groups 1 belongs to emm 44(ST477) and 
113(ST499 and 500). 
The second clonal group from the community comprised of ST525, 109 and 528.The 
predicted founder was ST525 with bootstrap value 32%. The third clonal group belongs to 
emm 105, the STs were ST491, 151 and 492 with predicted founder ST491.Group 4 had ST 
534 as predicted founder, the group had ST534, 591 and 529 as clonal complex. This 
complex belongs to emm 49.4.Group 5 and 6 has no predicted founder; group 5 consisted of 
ST 535 and 526 while group 6 consisted ST 496 and 532. 
More clonal groups were found in hospital eBURST rather than Community GAS isolates 
eBURST, but predicted founder were more from community rather than Hospital GAS 
isolates eBURST. With the eBurst data and the population snapshot, the sequence types 
from both community and the hospital GAS isolates which shared close relationship were 
inferred. There are clonal complexes found within GAS isolates from the community and 
the hospital GAS isolates but it is found more in community than hospital.   
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6.13. Phylogeny of GAS isolates based on their emm types 
A phylogenetic tree was constructed based on 500 base pairs of 49 representative emm types 
which were selected for multi locus sequence typing. The evolutionary history was inferred 
using the Neighbor-Joining method. The optimal tree with the sum of branch length = 
16.07488345 is shown. The tree is drawn to scale, with branch lengths in the same units as 
those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Maximum Composite Likelihood method and are in the 
units of the number of base substitutions per site. Codon positions included were 
1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated 
from the dataset (Complete deletion option). Phylogenetic analyses were conducted in 
MEGA4[226] (Fig.14) . 
 The tree identifies two main branches.  The first branch was very small with 6 types while 
the second branch was very large and consisted of all remaining emm types. However, emm 
gene characterization alone does not provide any measure of genomic differentiation 
between GAS isolates because of high frequency of intragenic (point mutations) and 
intergenic recombination (deletion or addition of segments of chromosomes) 
6.14. Phylogeny of GAS isolates based on their MLST profiles 
A phylogenetic tree was constructed based on the 93 ST‟s of MLST. For this, a 
concatenated sequence was obtained by fusing all the seven loci‟s from the allelic profile 
(Fig.15). The concatenated sequences formed were of 3,314 base pairs. The evolutionary 
history was inferred using the Neighbor-Joining method. The optimal tree with the sum of 
branch length = 0.17490760 is shown. The tree is drawn to scale, with branch lengths in the 
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same units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the Maximum Composite Likelihood method 
and are in the units of the number of base substitutions per site. Codon positions included 
were 1st+2nd+3rd+Noncoding There were a total of 3134 positions in the final dataset. 
Phylogenetic analyses were conducted in MEGA4. ska 
The results from the tree showed a very similar picture as that of the emm tree. There were 
two main branches, of which one was very small with only three ST‟s. The second and 
larger branch had all the remaining ST‟s. The latter consisted of many smaller clusters 
where the ST‟s were very closely packed.  
When this ST types were compared to their respective emm types to ascertain the association 
between emm type and STs. Sequence types are very clonal within emm types except emm1 
(ST36, 469, 30, 15),  emm 12 (ST36, 28, 472), emm 18 (526,120), emm 55(100,528) . That is 
the clustering of ST‟s was in good agreement with emm types. The results when compared 
with eBURST results they showed similarity. The high degree of concordance between 
sequence types of MLST and emm type provides strong evidence that the MLST scheme 
gives accurate information or identifications of clones or clonal complex.  
 
6.15. Linkage disequilibrium Of the GAS isolates from community and Hospital 
One forty three GAS isolates representing 49 emm types and 93 STs were used to analyze 
whether the alleles at different loci within a population of GAS are randomly associated 
(linkage equilibrium), or whether there is a significant association between the alleles at 
different loci (linkage disequilibrium). The observed variance in the distribution of allelic 
mismatches in all pair-wise comparisons of the allelic profiles was computed and compared 
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to that expected in a freely recombining population. The extent of recombination within the 
GAS population was assessed by the index of association. The index of association can be 
calculated by the formula. 
 
IA = VO / VE -1 
      Ia = 0.367688 
Observed variance (V obs) 1.140165 
Expected variance (V exp) 0.833643 
Mean trial variance = 0.985549 
Max trials variance = 1.111028 
 
 
   Significant linkage disequilibrium is established if the observed variance, obtained with 
the real data set, is greater than the maximum variance observed with any of the randomized 
data sets with p values 0.05, 0.01 or 0.001. Index of association will not be significantly 
different from zero since VO and VE should be approximately the same in a population with 
linkage equilibrium.  If the observed variance is less than that obtained with the randomized 
data sets there is no deviation from linkage equilibrium. The observed variance (Vobs) was 
greater than the maximum variance obtained in 100 trials. Significant linkage disequilibrium 
was detected. The index of association can also be calculated at www.mlst.net where online 
soft-wares are available.  
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7. DISCUSSION 
Group A streptococcus (GAS) is a common human pathogen that is usually transmitted 
through the nasopharyngeal reservoir. Its clinical manifestations range from superficial 
infections, such as pharyngitis or impetigo, to invasive diseases, such as bacteremia and 
necrotizing fasciitis (NF), which may be accompanied by toxin‐mediated manifestations, 
such as streptococcal toxic shock syndrome (STSS). A surge in the incidence and severity of 
GAS infections since the 1980s has been documented in many industrialized countries. 
These increased rates appear to have persisted well into the 1990s, and they have been 
largely attributed to the emergence of GAS strains with high potential for causing severe 
human infection. Certain studies have pointed to an association between particular M 
serotypes (or emm genotypes) and severe GAS infection. A number of studies have also 
suggested that serious GAS disease is associated with the emergence of highly virulent GAS 
clones whereas others have found little or no evidence of this association.  
The population genetic structures of GAS infection from Southern India are very poorly 
reported. So our study was designed to explore the genetic structure of GAS causing human 
infections in Southern India using multi locus sequence typing. emm typing provides the 
basis for  the typing scheme. M proteins are one of the key virulence factors in causing GAS 
disease. Antigenic differences in the hyper variable region constitute the basis for the 
Lancefield classification of GAS which has been expanded after the cloning of M-protein 
(emm) gene and the standardization of emm typing based on the sequencing of the amino 
terminal nucleotide residues. Multi locus sequence typing (MLST) is a nucleotide sequence 
method for characterization of the genetic relationship between the organisms of bacterial 
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species and uses housekeeping genes. Unlike housekeeping lo, emm genes are highly 
variable. Therefore emm type would change more rapidly than alleles at housekeeping loci 
resulting in variation within emm gene among isolates of clonal complex. 
In our study, emm typing of 319 GAS isolates from the community identified 73 emm types 
on the whole, which were from four different sources namely pharyngitis, normal throat, 
impetigo and normal skin. Forty five emm types from community pharyngitis, forty seven 
emm types from Normal throat, thirty five emm types from impetigo and twenty five emm 
types from skin colonizers were identified. This confirmed the high heterogeneity among 
them. There were 19 sequence types and two new types stKNB3 & stKNB8 were identified 
among the community GAS isolates.  
The most common emm types were restricted to few types and differed from the site of 
isolation namely pharyngitis, normal throat, impetigo and normal skin. From the cases of 
pharyngitis emm 11 was the dominant while emm112 was the most common among normal 
throat and impetigo. In normal skin, emm 93 was the most common emm type. There were 
few types seen predominantly associated with pharyngitis, one such emm type is emm 110 
which accounted for 8 of the GAS isolates. emm 112 the most common among the seventy 
three emm types which accounted for 29 (9 %) of the GAS isolates and was found 
predominantly in normal throat (n=18) and impetigo skin (n= 8). Some impetigo types were 
also seen as colonizers in throat of asymptomatic children. They were emm 11, 28, 44, 49, 
55, 63, 82, 85, 92, 100, 105,111, 112, 113,119 and st854. So normal throat acts as a GAS 
reservoir in the community and harbors strain capable of causing disease. The colonization 
may occur in individual with GAS emm types and manifests as infection or carriage; it all 
depends on the individual‟s state of immunity, genetic constitution and the environment . 
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Studies from North India indicated out of the 94 GAS isolates when emm typed, thirty seven 
emm types were identified. The most frequently observed emm types were emm49 (8.5%) 
and emm112 (7.5%) followed by 6.5% of emm 1-2, emm 75 and emm 81. The predominant 
emm types from throat (emm49 and emm75) were different from those of skin (emm44, 
emm81 and emm112) samples. Despite the diversity in the emm type pattern of throat and 
skin isolates no significant association between emm type and source of isolation was 
observed [20, 268] .A study from Chennai revealed 22 emm types out of 34 GAS isolates, in 
which the most common type was found to be emm 49 followed by emm 82 and emm 74 
[269].  
The most common emm types among the South Indian GAS isolates were not the dominant 
types from North India though they had some similarities. emm49 and emm75, the most 
dominant emm types from throat GAS isolates (North India) were found in the throat GAS 
isolates from South India but increasing numbers were found in the throat colonizers only, 
while emm 11 was the most common emm type in our study. emm 112 the dominant emm 
type from our studies were found in the North Indian studies and it was found to be the most 
common emm type from the Skin isolates from our study and from the reported literature 
from the North India. The emm types reported in Chennai were also identified in our studies. 
The most frequently observed emm types from our study were not only different from 
previously reported most prevalent emm types in India  but also from epidemiological 
studies of isolates from other countries like Japan , Taiwan , Germany , Australia  and 
United States . The difference in the most prevalent emm types from this study in 
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comparison to earlier Indian reports could be due to the fact that the most prevalent emm 
type within population change over time, which can be predicted by continuing surveillance. 
From the foreign literatures there were reports indicating the association of particular emm 
types that have been strongly associated with GAS invasive disease and some emm types 
with acute pharyngitis and impetigo. The individual strains and clones that cause infections 
and their association between their genotypes and emm types have been studied in numerous 
laboratories .These studies showed that invasive disease in United States and developed 
countries is caused by small number of GAS clones. In United States approximately 30% of 
cases of invasive GAS diseases that occurred during the 1990s were caused by isolates of 
M1 and M3 serotypes.  
From our study, we found that there was no association between the emm types and the site 
of isolation from the community and the GAS isolates from the hospital, but the emm types 
from the community pharyngitis were found more among invasive GAS isolates from 
hospital rather than the emm types found in the hospital pharyngitis. The community 
pharyngitis emm types found in the Invasive GAS isolates were emm 58, 63, 74, 85, 86, 93, 
102, 105 and 110.So there is only minimal or no evidence to support the contention 
regarding the highly virulent GAS clones from Southern India. This is also supported by the 
study from North India where there was no association found between emm type and the 
source of isolation. 
Understanding the extent of importance of genetic and biochemically diversity among 
strains of the same or very close related species is a corner stone issue in microbiology 
disciplines, such as taxonomy, diagnosis, epidemiological studies diversity surveys, 
biogeography etc. The multi locus sequence typing method has emerged as method of 
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choice for exploring and cataloguing intra species genetic diversity, thus setting the stage for 
linking the genetic diversity to the biochemical and functional diversities of species. Typical 
applications of MLST method employ the sequencing of seven genes and subsequent 
phylogenetic analysis concatenated sequences, alignments to reveal the exact genetic 
relationships among the strains analyzed. 
In India; this is the first study using the technique multi locus sequence typing. From our 
MLST studies we confirmed that heterogeneity among GAS isolates is associated with 
allelic variations in seven housekeeping genes. Out of the 143 GAS isolates subjected to 
MLST, 93 sequence types (ST) were identified from 49 emm types. Among this 93 sequence 
types, 68 were new sequence types and 25 were known sequence types. High percentage of 
STs was hitherto unrecognized types. This shows that large number new genotypes develop 
in this community, probably because of highly susceptible hosts in the population. This new 
type also indicates there is constant evolution within the GAS isolates, though mutations 
within housekeeping genes are assumed to be slow or neutral. 
In light of the initial published data of MLST for GAS, where 212 GAS [38] isolates with 78 
emm types revealed hundred sequence types (1-100STs) and their isolation of human 
subjects dated back from 60 years. With a time period spanning 60years and 78 emm types, 
hundred sequence types were identified. From our study we were able to identify 93 
sequence types out of 49 emm types from 143 GAS isolates collected in a short span of time. 
 In comparison to the initial study of GAS MLST of Spratt and Debra Bessen [38], there 
were twenty three emm types which were also found in our study out of which only two 
emm types had similar sequence types (emm 12-ST36 and emm 93-ST10) and rest of the 
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emm types had different STs. According to another published data, where 137 GAS isolates 
from remote community of aboriginal community from Australia [252]  representing 31 
emm types subjected to MLST identified thirty three sequence types. In this study also 
revealed in comparison with our data showed that there were only few emm (n=4) types 
which shared similar STs, they are emm 100(ST119), emm 44/61(ST178), emm 85 (ST109) 
and emm 60(ST193). 
Published reports from Nepal [125] in relation to MLST of GAS revealed 45 emm types out 
of 120 noninvasive GAS isolates with fifty one STs. There were twenty five emm types 
found in Nepal study in relation to our MLST study, out of which only few emm 
(n=12)types shared same STS. They were emm 25.2 (ST350), emm 44 (ST351), emm 49.4 
(ST228), emm 55 (ST100), emm66 (ST249), emm77 (ST347), emm82 (ST320), emm85 
(ST109), emm100 (ST119), emm104 (ST353), emm105 (ST151) and emm119.2 (ST237). In 
general, sequence type from Nepal and our studies indicate that there are more STS common 
than other reported literatures from Australia [252] , United States [38], Germany [254] , 
London[253],and Portugal ; this could be due to geographical proximity. This clearly 
describes that the allelic profiles from our studies are very novel though they share emm 
types and housekeeping alleles with isolates from worldwide sources. 
More frequently, certain emm types showed multiple STs, showing how allelic variations 
among house keeping genes can alter the genotype of the same emm type. Out of forty nine 
emm types there were twenty five emm types with more than one sequence type .They are 
emm 1, 12, 18, 28, 44, 49.4, 55, 74, 75, 77, 85, 86, 92, 93, 100, 105, 108, 110, 111, 112, 113, 
118, st6735, st212 and st854.1. emm type 110 and 49.4 had five STs identified among them 
while six emm types 1, 18, 44, 105, 100 and 85 had four different sequence types, Four emm 
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types namely 92,113, 108 and 12 had three different STs and thirteen emm types had two 
different sequence types. Sixty five of the 93 sequence types were represented by single 
isolate. Genotypic variations had no association with the site from where the GAS isolates 
were recovered. This shows that these variations are not site-specific. Probably they undergo 
such variations to overcome any host related factors during their initial stages of 
colonization.  
The different sequence types within same emm type from our study when checked for 
maximum nucleotide identity; they had 99% nucleotide identity except emm 108 which had 
98% identity within STs. The allelic profiles of different sequence types within an emm type 
were analysed .Most of these allelic variations seen among these sequence types were single 
locus variations. Few were also double locus variations. But multi locus variations were 
rare. This shows that the allelic variations are due to random point mutations in the house 
keeping gene.  
Certain sequence types were found to have more than one emm type. They are known as 
emm variable sequence types. They were ST 36, ST 100, ST 357 and ST 477. emm type 1 
and 12 shared ST 36, emm type 55 and 92 shared ST 100, while emm type 75 and 108 had 
ST 357 and emm type 44 and 113 shared ST 477. Pair wise comparison of emm types 
sharing the same STs were done using clustal W .The maximum nucleotide identity was 
identified as follows ;( ST 36) emm type 1 and 12 had a percentage identity of 50.47%, 
(ST100) emm55 and 92 had percentage identity of 53.42%, (ST 357) had % identity of 
56.73% and (ST477) emm 44and 113 had percentage identity of 62.96% . The different emm 
types having same STs were mostly isolated from hospital pharyngitis and impetigo from 
community. From the reported literature of Awdesh Kalia, Karen, Debra Bessen and Spratt 
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on MLST for 495 GAS  isolate [38] representing 158 emm types with two hundred and 
thirty eight sequence types, there were twelve emm variable sequence types. They were 
ST65 (emm19,29and 30), ST83(emm17 and 47), ST84(emm14 and 51), ST3 (emm33 and 
st211), ST4(emm43 and52) ,ST9(emm86 and 97), ST10 (emm70, 80, 93, 98, 108 and 121), 
ST11(emm53 and101),ST123(emm115 and 123),ST174 (st2911and st3850), ST182(emm101 
and st5282) and ST39(emm4 and st104). The extent of similarity between emm sequences of 
those isolates that have the same ST but different emm types distinguishes variation in emm 
type. The large sequence difference between emm types strongly suggests horizontal gene 
transfer (HGT) followed by intergenomic recombination rather than point mutation [270] . 
The emm variable STs seen in Southern India was not found in the above reported literature 
which also supports that the population genetic structure of GAS is different for different 
parts of the world.      
In multi locus sequence typing, the relatedness among isolates is displayed as dendrogram, 
based on differences in allelic profiles, which identifies clusters of similar genotypes. 
Groups of isolates with closely related allelic profiles are known as clonal complex. Within 
each clonal complex it is usually possible to identify one predominant allelic profile and a 
number of less common variant allelic profiles. The simplest explanation for this pattern is 
that the predominant allelic profile (predicted founder) represents the genotype of the 
ancestral clone that give rise to the clonal complex, and the variants differ from this allelic 
profile at a single locus (SLV-single locus variants) represents the initial stages of 
diversification of clone. The ancestral clone can be defined using the BURST program 
which indicates the allelic profile within each clonal complex that differs from the largest 
number of other allelic profiles at only a single locus and, hence, is most likely to be 
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phylogenetically central [41] .In eBURST a clonal complex is defined as a group of STs in a 
population that share 6/7 alleles with at least one other ST in the group.  eBURST identifies 
clonal complex  and displays the evolution of STs within clonal complex from the predicted 
founder or founder ST The predicted founder ST has increased number of Single locus 
variants (SLV) supported by bootstrap values.              
The population snapshot of eBURST clearly represents the clonal groups found among the 
93 sequence types of 143 GAS isolates. There were 19 groups with eight groups having the 
predicted founder out of which two had bootstrap value more than 60%.This 19 groups 
infers that two third of the allelic profile or the sequence types are clonal in nature Among 
the 19 groups, there are also groups without predicted founder which does not explain 
evolutionary descents. The group 1 clonal complex with predicted founder ST534 having a 
bootstrap value of 70% comprising of ST534, ST228, ST517, ST531, ST529 and ST478 
belonged to emm type 49.4 except ST 517 which belonged to newly identified emm type 
stKNB6.ST517 is a single locus variant of ST534 which represents the relationship between 
emm 49.4 and stKNB6 indicating they are clonal in nature. 
The second group of clonal complex of the eBURST explains the clonal complex of five 
sequence types ST109, ST525, ST484, ST514 and ST 528 which belong to emm 85 except 
ST528 which belong to emm 55. ST 109 being the predicted founder differs from the ST 528 
by DLV. eBurst clearly represents the clonality  between two different emm types 85 and 
55.The approach used in eBURST simplifies the problem of depicting the evolutionary 
relationship among closely related genotypes that are poorly represented on a tree. eBURST 
also depicted the relationship or clonality of sequence types  found within each group and 
between different emm types within the same group namely group 4( between emm types 74 
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and 18), group 5(between emm 44 and113) group 6 (emm 100), group 7(emm18),and 
group8(emm110). eBURST does not make inference about the relationship about the 
distantly related genotypes that belong to different group due to the extent of homologous 
recombination which is high [263].There was one emm variable ST(ST477) which formed a 
clonal complex  identified by eBURST . Single locus variants (SLV) are found only in the 
clonal groups, whereas double locus variants (DLV) are found between the clonal groups, 
between singletons and between singletons and groups. There were 35 pairs of SLV among 
143 GAS isolates from hospital and community within the 19 clonal groups. From the 
eBURST it can be clearly understood that two third of the GAS isolates are clonal in nature 
from Southern India which causes infection. 
According to the BURST algorithm, a genotype occasionally increases in frequency, as a 
consequence of genetic drift or natural selection, and diversifies by the accumulation of 
mutations or localized recombinational replacements, to result in slight variants of the 
founding genotype. In the context of MLST, the members of this emerging clone will 
initially be indistinguishable in allelic profile (same ST) but overtime they will diversify to 
produce a number of variants in which one of the seven MLST loci has been altered and 
forms SLVs. Further diversification will produce variants of the founding ST that differ at 
two of the seven loci and forms DLVs. Bacterial population should therefore consist of 
clonal complexes which provided they are new(young) complexes, should easily be apparent 
using multi locus approaches to strain characterization. According to MLST, the founding 
ST identified should contain increased number of SLVs. The predicted founders among 143 
GAS isolates are ST534, ST109, ST120, ST477, ST119 and ST535. ST534 had 4SLVs with 
bootstrap value 70% and average genetic distance of 1.2.Bootstrapping provides degree of 
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confidence in the assignment founder of clonal complex. Another useful measure provided 
by BURST is the average genetic distance (measured as the average number of allelic 
differences) of each ST from all other ST‟s in a clonal complex. The ST within a clonal 
complex that has minimum average distance is likely predicted founder [263]. ST 109 had 
three SLV with average genetic distance 1.25 which was less than other sequence type‟s 
average genetic distance within clonal complex. ST120, ST477, ST119 and ST535 had two 
SLVs with average genetic one within their respective clonal complex. So the predicted 
founders found in BURST for 143 GAS isolates are the likely predicted founders. 
BURST algorithm was able to identify the young clonal complexes among the ninety three 
sequence types from 143 GAS isolates. The simple or young clonal complex has a predicted 
founder with SLVs; the average genetic distance from the founding ST to all other STs in 
the clonal complex will be one, and all other ST will have a greater average distance [263]. 
There were three clonal complexes which matched the criteria for young complexes; they 
were ST120, ST477 and ST535.This sequence types had an average distance of one, and all 
other sequence type had 1.5 as their average distance. 
When the clonal complex with ancestral clones and their associated SLVs have been 
identified, it is possible to distinguish SLVs that have arisen by recombination from those 
that have arisen by point mutation. These distinctions are made on the basis of two criteria: 
the number of nucleotide sites that differ between the variant allele in the SLV and the 
typical allele in the putative ancestral clone, and the frequency at which the variant allele is 
found elsewhere in the database. The occurrence of multiple point mutations at one locus 
with no changes at the other six loci is unlikely, and variant alleles that differ at multiple 
nucleotide sites are therefore considered to be recombinational replacements [271]. 
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However, differences at a single site could result from either point mutation or from 
recombinational replacements between very similar sequences that introduce only a single 
nucleotide difference. These types of events can be distinguished, as a point mutation within 
a house keeping locus is very likely to result in a variant allele that is unique within MLST 
database.  
There were two clonal complexes among the 143 GAS isolates with ninety three sequence 
types showing bootstrap value more than 60% ,with predicted founders ST534 and ST109 
from BURST analysis, were checked for the number of nucleotide site difference between 
the variant allele within complex. Group1 clonal complex comprised of sequence types 
ST534, ST 228, ST478, ST517, ST529 and ST531. ST534 was the predicted founder. ST534 
was found to be SLV of ST228, ST517, ST529 and ST531 and double locus variant for 
ST478. ST228 and ST517 differed from ST534 at the loci muts (DNA mismatch repair 
protein). ST529 and ST 531 had a variable allele at the loci gtr (glutamine transporter 
protein) from ST534. ST478 a DLV, differed from ST 534 at the locus mutS and gtr.  ST534 
had an alignment score of 99 with ST 228 for the loci muts when checked for pair wise 
alignment.ST534 had the allele number 3 while ST228 had allele number 11 for the loci 
mutS. These two alleles when compared for nucleotide difference, they differed from each 
other by three nucleotides. Similarly the allele number of ST 534 and ST517 at the loci mutS 
showed a nucleotide difference of two and their respective allele numbers were 3 and 5. 
ST534 when compared with ST529 variable allele at the loci gtr, had three nucleotide 
difference.ST534 and ST531 had varied allele which differed by two nucleotide, the allele 
number were 31 and 35 respectively for the loci gtr. All the SLV of ST534 differed from 
each other by nucleotide difference of 2-3 nucleotides and had alignment score of 99.  
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Group 2 clonal complexes comprised of sequence type ST109, ST484, ST514, ST525 and 
ST528. ST109 was the predicted founder. ST109 had three SLVs; they are ST484, ST514 
and ST 525. ST528 was a DLV of ST109. ST109 varied at the loci gki (glucose kinase), gtr 
(glutamine transporter protein), mutS (DNA mismatch repair protein) and yqiL (acetyl CoA 
acetyl transferase) with rest of the sequence types. ST525 differed from ST109 at the loci 
gki. ST484 differed from ST109 at the loci gtr. ST528 differed from ST109 at the loci mutS. 
ST514 differed from ST 109 at the loci yqiL. ST528 differed from ST109 at the locus gki 
and mutS. These SLVs of ST109 were checked for nucleotide difference with the respective 
locus. The ST 109 with ST 525 for the locus gki had a nucleotide difference of one and it 
was the same between ST109 and ST528. ST109 with ST484 had a nucleotide difference of 
one with loci gtr. With loci yqiL, ST 109 and ST514 the alleles varied by a nucleotide 
difference of two. ST109 and ST 528 which is a DLV had a maximum nucleotide difference 
of five. 
The nucleotide differences in association with the predicted founder within the clonal 
complex which had bootstrap value more than 60% showed that the varied alleles or alleles 
which differed from the predicted founder at different locus with other sequence types 
differed by a nucleotide difference of  one to five. This clearly shows that the allelic 
variation can be due to point mutation which has been accumulated over time or due to 
recombination. Although we cannot, at present estimate the rate of recombination in nature, 
when combined with strong selective pressure, even relatively low rates of recombination 
can play a fundamental role in accelerating the evolution of functional diversity. 
The clonal complexes present in the community and the clinical GAS isolates were revealed 
using BURST algorithm. There were 46 sequence types identified within seventy three 
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community GAS isolate. Using the stringent definition of eBURST the population snap shot 
of community GAS isolates was obtained. There were six groups out of which only four 
clonal complexes had the predicted founder. The predicted founders are ST525, ST477, 
ST491 and ST534.The average genetic distance of the predicted founder sequence type was 
checked in respect to the other sequence types found within the clonal complex, it was found 
that three clonal complex were young clonal complex. The predicted founders which had 
young clonal complex were ST525, ST477 and ST491. Community GAS isolates had thirty 
singletons among forty six sequence types. Whereas the clinical GAS isolates population 
snapshot of BURST with seventy GAS isolates and sixty one sequence types showed that 
there were eleven groups with two predicted founder among them. The two predicted 
founder were ST109 and ST228. The clonal complex formed by the predicted founder 
ST109 and ST 228 were young clonal complex and thirty six singletons were found. 
In relation to clinical the community had forty six sequence types and four clonal complexes 
with predicted founder, whereas there were only two clonal complexes with predicted 
founder out of sixty one sequence types in the clinical. Community GAS isolates had only 
six groups in comparison to clinical GAS isolates which had eleven groups. There were two 
young clonal complexes in the clinical GAS isolates and four young clonal complexes in the 
community GAS isolates. These findings may indicate that the evolution occurs more in 
clinical GAS isolates than community GAS isolates. The reasons being more new sequence 
types were observed in clinical GAS isolates: Secondly more clonal groups were found in 
clinical GAS isolates (with or without predicted founder); more SLVs were also found in 
clinical isolates. 
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Molecular phylogenetics have become an integral part of research endeavors in diverse areas 
of molecular biology, population genetics, developmental biology and evolutionary biology 
and has implications for ecology and medicine. The observed heterogeneity of evolutionary 
rates among lineages in a gene is caused partly by the nondeterministic nature of the 
evolutionary process, partly by differences in intensity and type of natural selection and 
partly by unknown factors. Tree building methods, with the exception of UPGMA, don‟t 
assume constancy of evolutionary rates vary significantly among lineages. However some 
methods are known to produce consistently incorrect results when the evolutionary rates 
vary significantly among lineages. Felsenstein showed that if a four sequence tree contains 
two long and two short branches, then the long branches tend to cluster together in the 
maximum parsimony (MP) trees even if they are distantly related (long-branch attraction 
problem). One to avoid this problem is by using a large number of sequences such that the 
long branches are broken. Another way to minimize the effects of long-branch attraction is 
to use maximum likelihood method (ML). 
The phylogenetic analyses based on the concatenated sequences of ninety three sequence 
types of MLST were conducted using the molecular evolutionary genetics analysis software 
(MEGA 4) [271].The neighbor-joining (NJ) method was used which is widely used in 
reconstructing phylogenies because of its computational speed and the high accuracy in 
phylogenetic inference. The tree size does not influence the efficiency of NJ in constructing 
shallow and deep branches, in which the evolutionary process is assumed to be 
homogeneous in all lineages. Maximum likelihood method is generally regarded as the gold 
standard of molecular phylogenetic reconstruction by using which the evolutionary 
distance[272]. 
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The ninety three sequence types were used for construction of the phylogenetic tree. Several 
clusters were formed among genotypes which were closely related. The STs within the 
clusters were compared to their respective emm types to ascertain the association between 
emm type and ST. The STs were found to be clonal in respect to their emm types. The 
cluster containing ST534, ST228, ST517, ST529, ST531 and ST478 all fall under a single 
emm type 49.4 except ST517 which belongs to stKNB6.  Many clusters were found in which 
the STs was in good agreement with emm types, but there were some exceptions. They are 
emm1 (ST36, 469, 30, 15), emm 12 (ST36, 28, 472), emm 18 (526,120) and emm 
55(100,528). In tree the evolution of STs was not very clear as in BURST snapshot. The 
approach used in BURST greatly simplifies the problem of depicting the evolutionary 
relationship among closely related genotypes, which are poorly represented on tree. So 
eBURST displays the relatedness among GAS isolates very clearly. 
The population structures of bacterial species are complex and often controversial. The 
existence of clones within bacterial populations, and of linkage disequilibrium between 
alleles at different loci, is often cited as evidence for low rates of recombination.  
The linkage disequilibrium was calculated from the distribution of allelic mismatches 
between all the GAS isolates using the index of association. Significant linkage 
disequilibrium was detected because the observed variance was found to be greater than the 
expected variance which indicates there is association between allele at different loci in the 
seven housekeeping genes. 
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8. SUMMARY AND CONCLUSION 
1. Seventy three emm types were identified among the 319 GAS isolates from the four 
different sites from community, thirty emm types from 41 GAS isolates of hospital 
pharyngitis and 37 emm types from 58 invasive GAS isolates, this indicates the role 
of multiple emm types in causing human infection. This also clearly explains the 
absence of association between emm types and their site of isolation and depicts the 
high heterogeneity seen among the GAS isolates from South India. 
2. Some emm types which cause impetigo were also seen as colonizers in throat of 
asymptomatic children. So normal throat acts as a GAS reservoir in the community 
and harbors strain capable of causing disease. 
3. The dominant emm types found in South Indian community were different from the 
most common emm types reported from other regions of the world. 
4. The difference in the most prevalent emm types from this study in comparison to 
earlier Indian reports could be due to the fact that the most prevalent emm type 
within population change over time, which can be predicted by continuing 
surveillance. 
5. Despite the diversity in the emm type pattern of throat and skin isolates no significant 
association between emm type and source of isolation was observed. 
6. Multi locus sequence typing of 143 GAS isolates identified ninety three sequence 
types out of which sixty eight were new sequence types. ST338/emm 63 was the 
dominant type followed by ST00/emm55&92. 
7. Multi locus sequence typing studies revealed new sequence types which had the 
same alleles but arranged in different combinations. These different combinations in 
97 
 
turn formed sixty eight novel sequence types which were not found in other parts of 
the world.  
8. The multi locus sequence typing using the house keeping genes showed that this 
technique can identify heterogeneity among individual emm types. 
9. The sequence types within an emm type found in our study were also found in Nepal 
in higher numbers compared to the studies from Australia, United States of America, 
Germany, Portugal and London. These finding highlights that the population genetic 
structure of GAS isolates varies based on geographical proximity. 
10. Genotypic variations had no association with the site from where the GAS isolates 
were recovered. This shows that these variations are not site-specific. Probably they 
undergo such variations to overcome any host related factors during their initial 
stages of colonization.  
11. High percentage of sequence types from MLST were new (68 / 93STs) types. This 
shows that large number new genotypes develop in this community, probably 
because of highly susceptible hosts in the population.    
12. The eBURST analysis showed that about two thirds of 143 isolates subjected to 
MLST had varying degrees of clonality. Comparison of nucleotide sequences using 
clustalW showed 99% identity. Most of these allelic variations are single locus 
variations. Few were also double locus variations. But multi locus variations were 
rare. This shows that the allelic variations were more due to random point mutations 
than recombination in the house keeping gene loci. 
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13. eBURST analysis clearly indicates that two third of the GAS isolates indicated that 
they are clonal in nature. 
14. Significant linkage disequilibrium was detected which indicates the presence of low 
level of recombination. 
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CONCLUSION 
This study was looked at to study the clonal diversity of GAS causing human infections 
in Southern India (or) population genetic structure of GAS disease in South India. These 
facets of this study have been poorly reported from India. This is the first study in India 
utilizing the technique multi locus sequence typing (MLST) for GAS which increased 
the information on diversity of GAS infections. From our study we have found out GAS 
isolates in relation to emm typing, shows high heterogeneity. Our MLST studies 
indicated that, there are new sequence types found which were not reported in any part 
of the world. It also depicted the high heterogeneity found within individual emm types 
in respect to sequence types. There was no association found between sequence types 
and to their site of isolation. The sequence types found based on their allelic profile of 
GAS isolates clearly explained there is no association between their STs and their site of 
isolation. eBURST population snap shot identified the clonal complexes present in the 
GAS isolates from the community and the hospital isolates and indicated that two third 
of the GAS  population are clonal in nature with young clonal complexes. 
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9.  RECOMMENDATIONS 
 What are the environmental factors that convert a non-invasive to invasive? 
 What host factors are involved in the development of the susceptible to severe 
invasive disease? 
 How does one integrate Horizontal Gene Transfer (HGT) in context to genetic 
exchange and to arrive at meaningful microbiological concepts? 
 How does one reach the robust conclusion on the presence or absence of HGT? 
 Role of Linkage disequilibrium- Index of association. 
 Group A Streptococcus Vaccine for highly diverse GAS population. 
 Exploitation of functional genomics and experimental models to develop GAS 
vaccine. 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig.1. Distribution of emm types from Community Pharyngitis GAS isolates (n=101) 
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Fig.2.Distribution of emm types from community asymptomatic throat carriers GAS isolates (n=113) 
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Fig.3.Distribution of emm types from community impetigo GAS isolates (n=65) 
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Fig.4.Distribution of emm types from community normal skin GAS isolates (n=40) 
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Fig.5. Distribution of emm types from Hospital pharyngitis GAS isolates (n=41) 
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Fig.6. Distribution of emm types from invasive GAS isolates from Hospital (n=58) 
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Fig.7.Multiple Sequence Alignment of ST 15, 36,469,530 of emm 1 
 
ST469           AATCTTAATTGGAAAGAAACCCAAGAAGTCGGTTCCGTTGTTGAAAAAGAATTGGGCATT 60 
ST530           AACCTTAATTGGAAAGAAACCCAAGAAGTCGGTTCCGTTGTTGAAAAAGAATTGGGCATT 60 
ST36            AACCTTAATTGGAAAGAAACCCAAGAAGTCGGTTCCGTTGTTGAAAAAGAATTGGGCATT 60 
ST15            AACCTTAATTGGAAAGAAACCCAAGAAGTCGGTTCCGTTGTTGAAAAAGAATTGGGCATT 60                
                ** ******************************************************** 
 
ST469           CCTTTTGCCATTGACAATGATGCCAATGTGGCTGCCCTTGGTGAACGTTGGGTAGGTGCT 120 
ST530           CCTTTTGCCATTGACAATGATGCCAATGTGGCTGCCCTTGGTGAACGTTGGGTAGGTGCT 120 
ST36            CCTTTTGCCATTGACAATGATGCTAATGTGGCTGCCCTTGGTGAACGTTGGGTAGGTGCT 120 
ST15            CCTTTTGCCATTGACAATGATGCCAATGTGGCTGCCCTTGGTGAACGTTGGGTAGGTGCT 120                 
                *********************** ************************************ 
 
ST469           GGTGAAAATAACCCAGATGTCGTCTTCATGACACTTGGAACAGGTGTCGGTGGAGGCATT 180 
ST530           GGTGAAAATAACCCAGATGTCGTCTTCATGACACTTGGAACAGGTGTCGGTGGAGGCATT 180 
ST36            GGTGAAAATAACCCAGATGTCGTCTTCATGACACTTGGAACAGGTGTCGGTGGAGGCATT 180 
ST15            GGTGAAAATAACCCAGATGTCGTCTTCATGACACTTGGAACAGGTGTTGGTGGAGGCATT 180                 
                *********************************************** ************ 
 
ST469           ATTGCTGATGGTAACTTGATTCATGGTGTTGCAGGAGCAGGTGGTGAAATCGGCCACATT 240 
ST530           ATTGCTGATGGTAACTTGATTCATGGTGTTGCAGGAGCAGGTGGTGAAATCGGCCACATG 240 
ST36            ATTGCTGATGGTAACTTGATTCATGGTGTTGCAGGAGCAGGTGGTGAAATCGGCCACATG 240 
ST15            ATTGCTGATGGTAACTTGATTCATGGTGTTGCAGGAGCAGGTGGTGAAATCGGCCACATG 240                 
                ***********************************************************  
 
ST469           ATTGTTGAGCCAGAAAATGGCTTTGCTTGTACTTGTGGCTCACACGGCTGTTTGGAAACA 300 
ST530           ATTGTTGAGCCAGAAAATGGCTTTGCTTGTACTTGTGGCTCACACGGCTGTTTGGAAACA 300 
ST36            ATTGTTGAGCCAGAAAATGGCTTTGCTTGTACTTGTGGCTCACACGGCTGTTTGGAAACA 300 
ST15            ATTGTTGAGCCAGAAAATGGCTTTGCTTGTACTTGTGGCTCACACGGCTGTTTGGAAACA 300 
                ************************************************************ 
 
ST469           GTAGCTTCAGCAACAGGAGTTGTCAAAGTGGCACGTTTACTGGCAGAAGCCTACGAAGGG 360 
ST530           GTAGCTTCAGCAACAGGAGTTGTCAAAGTGGCACGTTTACTGGCAGAAGCCTACGAAGGG 360 
ST36            GTAGCTTCAGCAACAGGAGTTGTCAAAGTGGCACGTTTATTGGCAGAAGCTTATGAAGGG 360 
ST15            GTAGCTTCAGCAACAGGAGTTGTCAAAGTGGCACGTTTACTGGCAGAAGCTTATGAAGGG 360                 
                *************************************** ********** ** ****** 
 
ST469           GATTCAGCCATCAAAGCAGCTATTGACAATGGTGAAGGTGTTACCAGTAAAGACATTTTC 420 
ST530           GATTCAGCCATCAAAGCAGCTATTGACAATGGTGAAGGTGTTACCAGTAAAGACATTTTC 420 
ST36            GATTCAGCCATCAAAGCAGCTATTGACAATGGTGAAGGTGTTACCAGCAAAGATATTTTT 420 
ST15            GATTCAGCCATCAAAGCAGCTATTGACAATGGTGAAGGTGTTACCAGTAAAGACATTTTT 420                 
                *********************************************** ***** *****  
 
ST469           ATGGCGGCTGAAGCAGGGGATTCCTTTGCTGATTCTGTTGTGGAAAAGGTTGGTTACTAC 480 
ST530           ATGGCGGCTGAAGCAGGGGATTCCTTTGCTGATTCTGTTGTGGAAAAGGTTGGTTACTAC 480 
ST36            ATGGCAGCTGAAGCAGGGGATTCCTTTGCTGATTCTGTTGTGGAAAAGGTTGGTTACTAC 480 
ST15            ATGGCAGCAGAAGCAGGGGATTCCTTTGCTGATTCTGTTGTGGAAAAGGTTGGTTACTAC 480                 
                ***** ** *************************************************** 
 
 
 
 
 
ST469           CTTGGCCTTGCTTCAGCAACCTTACTTCGAACTATGAATCTTTTGGAAGTACCAACTAAG 540 
ST530           CTTGGCCTTGCTTCAGCAACCTTACTTCGAACTATGAATCTTTTGGAAGTACCAACTAAG 540 
ST36            CTTGGCCTTGCTTCAGCAACCTTACTTCGAACTATGAATCTTTTGGAAGTACCAACTAAG 540 
ST15            CTTGGCCTTGCTTCAGCAACCTTACTTCGAACCATGAATCTTTTGGAAGTACCAACTAAG 540                 
                ******************************** *************************** 
 
ST469           GGACAGATTAGGTTTGAGGGGATTGATATTACCGATAAGAAGAATGATATTTTCAGCATG 600 
ST530           GGACAGATTAGGTTTGAGGGGATTGATATTACCGATAAGAAGAATGATATTTTCAGCATG 600 
ST36            GGACAGATTAGGTTTGAGGGGATTGATATTACCGATAAGAAGAATGATATTTTCAGCATG 600 
ST15            GGACAGATTAGGTTTGAGGGGATTGATATTACCGATAAGAAGAACGATATTTTCAGCATG 600                 
                ******************************************** *************** 
 
ST469           CGTGAAAAAATGGGAATGGTTTTCCAGCAGTTTAACCTCTTTCCCAATATGACTATTTTA 660 
ST530           CGTGAAAAAATGGGAATGGTTTTCCAGCAGTTTAACCTCTTTCCCAATATGACTATTTTA 660 
ST36            CGTGAAAAAATGGGAATGGTTTTCCAGCAGTTTAACCTCTTTCCCAATATGACTATTTTA 660 
ST15            CGTGAAAAAATGGGGATGGTTTTTCAGCAGTTTAACCTCTTTCCCAATATGACTGTTTTA 660                 
                ************** ******** ****************************** ***** 
 
ST469           GAAAATATCACTTTATCGCCAATCAAAACTAAGGGAATGGCTAAAGCAGAGGCTGACAAA 720 
ST530           GAAAATATCACTTTATCGCCAATCAAAACTAAGGGAATGGCTAAAGCAGAGGCTGACAAA 720 
ST36            GAAAATATCACTTTATCGCCAATCAAAACTAAGGGAATGGCTAAAGCAGAGGCTGACAAA 720 
ST15            GAAAATATCACTTTATCGCCAATCAAAACTAAGGGAATGGCTAAAGCAGAGGCTGACAAA 720 
                ************************************************************ 
 
ST469           ACAGCCTTGAGCTTGTTGGACAAAGTTGGATTATCAGAAAAAGCCAAGGCTTATCCTGCT 780 
ST530           ACAGCCTTGAGCTTGTTGGACAAAGTTGGATTATCAGAAAAAGTCAAGGCTTATCCTGCT 780 
ST36            ACAGCCTTGAGCTTGTTGGACAAAGTTGGATTATCAGAAAAAGCCAAGGCTTATCCTGCT 780 
ST15            ACAGCCTTGAGCTTGTTGGACAAAGTTGGATTATCAGAAAAAGCCAAGGCTTATCCTGCT 780                 
                ******************************************* **************** 
 
ST469           AGTCTTTCTGGTGGGCAACAGCAGCGGATTGCGATTGCGCGTGGACTGGCTATGGATCCA 840 
ST530           AGTCTTTCTGGTGGGCAACAGCAGCGGATTGCGATTGCGCGTGGACTAGCTATGGATCCA 840 
ST36            AGTCTTTCTGGTGGGCAACAGCAGCGGATTGCGATTGCGCGTGGACTGGCTATGGATCCA 840 
ST15            AGTCTTTCTGGTGGGCAACAGCAGCGGATTGCGATTGCGCGTGGACTGGCTATGGATCCA 840                 
                *********************************************** ************ 
 
ST469           GATGTTTTACTCTTTGATGAACCAACTTCAGCTCTAGACCCAGAAATGGTGGGTGAGGTC 900 
ST530           GATGTTTTACTCTTTGATGAACCAACTTCAGCTCTAGACCCAGAAATGGTGGGTGAGGTC 900 
ST36            GATGTTTTACTCTTTGATGAACCAACTTCAGCTCTAGACCCAGAAATGGTGGGTGAGGTC 900 
ST15            GATGTTTTACTCTTTGATGAACCAACTTCAGCTCTAGACCCAGAAATGGTGGGTGAGGTC 900 
                ************************************************************ 
 
ST469           TTGGCTGTCATGCAAGATTTGGCTAAATCTGGGATGACTATGGTTATTGCATGCAATACC 960 
ST530           TTGGCTGTCATGCAAGATTTGGCTAAATCTGGGATGACTATGGTTATTGCATGCAATACC 960 
ST36            TTGGCTGTCATGCAAGATTTGGCTAAATCTGGGATGACTATGGTTATTGCATGCAATACC 960 
ST15            TTGGCTGTCATGCAAGATTTGGCTAAATCTGGGATGACTATGGTTATTGCATGCAATACC 960 
                ************************************************************ 
 
ST469           GCAACAGCGGTGGCTTGGGAAGAAGTAAAAGCAGCTTTAGATATTCCTGTTTTAGGGGTT 1020 
ST530           GCAACAGCGGTGGCTTGGGAAGAAGTAAAAGCAGCTTTAGATATTCCTGTTTTAGGAGTT 1020 
ST36            GCAACAGCGGTGGCTTGGGAAGAAGTAAAAGCAGCTTTAGATATTCCTGTTTTAGGGGTT 1020 
ST15            GCAACAGCGGTGGCTTGGGAAGAAGTAAAAGCAGCTTTAGATATTCCTGTTTTAGGGGTT 1020                 
                ******************************************************** *** 
 
 
 
 
ST469           GTCTTACCGGGGGCAAGCGCAGCTATTAAATCAACGACAAAAGGCCAGGTTGGGGTCATC 1080 
ST530           GTCTTACCGGGGGCAAGCGCAGCTATTAAATCAACGACAAAAGGCCAGGTTGGGGTCATC 1080 
ST36            GTCTTACCGGGGGCAAGCGCAGCTATTAAATCAACGACAAAAGGCCAGGTTGGGGTCATC 1080 
ST15            GTCTTACCGGGGGCAAGCGCAGCTATTAAATCAACGACAAAAGGCCAGGTTGGGGTCATC 1080 
                ************************************************************ 
 
ST469           GGAACCCCAATGACAGTGGCTTCAGACATTTATCGCAAAAAAATCCAGCTATTAGCACCA 1140 
ST530           GGAACCCCAATGACAGTGGCTTCAGACATTTATCGCAAAAAAATCCAGCTATTAGCACCA 1140 
ST36            GGAACCCCAATGACAGTGGCTTCAGACATTTATCGCAAAAAAATCCAGCTATTAGCACCA 1140 
ST15            GGAACCCCAATGACAGTGGCTTCAGACATTTATCGCAAAAAAATCCAGCTATTAGCACCA 1140 
                ************************************************************ 
 
ST469           TCTATTCAAGTAAGGAGTCTTGCTTGCCCGAAGTTTGTACCGATTGTGGAATCAAATGAG 1200 
ST530           TCTATTCAAGTAAGGAGTCTTGCTTGCCCGAAGTTTGTACCGATTGTGGAATCAAATGAG 1200 
ST36            TCTATTCAAGTAAGGAGTCTTGCTTGCCCGAAGTTTGTACCGATTGTGGAATCAAATGAG 1200 
ST15            TCTGTTCAAGTAAGGAGTCTTGCTTGCCCGAAGTTTGTACCGATTGTGGAATCAAATGAG 1200                 
                *** ******************************************************** 
 
ST469           ATGTGTTCGAGTATAGCTAAAAAAATAGTTTATGACAGTCTAGCACCATTAGTCGGTAAA 1260 
ST530           ATGTGTTCGAGTATAGCTAAAAAAATAGTTTATGACAGTCTAGCACCATTAGTCGGTAAA 1260 
ST36            ATGTGTTCGAGTATAGCTAAAAAAATAGTTTATGACAGTCTAGCACCATTAGTCGGTAAA 1260 
ST15            ATGTGTTCGAGTATAGCTAAAAAAATAGTTTATGACAGTCTAGCACCATTAGTCGGTAAA 1260 
                ************************************************************ 
 
ST469           ATAGATACCCTTGTACTAGGATGTACTCACTATCCCTTGTTACGACCAATTATCCAAAAT 1320 
ST530           ATAGATACCCTTGTACTAGGATGTACTCACTATCCCTTGTTACGACCAATTATCCAAAAT 1320 
ST36            ATAGATACCCTTGTACTAGGATGTACTCACTATCCCTTGTTACGACCAATTATCCAAAAT 1320 
ST15            ATAGATACCCTTGTACTAGGATGTACTCACTATCCCTTGTTACGACCAATTATCCAAAAT 1320 
                ************************************************************ 
 
ST469           GTTATGGGGCCATCTGTTAAGCTGATTGACAGTGGAGCAGAATGCGTCCGAGATATCTCT 1380 
ST530           GTTATGGGGCCATCTGTTAAGCTGATTGACAGTGGAGCAGAATGCGTCCGAGATATCTCT 1380 
ST36            GTTATGGGGCCATCTGTTAAGCTGATTGACAGTGGAGCAGAATGCGTCCGAGATATCTCT 1380 
ST15            GTTATGGGGCCATCTGTTAAGCTGATTGACAGTGGAGCAGAATGCGTCCGAGATATCTCT 1380 
                ************************************************************ 
 
ST469           GTCTTAACCTATATTAATCGTTTACAGAAACTGGCTAAAATTTTGGCAACGGTAGATGTT 1440 
ST530           GTCTTAACCTATATTAATCGTTTACAGAAACTGGCTAAAATTTTGGCAACGGTAGATGTT 1440 
ST36            GTCTTAACCTATATTAATCGTTTACAGAAACTGGCTAAAACTTTGGCAACGGTGGATGTT 1440 
ST15            GTCTTAACCTATATTAATCGTTTACAGAAACTGGCTAAAATTTTGGCAACGGTAGATGTT 1440                 
                **************************************** ************ ****** 
 
ST469           TTGCAAAGTTTAGCAGTCGTTGCTGAAACCAATCATTATATCCGGCCGCAGTTCAATGAT 1500 
ST530           TTGCAAAGTTTAGCAGTCGTTGCTGAAACCAATCATTATATCCGGCCGCAGTTCAATGAT 1500 
ST36            TTGCAAAGTTTAGCAGTCGTTGCTGAAACCAATCATTATATTCGGCCGCAGTTCAATGAT 1500 
ST15            TTGCAAAGTTTAGCAGTCGTTGCTGAAACCAATCATTATATCCGGCCGCAGTTCAATGAT 1500                 
                ***************************************** ****************** 
 
ST469           AATCATGTGATTACAATTCAAGAAGGTCGTCACGCGGTTGTTGAAAAGGTTATGGGAGTG 1560 
ST530           AATCATGTGATTACAATTCAAGAAGGTCGTCACGCGGTTGTTGAAAAGGTTATGGGAGTG 1560 
ST36            AATCATGTGATTACAATTCAAGAAGGTCGTCACGCCGTTGTTGAAAAGGTTATGGGAGTG 1560 
ST15            AATCATGTGATTACAATTCAAGAAGGTCGTCACGCGGTTGTTGAAAAGGTTATGGGAGTG 1560                 
                *********************************** ************************ 
 
 
 
 
ST469           CAGGAATACATTCCCAATAGTATCTCTTTTGACCAACAGACCAGTATTCAGCTGATTACA 1620 
ST530           CAGGAATACATTCCCAATAGTATCTCTTTTGACCAACAGACCAGTATTCAGCTGATTACA 1620 
ST36            CAGGAATACATTCCCAATAGTATCTCTTTTGACCAACAGACCAGTATTCAGCTGATTACA 1620 
ST15            CAGGAATACATTCCCAATAGTATCTCTTTTGACCAACAGACCAGTATTCAGCTGATTACA 1620 
                ************************************************************ 
 
ST469           GGTCCAAATATGAGTGGTAAGTCGACTTATATGAGACAGCTGGCCTTAACGGTTATCATG 1680 
ST530           GGTCCAAATATGAGTGGTAAGTCGACTTATATGAGACAGCTGGCCTTAACGGTTATCATG 1680 
ST36            GGTCCAAATATGAGTGGTAAGTCGACTTATATGAGACAGCTGGCCTTAACGGTTATCATG 1680 
ST15            GGTCCAAATATGAGTGGTAAGTCGACTTATATGAGACAGCTGGCCTTAACGGTTATCATG 1680 
                ************************************************************ 
 
ST469           GCCCAGATGGGTTCATTTGTGGCTGCTGACCATGTTGATTTACCTTTATTTGATGCGATT 1740 
ST530           GCCCAGATGGGTTCATTTGTGGCTGCTGATCATGTTGATTTACCTTTATTTGATGCGATT 1740 
ST36            GCCCAGATGGGTTCATTTGTGGCTGCTGATCATGTTGATTTACCTTTATTTGATGCGATT 1740 
ST15            GCCCAGATGGGTTCATTTGTGGCTGCTGACCATGTTGATTTACCTTTATTTGATGCGATT 1740                 
                ***************************** ****************************** 
 
ST469           TTTACGCGTATTGGGGCTGCTGATGATTTGATTTCTGGGCAATCAACCTTTCCTATGGCC 1800 
ST530           TTTACGCGTATTGGGGCTGCTGATGATTTGATTTCTGGGCAATCAACCTTTCCTATGGCC 1800 
ST36            TTTACGCGTATTGGGGCTGCTGATGATTTGATTTCTGGGCAATCAACCTTTCCTATGGCC 1800 
ST15            TTTACGCGTATTGGGGCTGCTGATGATTTGATTTCTGGGCAATCAACCTTTCCTATGGCC 1800 
                ************************************************************ 
 
ST469           TATGTTCTTTGGAATCACTTCATGAACATCAATCCCAAAACAAGCCGTAATTGGTCAAAC 1860 
ST530           TATGTTCTTTGGAATCACTTCATGAACATCAATCCCAAAACAAGCCGTAATTGGTCAAAC 1860 
ST36            TATGTTCTTTGGAATCACTTCATGAACATCAATCCCAAAACAAGCCGTAATTGGTCAAAC 1860 
ST15            TATGTTCTTTGGAATCACTTCATGAACATCAATCCCAAAACAAGCCGTAATTGGTCAAAC 1860 
                ************************************************************ 
 
ST469           AGAGACCGTTTTATCCTATCAGCAGGTCATGGAAGCGCCATGCTTTATAGCTTGTTGCAT 1920 
ST530           AGAGACCGTTTTATCCTATCAGCAGGTCATGGAAGTGCCATGCTTTATAGCTTGTTACAC 1920 
ST36            AGAGACCGTTTTATCCTATCAGCAGGTCATGGAAGTGCCATGCTTTATAGCTTGTTGCAT 1920 
ST15            AGAGACCGTTTTATCCTATCAGCAGGTCATGGAAGTGCCATGCTTTATAGCTTGTTACAC 1920                 
                *********************************** ******************** **  
 
ST469           TTAGCAGGTTATGATTTATCTGTAGAAGATTTAAAGAACTTCCGTCAATGGGGTTCTAAA 1980 
ST530           TTAGCTGGTTATGATTTATCTGTAGAAGATTTAAAGAACTTCCGTCAATGGGGTTCTAAA 1980 
ST36            TTAGCAGGTTATGATTTATCTGTAGAAGATTTAAAGAACTTCCGTCAATGGGCTTCTAAA 1980 
ST15            TTAGCTGGTTATGATTTATCTGTAGAAGATTTAAAGAACTTCCGTCAATGGGGTTCTAAA 1980                 
                ***** ********************************************** ******* 
 
ST469           ACACCAGGTCACCCAGAAGTGAACCACACAGACGGTGTCGAAGCAACCACAGGACCTCTT 2040 
ST530           ACACCAGGTCACCCAGAAGTGAACCACACAGACGGTGTCGAAGCAACCACAGGACCTCTT 2040 
ST36            ACACCAGGTCACCCAGAAGTGAACCACACAGACGGTGTCGAAGCAACCACAGGACCTCTT 2040 
ST15            ACACCAGGTCACCCAGAAGTGAACCACACAGACGGTGTCGAAGCAACCACAGGACCTCTT 2040 
                ************************************************************ 
 
ST469           GGTCAAGGGATCGCAAATGCCGTTGGTATGGCCATGGCAGAAGCTCACCTAGCAGCTAAA 2100 
ST530           GGTCAAGGGATCGCAAATGCCGTTGGGATGGCCATGGCAGAAGCTCATCTAGCAGCTAAA 2100 
ST36            GGTCAAGGGATCGCAAATGCCGTTGGTATGGCCATGGCAGAAGCTCACCTAGCAGCTAAA 2100 
ST15            GGTCAAGGGATCGCAAATGCCGTTGGTATGGCCATGGCAGAAGCTCATCTAGCAGCTAAA 2100                 
                ************************** ******************** ************ 
 
 
 
 
ST469           TTTAACAAACCAGGCTTTGACATCGTTGATCACTACACATTTGCTTTGAATGGTGACGGT 2160 
ST530           TTTAACAAACCAGGCTTTGACATCGTTGATCACTACACATTTGCTTTGAATGGTGACGGT 2160 
ST36            TTTAACAAACCAGGCTTTGACATCGTTGATCACTACACATTTGCTTTGAATGGTGACGGT 2160 
ST15            TTTAACAAACCAGGCTTTGACATCGTTGATCACTACACCTTTGCTTTGAATGGTGACGGT 2160                 
                ************************************** ********************* 
 
ST469           GACCTTATGGAAGGGGTCAGCCAAGAAGCAGCAAGTATGGCAGGACATTTAAAACTTGGG 2220 
ST530           GACCTTATGGAAGGGGTCAGCCAAGAAGCAGCAAGTATGGCAGGACATTTAAAACTTGGG 2220 
ST36            GACCTTATGGAAGGGGTCAGCCAAGAAGCAGCAAGTATGGCAGGACATTTAAAACTTGGG 2220 
ST15            GACCTTATGGAAGGGGTCAGCCAAGAAGCAGCAAGTATGGCAGGACATTTAAAACTTGGG 2220 
                ************************************************************ 
 
ST469           AAATTGGTCTTGCTATATGATTCAAACGACGGAGAGAATATTCTAAAGGTAGATAATTTT 2280 
ST530           AAATTGGTCTTGCTATATGATTCAAACGACGGAGAGAATATTCTAAAGGTAGATAATTTT 2280 
ST36            AAATTGGTCTTGCTATATGATTCAAACGACGGAGAGAATATTCTAAAGGTAGATAATTTT 2280 
ST15            AAATTGGTCTTGCTATATGATTCAAACGACGGAGAGAATATTCTAAAGGTAGATAATTTT 2280 
                ************************************************************ 
 
ST469           TTAACTCATCAAGTTGATTACCGGTTGATGAAAGCAATTGGTAAAGTGTTTGCTCAAAAA 2340 
ST530           TTAACTCATCAAGTTGATTACCGGTTGATGAAAGCAATTGGTAAAGTGTTTGCTCAAAAA 2340 
ST36            TTAACTCATCAAGTTGATTACCGGTTGATGAAAGCAATTGGTAAAGTGTTTGCTCAAAAA 2340 
ST15            TTAACTCATCAAGTTGATTACCGGTTGATGAAAGCAATTGGTAAAGTGTTTGCTCAAAAA 2340 
                ************************************************************ 
 
ST469           TATGCTGAGGCTGGCATTACAAAAGTGGTTACAATCGAAGCTTCAGGTATTGCACCAGCC 2400 
ST530           TATGCTGAGGCTGGCATTACAAAAGTGGTTACAATCGAAGCTTCAGGTATTGCACCAGCC 2400 
ST36            TATGCTGAGGCTGGCATTACAAAAGTGGTTACAATCGAAGCTTCAGGTATTGCACCAGCC 2400 
ST15            TATGCTGAGGCTGGCATTACAAAAGTGGTTACAATCGAAGCTTCAGGTATTGCACCAGCC 2400 
                ************************************************************ 
 
ST469           GTATACGCTGCAGAAGCAATGGATGTTCCTATGATTTTTGCGAAAAAACATAAAAACATT 2460 
ST530           GTATACGCTGCAGAAGCAATGGATGTTCCTATGATTTTTGCGAAAAAACATAAAAACATT 2460 
ST36            GTATACGCTGCAGAAGCAATGGATGTTCCTATGATTTTTGCGAAAAAACATAAAAACATT 2460 
ST15            GTATACGCTGCAGAAGCAATGGATGTTCCTATGATTTTTGCGAAAAAACATAAAAACATT 2460 
                ************************************************************ 
 
ST469           ACCATGACAGAAGGCATTTTGACAGCAGAAGTTTATTCTTTCACTAAACAAGTGACGAGC 2520 
ST530           ACCATGACAGAAGGCATTTTGACAGCAGAAGTTTATTCTTTCACTAAACAAGTGACGAGC 2520 
ST36            ACCATGACAGAAGGCATTTTGACAGCAGAAGTTTATTCTTTCACTAAACAAGTGACGAGC 2520 
ST15            ACCATGACAGAAGGCATTTTGACAGCAGAAGTTTATTCTTTCACTAAACAAGTGACGAGC 2520 
                ************************************************************ 
 
ST469           ACGGTGTCTATCGCTGGTAAATTCCTATCTAAAGAAGACAAGGTTTTGATTATTGATGAC 2580 
ST530           ACGGTGTCTATCGCTGGTAAATTCCTATCTAAAGAAGACAAGGTTTTGATTATTGATGAC 2580 
ST36            ACGGTGTCTATCGCTGGTAAATTCCTATCTAAAGAAGACAAGGTTTTGATTATTGATGAC 2580 
ST15            ACGGTGTCTATCGCTGGTAAATTCCTATCTAAAGAAGACAAGGTTTTGATTATTGATGAC 2580 
                ************************************************************ 
 
ST469           TTTTTAGCTAATGGTCAGGCAGCCAAAGGCTTGATCGAGATTATTGGTCAAGCAGGGGCA 2640 
ST530           TTTTTAGCTAATGGTCAGGCAGCCAAAGGCTTGATTGAGATTATTGGTCAAGCAGGGGCA 2640 
ST36            TTTTTAGCTAATGGTCAGGCAGCCAAAGGCTTGATTGAGATTATTGGTCAAGCAGGGGCA 2640 
ST15            TTTTTAGCTAATGGTCAGGCAGCCAAAGGCTTGATCGAGATTATTGGTCAAGCAGGGGCA 2640                 
                *********************************** ************************ 
 
 
 
 
ST469           CAAGTCGTCGGCGTTGGTATTGTGATTGAGAAATCTTTCCAAGATGGTCGTCGATTGATT 2700 
ST530           CAAGTCGTCGGCGTTGGTATTGTGATTGAGAAATCTTTCCAAGATGGTCGTCGATTGATT 2700 
ST36            CAAGTCGTCGGCGTTGGTATTGTGATTGAGAAATCTTTCCAAGATGGTCGTCGATTGATT 2700 
ST15            CAAGTCGTCGGCGTTGGTATTGTGATTGAGAAATCTTTCCAAGATGGTCGTCGATTGATT 2700 
                ************************************************************ 
 
ST469           TTTGCAGCTGATAGCCAACGTAAAGCCCAACTTGCCATAGAAAAAGGTCGTTTCAAAGAA 2760 
ST530           TTTGCAGCTGATAGCCAACGTAAAGCCCAACTTGCCATAGAAAAAGGTCGTTTCAAAGAA 2760 
ST36            TTTGCAGCTGATAGCCAACGTAAAGCCCAACTTGCCATAGAAAAAGGTCGTTTCAAAGAA 2760 
ST15            TTTGCAGCTGATAGCCAACGTAAAGCCCAACTTGCCATAGAAAAAGGTCGTTTCAAAGAA 2760 
                ************************************************************ 
 
ST469           GAGATTGCACCTGTCACTATTCCTCAGCGTAAAGGTGAACCTTTACTCGTTGATCAAGAT 2820 
ST530           GAGATTGCACCTGTCACTATTCCTCAGCGTAAAGGTGAACCTTTACTCGTTGATCAAGAT 2820 
ST36            GAGATTGCACCTGTCACTATTCCTCAGCGTAAAGGTGAACCTTTACTCGTTGATCAAGAT 2820 
ST15            GAGATTGCACCTGTCACTATTCCTCAGCGTAAAGGTGAACCTTTACTCGTTGATCAAGAT 2820 
                ************************************************************ 
 
ST469           GAATACCCTAAATTTGGAACGACAGTGGATAAGTTAGCAAAGTTACGCCCTGCTTTTATC 2880 
ST530           GAATACCCTAAATTTGGAACGACAGTGGATAAGTTAGCAAAGTTACGCCCTGCTTTTATC 2880 
ST36            GAATACCCTAAATTTGGAACGACAGTGGATAAGTTAGCAAAGTTACGCTCTGCTTTTATC 2880 
ST15            GAATACCCTAAATTTGGAACGACAGTGGATAAGTTAGCAAAGTTACGCTCTGCTTTTATC 2880                         
                ************************************************ *********** 
 
ST469           AAAGATGAGGGGACAGTAACTGCTGGTAATGCTTCAGGAATCAATGATGGAGCAGCAGCA 2940 
ST530           AAAGATGAGGGGACAGTAACTGCTGGTAATGCTTCAGGAATCAATGATGGAGCAGCGGCA 2940 
ST36            AAAGATGAGGGGACAGTAACTGCTGGTAATGCTTCAGGAATCAATGATGGAGCAGCGGCA 2940 
ST15            AAAGATGAGGGGACAGTAACTGCTGGTAATGCTTCAGGAATCAATGATGGAGCAGCGGCA 2940                   
                ******************************************************** *** 
 
ST469           ATTTTATTGATGAGTAAAGAAAAAGCTGAAGAATTAGGGCTCCCTATTTTAGCTAAAATC 3000 
ST530           ATTTTATTGATGAGTAAAGAAAAAGCTGAAGAATTAGGGCTCCCTATTTTAGCTAAAATC 3000 
ST36            ATTTTATTGATGAGTAAAGAAAAAGCTGAAGAATTAGGGCTCCCTATTTTAGCTAAAATC 3000 
ST15            ATTTTATTGATGAGTAAAGAAAAAGCTGAAGAATTAGGGCTCCCTATTTTAGCTAAAATC 3000 
                ************************************************************ 
 
ST469           ACTAGTTATGCAAGTGCAGGTGTAGACCCAAGTATTATGGGCTGCGGACCAATACCTGCT 3060 
ST530           ACTAGTTATGCAAGTGCAGGTGTAGACCCAAGTATTATGGGCTGCGGACCAATACCTGCT 3060 
ST36            ACTAGTTATGCAAGTGCAGGTGTAGACCCAAGTATTATGGGCTGCGGACCAATACCTGCT 3060 
ST15            ACTAGTTATGCAAGTGCAGGTGTAGACCCAAGTATTATGGGCTGCGGACCAATACCTGCT 3060 
                ************************************************************ 
 
ST469           ACGAAAAAGGCTCTTGCAAAGGCTCAGCTGACAATTGATGACATTGATTTGATTGAAGCA 3120 
ST530           ACGAAAAAGGCTCTTGCAAAGGCTCAGCTGACAATTGATGACATTGATTTGATTGAAGCA 3120 
ST36            ACGAAAAAGGCTCTTGCAAAGGCTCAGCTGACAATTGATGACATTGATTTGATTGAAGCA 3120 
ST15            ACGAAAAAGGCTCTTGCAAAGGCTCAGCTGACAATTGATGACATTGATTTGATTGAAGCA 3120 
                ************************************************************ 
 
ST469           AACGAAGCTTTTGC 3134 
ST530           AACGAAGCTTTTGC 3134 
ST36            AACGAAGCTTTTGC 3134 
ST15            AACGAAGCTTTTGC 3134 
                ************** 
 
 
Fig.8. eBURST Snap shot of Community and Hospital GAS isolates (n = 143) 
 
Black line represents groups created by eBurst definition, Pink line represents SLV, Blue line represents DLV, Black dot represents the STs and size of the dot 
represents the number of GAS isolate in each ST, Blue dot represents the predicted founder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9.Clonal Complexes found among the 93 ST’s from Hospital and Community GAS Isolates 
a. Group 1 Clonal Complex 
 
 
 
 
 
 
 
b.Group 2 Clonal Complex 
 
 
 
 
 
Black line represents groups created by eBurst definition, Pink line represents SLV, Blue line represents DLV, Black dot represents the STs and size 
of the dot represents the number of GAS isolate in each ST, Blue dot represents the predicted founder. Note: the clonal complex diagram has been 
slightly modified from the original population snap shot so the SLV and the DLV can be appreciated in the figure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10.eBURST Snap shot of Community and Hospital GAS isolates with Single locus Variant (n = 143) 
Pink line represents SLV, Black dot represents the STs and size of the dot represents the number of GAS isolate in each ST, Blue dot represents the 
predicted founder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11.eBURST Snap shot of Community and Hospital GAS isolates with Double locus Variant (n = 143) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Black line represents groups created by eBurst definition,  Blue line represents DLV, Black dot represents the STs and size of the dot represents the number of GAS 
isolate in each ST, Blue dot represents the predicted founder  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.12.eBURST Snap shot of Hospital GAS isolates (n = 70) 
Black line represents groups created by eBurst definition, Pink line represents SLV, Blue line represents DLV, Black dot represents the STs and size of the dot 
represents the number of GAS isolate in each ST, Blue dot represents the predicted founder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13.eBURST Snap shot of Community GAS isolates (n = 73) 
Black line represents groups created by eBurst definition, Pink line represents SLV, Blue line represents DLV, Black dot represents the STs and size of the dot 
represents the number of GAS isolate in each ST, Blue dot represents the predicted founder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14.Phylogenetic Tree of emm types  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15.Phylogenetic Tree of Sequence types  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.1. Distribution of emm types among the community GAS isolates (n=319) 
 
emm type Pharyngitis Normal Throat Impetigo Normal skin Total  emm type Pharyngitis 
Normal 
Throat 
Impetigo Normal skin Total 
 112 1 18 8 2 29  104 2 1 0 0 3 
11 9 4 2 0 15  st212 2 1 0 0 3 
82 5 4 1 2 12  st854 0 2 1 0 3 
100 0 3 6 2 11  stNS554 2 1 0 0 3 
63 4 3 2 1 10  9 2 0 0 0 2 
93 2 0 4 4 10  65 0 2 0 0 2 
85 4 3 2 0 9  103 0 2 0 0 2 
105 1 5 2 1 9  116 1 0 1 0 2 
108 5 2 0 2 9  119 0 1 1 0 2 
49.4 2 4 1 1 8  st2460 2 0 0 0 2 
110 8 0 0 0 8  stC36 0 1 1 0 2 
113 2 4 2 0 8  stD432 1 0 1 0 2 
1 3 3 1 0 7  stKNB3 0 2 0 0 2 
44 0 1 3 3 7  stKNB8 1 1 0 0 2 
66 0 5 2 0 7  stNS292 2 0 0 0 2 
111 0 4 1 2 7  3 1 0 0 0 1 
18 3 2 0 1 6  25 0 0 0 1 1 
55 3 1 2 0 6  33 1 0 0 0 1 
92 3 1 2 0 6  54 0 1 0 0 1 
12 2 0 2 1 5  57 0 0 1 0 1 
28 1 2 2 0 5  70 0 1 0 0 1 
36 0 2 0 3 5  71 0 0 1 0 1 
56 0 3 1 1 5  73 0 1 0 0 1 
69 1 1 1 2 5  79 0 0 0 1 1 
75 0 3 1 1 5  81.2 0 1 0 0 1 
77 2 1 0 2 5  88 1 0 0 0 1 
86 2 3 0 0 5  122 0 0 1 0 1 
st1389 1 0 2 2 5  st11014 1 0 0 0 1 
st2147 2 2 0 1 5  st1731 1 0 0 0 1 
53 1 2 1 0 4  st465 1 0 0 0 1 
68 1 2 1 0 4  st5282 0 1 0 0 1 
74 3 0 0 1 4  st62 1 0 0 0 1 
102 1 0 2 1 4  stCQ343 0 0 0 1 1 
15 0 2 1 0 3  stG245 0 1 0 0 1 
48 0 0 2 1 3  stG485 0 1 0 0 1 
58 3 0 0 0 3  Total 101 113 65 40 319 
60 2 1 0 0 3  
78 2 1 0 0 3  
 
 
 
 
 
 
 
 
 
Table.2.Distribution of emm types common to Community and hospital associated 
Pharyngitis  
 
                    *14 types that accounted for 52.5% of the 101 GAS isolates    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
emm type* Community Pharyngitis (101) Hospital  Pharyngitis (41) 
11 9 (8.9%) 1(2.4%) 
110 8(7.9%) - 
82 5(4.9%) - 
108 5(4.9%) - 
63 4(3.96%) 1(2.4%) 
85 4(3.96%) 1(2.4%) 
1 3(2.97%) 1(2.4%) 
18 3(2.97%) - 
55 3(2.97%) 3(7.3%) 
92 3(2.97%) - 
74 3(2.97%) - 
58 3(2.97%) - 
Table.3.Distribution of Invasive emm types among Community and Hospital Pharyngeal 
GAS isolates 
emm Type* 
Invasive GAS 
Disease (60) 
Community 
Associated 
Pharyngitis(101) 
Hospital Associated 
Pharyngitis (41)   
56 2 - - 
58 2 3 - 
63 3 4 1 
66 2 - - 
74 3 3 - 
85 3 4 1 
86 2 2 - 
93 2 2 2 
100 2 - - 
102 2 1 - 
105 2 1 - 
110 4 8 - 
124 2 - - 
st6735 2 - - 
st854.1 3 - - 
*Represent 36 (62%) of the 58 GAS isolates associated with invasive disease; remaining 24 isolates accounted for one 
isolate each.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.4.GAS isolates selected for MLST from the community (n=73) 
emm Type Pharyngitis 
Normal 
Throat 
Impetigo 
Normal 
Skin 
Number of 
strains 
selected 
1 1 1 1 0 3 
11 1 1 1 0 3 
12 1 0 1 0 2 
18 1 1 0 1 3 
28 1 1 1 0 3 
44 0 1 1 1 3 
49 1 1 1 1 4 
55 1 1 1 0 3 
63 1 1 1 1 4 
66 0 1 1 0 2 
75 0 0 0 1 1 
77 1 1 0 0 2 
82 1 1 1 1 4 
85 1 1 1 0 3 
92 1 1 1 0 3 
93 1 0 1 1 3 
100 0 1 1 1 3 
105 1 1 1 1 4 
108 1 1 0 1 3 
110 1 0 0 0 1 
111 0 1 1 1 3 
112 1 1 1 1 4 
113 2 1 1 0 4 
st212 0 1 0 0 1 
stKNB3 0 1 0 0 1 
stKNB8 1 1 0 0 2 
stNS554 1 0 0 0 1 
Total 21 22 18 12 73 
 
 
 
 
 
 
 
 
Table.5. STs of GAS isolates from the community and the hospital (n=143) 
gki gtr muri muts recp xpt yqil ST emm-types No. 
2 6 8 5 2 3 2 15 1 1 
26 2 2 5 31 3 1 469 1 1 
4 25 4 4 4 2 4 530 1 1 
5 2 2 6 6 2 2 36 1,12 3 
51 2 8 25 33 3 75 470 8 1 
3 4 70 7 1 5 4 471 11 4 
4 3 4 4 4 2 4 28 12 1 
4 2 2 58 6 2 2 472 12 1 
47 3 2 5 10 64 12 513 15.1 1 
43 2 2 7 1 3 1 120 18 1 
5 2 2 3 2 34 31 526 18 1 
4 2 2 3 2 34 31 535 18 1 
4 28 2 3 2 34 31 523 18.12 1 
14 2 8 6 55 40 6 350 25.2 1 
4 36 8 7 51 3 76 473 28 1 
4 79 8 7 51 3 76 474 28 3 
1 31 8 6 36 53 4 475 43.3 1 
4 4 3 6 14 3 4 178 44 3 
24 4 3 6 14 3 4 351 44 1 
4 3 3 6 14 3 77 476 44 1 
57 3 8 25 1 3 78 477 44,113 2 
4 31 8 11 34 3 40 228 49.4 1 
4 2 8 11 34 3 40 478 49.4 1 
4 6 8 3 34 3 40 529 49.4 1 
4 35 8 3 34 3 40 531 49.4 1 
4 31 8 3 34 3 40 534 49.4 2 
90 6 8 7 4 3 59 363 53 1 
4 37 8 2 33 3 4 528 55 1 
34 2 2 21 1 29 16 100 55,92 5 
40 2 9 6 41 34 12 512 56 1 
29 32 2 5 33 5 4 516 58.8 1 
48 31 41 9 2 2 36 193 60 1 
85 2 14 5 19 58 58 338 63 7 
13 31 8 5 19 3 1 249 66 3 
103 37 2 24 4 2 79 479 73 1 
43 2 2 7 1 3 80 480 74 2 
43 32 2 7 1 3 1 520 74 1 
16 35 2 5 61 3 25 481 75 1 
75 2 44 4 66 3 1 357 75,108 2 
4 31 2 11 34 3 2 347 77 1 
4 31 2 11 34 3 21 482 77 3 
79 37 44 36 51 8 25 521 81.2 1 
4 63 8 5 73 3 4 320 82 4 
42 37 8 22 33 3 4 109 85 3 
42 2 8 22 33 3 4 484 85 2 
42 37 8 22 33 3 63 514 85 1 
4 37 8 22 33 3 4 525 85 1 
4 2 36 5 4 23 1 503 86.2 1 
4 12 36 11 4 23 1 518 86.2 1 
4 3 2 59 2 2 4 485 92 2 
42 3 2 5 2 2 4 524 92 1 
2 2 9 13 2 14 2 10 93 4 
2 6 9 13 2 14 2 502 93 1 
2 6 8 3 2 32 1 119 100 2 
2 3 8 3 2 32 1 487 100 1 
55 6 8 3 90 32 1 488 100 1 
gki gtr muri muts recp xpt yqil ST emm-types No. 
2 12 8 3 2 32 1 486 100.3 1 
13 45 71 4 76 3 6 489 102.2 2 
25 37 8 7 2 3 1 353 104 1 
2 28 2 17 4 5 1 151 105 2 
2 31 2 17 4 5 1 490 105 1 
2 28 2 17 4 76 1 491 105 2 
55 28 2 17 4 76 1 492 105 1 
2 6 3 22 2 2 2 527 108 1 
2 6 8 2 2 2 2 533 108 1 
25 4 8 6 30 25 4 493 110 1 
25 3 8 6 30 25 4 494 110 1 
25 81 8 6 30 25 39 495 110 1 
25 37 8 6 30 25 4 522 110 1 
25 2 8 6 30 25 39 515 110.3 1 
2 6 8 3 2 8 22 496 111 2 
2 31 8 3 2 8 22 532 111 1 
4 2 2 60 21 3 81 497 112 4 
4 19 3 60 21 3 81 498 112 1 
57 3 8 25 1 3 76 499 113 2 
57 3 8 25 19 3 78 500 113 1 
29 32 8 5 48 5 25 501 118 1 
29 31 2 5 48 5 25 511 118 1 
4 59 2 5 44 33 1 237 119.2 1 
51 49 8 25 33 3 27 544 124 2 
51 2 2 25 2 5 31 504 st1731 1 
104 80 2 7 35 2 2 483 st212 1 
104 82 2 7 35 2 2 505 st212 1 
105 6 2 6 1 49 4 506 st6735 1 
105 3 2 6 1 49 4 507 st6736 1 
4 3 54 6 34 8 44 224 st854.1 2 
4 2 54 6 34 8 44 519 st854.1 1 
89 3 63 25 4 3 32 361 stKNB3 1 
4 36 12 18 2 3 4 508 stKNB3 1 
4 31 8 5 34 3 40 517 stKNB6 1 
106 13 3 61 1 28 82 509 stKNB8 2 
4 36 2 18 2 3 4 114 stKNB9 1 
29 31 6 5 19 77 4 510 stNS554 2 
 
Glucose kinases (gki),    Glutamine transporter protein (gtr), Glutamate racemase (murI), DNA mismatch repair protein (mutS) 
Transketolase (recP), Xanthine phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase (Yqil)   
 
 
 
 
 
 
 
Table.6.Allelic profile of newly identified Sequence Types (ST) (n=68) 
ST gki gtr muri muts recp xpt yqil 
469 26 2 2 5 31 3 1 
470 51 2 8 25 33 3 75 
471 3 4 70 7 1 5 4 
472 4 2 2 58 6 2 2 
473 4 36 8 7 51 3 76 
474 4 79 8 7 51 3 76 
475 1 31 8 6 36 53 4 
476 4 3 3 6 14 3 77 
477 57 3 8 25 1 3 78 
478 4 2 8 11 34 3 40 
479 103 37 2 24 4 2 79 
480 43 2 2 7 1 3 80 
481 16 35 2 5 61 3 25 
482 4 31 2 11 34 3 21 
483 104 80 2 7 35 2 2 
484 42 2 8 22 33 3 4 
485 4 3 2 59 2 2 4 
486 2 12 8 3 2 32 1 
487 2 3 8 3 2 32 1 
488 55 6 8 3 90 32 1 
489 13 45 71 4 76 3 6 
490 2 31 2 17 4 5 1 
491 2 28 2 17 4 76 1 
492 55 28 2 17 4 76 1 
493 25 4 8 6 30 25 4 
494 25 3 8 6 30 25 4 
495 25 81 8 6 30 25 39 
496 2 6 8 3 2 8 22 
497 4 2 2 60 21 3 81 
498 4 19 3 60 21 3 81 
499 57 3 8 25 1 3 76 
500 57 3 8 25 19 3 78 
501 29 32 8 5 48 5 25 
502 2 6 9 13 2 14 2 
503 4 2 36 5 4 23 1 
504 51 2 2 25 2 5 31 
505 104 82 2 7 35 2 2 
506 105 6 2 6 1 49 4 
507 105 3 2 6 1 49 4 
508 4 36 12 18 2 3 4 
509 106 13 3 61 1 28 82 
510 29 31 6 5 19 77 4 
511 29 31 2 5 48 5 25 
512 40 2 9 6 41 34 12 
513 47 3 2 5 10 64 12 
514 42 37 8 22 33 3 63 
515 25 2 8 6 30 25 39 
516 29 32 2 5 33 5 4 
517 4 31 8 5 34 3 40 
518 4 12 36 11 4 23 1 
519 4 2 54 6 34 8 44 
520 43 32 2 7 1 3 1 
521 79 37 44 36 51 8 25 
522 25 37 8 6 30 25 4 
523 4 28 2 3 2 34 31 
524 42 3 2 5 2 2 4 
ST gki gtr muri muts recp xpt yqil 
525 4 37 8 22 33 3 4 
526 5 2 2 3 2 34 31 
527 2 6 3 22 2 2 2 
528 4 37 8 2 33 3 4 
529 4 6 8 3 34 3 40 
530 4 25 4 4 4 2 4 
531 4 35 8 3 34 3 40 
532 2 31 8 3 2 8 22 
533 2 6 8 2 2 2 2 
534 4 31 8 3 34 3 40 
535 4 2 2 3 2 34 31 
544 51 49 8 25 33 3 27 
 
Glucose kinases (gki),    Glutamine transporter protein (gtr), Glutamate racemase (murI), DNA mismatch repair protein (mutS) 
Transketolase (recP), Xanthine phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase (Yqil)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.7.Allelic profile of GAS Pharyngitis from the community(n=21) 
gki gtr muri muts recp xpt yqil ST emm type 
26 2 2 5 31 3 1 469* 1 
3 4 70 7 1 5 4 471* 11 
4 2 2 58 6 2 2 472* 12 
5 2 2 3 2 34 31 526* 18 
4 79 8 7 51 3 76 474* 28 
4 31 8 3 34 3 40 534* 49.4 
34 2 2 21 1 29 16 100 55 
85 2 14 5 19 58 58 338 63 
4 31 2 11 34 3 21 482* 77 
4 63 8 5 73 3 4 320 82 
4 37 8 22 33 3 4 525* 85 
42 3 2 5 2 2 4 524* 92 
2 2 9 13 2 14 2 10 93 
2 28 2 17 4 5 1 151 105 
2 6 3 22 2 2 2 527* 108 
25 81 8 6 30 25 39 495* 110 
4 2 2 60 21 3 81 497* 112 
57 3 8 25 1 3 76 499* 113 
57 3 8 25 1 3 76 499* 113 
106 13 3 61 1 28 82 509* stKNB8 
29 31 6 5 19 77 4 510* stNS554 
Glucose kinase (gki),   Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein 
(mutS)Transketolase (recP), Xanthine phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase  (Yqil),  *=New types 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.8.Allelic profile of Normal Throat carriers of GAS from community(n=22) 
gki gtr muri muts recp xpt yqil ST emm type 
4 25 4 4 4 2 4 530* 1 
3 4 70 7 1 5 4 471* 11 
43 2 2 7 1 3 1 120 18 
4 79 8 7 51 3 76 474* 28 
57 3 8 25 1 3 78 477* 44 
4 6 8 3 34 3 40 529* 49.4 
4 37 8 2 33 3 4 528* 55 
85 2 14 5 19 58 58 338 63 
13 31 8 5 19 3 1 249 66 
4 31 2 11 34 3 21 482* 77 
4 63 8 5 73 3 4 320 82 
42 37 8 22 33 3 4 109 85 
4 3 2 59 2 2 4 485* 92 
2 6 8 3 2 32 1 119 100 
2 28 2 17 4 76 1 491* 105 
75 2 44 4 66 3 1 357 108 
2 6 8 3 2 8 22 496* 111 
4 2 2 60 21 3 81 497* 112 
57 3 8 25 19 3 78 500* 113 
104 82 2 7 35 2 2 505* st212 
89 3 63 25 4 3 32 361 stKNB3 
106 13 3 61 1 28 82 509* stKNB8 
Glucose kinase (gki),   Glutamine transporter protein (gtr), Glutamate racemase (murI), DNA mismatch repair protein  (mutS) 
Transketolase (recP), Xanthine phosphoribosyl transferase (xpt) ,Acetyl-coA acetyl transferase  (Yqil)     *=New types 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.9. Genetic relatedness among emm types from community Pharyngitis and Normal throat 
emm type ST of Pharyngitis GAS ST of Normal Throat GAS 
11 471 471 
28 474 474 
63 338 338 
77 482 482 
82 320 320 
112 497 497 
stKNB8 509 509 
 
 
Table.10. Genetic diversity among emm types from community Pharyngitis and Normal throat 
emm type ST of Pharyngitis GAS ST of Normal Throat GAS 
1 469 530 
18 526 120 
49 534 529 
55 100 528 
85 525 109 
92 524 485 
105 151 491 
113 499 500 
 
            
 
 
 
 
 
 
 
 
 
 
   Table.11.Allelic profile of GAS Impetigo from community (n=18) 
gki gtr muri muts recp xpt yqil ST emm type 
2 6 8 5 2 3 2 15 1 
3 4 70 7 1 5 4 471* 11 
5 2 2 6 6 2 2 36 12 
4 79 8 7 51 3 76 474* 28 
4 4 3 6 14 3 4 178 44 
4 35 8 3 34 3 40 531* 49.4 
34 2 2 21 1 29 16 100 55 
85 2 14 5 19 58 58 338 63 
13 31 8 5 19 3 1 249 66 
4 63 8 5 73 3 4 320 82 
42 37 8 22 33 3 4 109 85 
34 2 2 21 1 29 16 100 92 
2 2 9 13 2 14 2 10 93 
2 6 8 3 2 32 1 119 100 
55 28 2 17 4 76 1 492* 105 
2 31 8 3 2 8 22 532* 111 
4 19 3 60 21 3 81 498* 112 
57 3 8 25 1 3 78 477* 113 
Glucose kinase (gki),   Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS) 
Transketolase (recP), Xanthine phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase  (Yqil)  *=New types 
 
 
Table.12. Genetic relatedness among emm types from community Impetigo and Normal throat 
emm type ST of Impetigo GAS ST of Normal Throat GAS 
11 471 471 
28 474 474 
63 338 338 
66 249 249 
82 320 320 
85 109 109 
100 119 119 
 
 
 
 
 
 
 
Table.13. Genetic diversity among emm types from community Impetigo and Normal throat 
emm type ST of Impetigo GAS ST of Normal Throat GAS 
1 15 530 
44 178 477 
55 100 528 
92 100 485 
105 492 491 
111 532 496 
112 498 497 
113 477 500 
 
 
Table.14.Allelic profile of GAS skin colonisers from community (n=12) 
gki gtr muri muts recp xpt yqil ST emm type 
4 2 2 3 2 34 31 535* 18 
4 4 3 6 14 3 4 178 44 
4 31 8 3 34 3 40 534* 49.4 
85 2 14 5 19 58 58 338 63 
16 35 2 5 61 3 25 481* 75 
4 63 8 5 73 3 4 320 82 
2 2 9 13 2 14 2 10 93 
55 6 8 3 90 32 1 488* 100 
2 28 2 17 4 76 1 491* 105 
2 6 8 2 2 2 2 533* 108 
2 6 8 3 2 8 22 496* 111 
4 2 2 60 21 3 81 497* 112 
Glucose kinase (gki),   Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein 
(mutS)Transketolase (recP), Xanthine phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase  (Yqil)  *=New types 
 
 
 
 
 
 
 
 
Table.15. Distribution of allelic profiles of Hospital Pharyngitis GAS    isolates(n=20) 
gki gtr muri muts recp xpt yqil ST emm_type 
5 2 2 6 6 2 2 36 1 
3 4 70 7 1 5 4 471* 11 
4 3 4 4 4 2 4 28 12 
5 2 2 6 6 2 2 36 12 
4 4 3 6 14 3 4 178 44 
24 4 3 6 14 3 4 351 44 
4 31 8 11 34 3 40 228 49.4 
34 2 2 21 1 29 16 100 55 
85 2 14 5 19 58 58 338 63 
103 37 2 24 4 2 79 479* 73 
75 2 44 4 66 3 1 357 75 
4 31 2 11 34 3 21 482* 77 
4 31 2 11 34 3 2 347 77 
42 37 8 22 33 3 4 109 85 
4 3 2 59 2 2 4 485* 92 
2 2 9 13 2 14 2 10 93 
29 32 8 5 48 5 25 501* 118 
104 80 2 7 35 2 2 483* st212 
4 36 12 18 2 3 4 508* stKNB3.2 
29 31 6 5 19 77 4 510* stNS554.1 
Glucose kinases (gki),    Glutamine transporter protein (gtr), Glutamate racemase (murI), DNA mismatch repair protein 
(mutS)Transketolase (recP), Xanthine phosphoribosyl transferase (xpt), Acetyl-coA acetyl transferase (Yqil) , *=New types  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.16. Allelic profiles of Invasive blood Hospital GAS isolates(n=32) 
source gki gtr muri muts recp xpt yqil ST 
emm -
types 
blood 51 2 8 25 33 3 75 470* 8 
blood 4 28 2 3 2 34 31 523* 18 
blood 1 31 8 6 36 53 4 475* 43.3 
blood 4 3 3 6 14 3 77 476* 44 
blood 4 2 8 11 34 3 40 478* 49.4 
blood 90 6 8 7 4 3 59 363 53 
blood 34 2 2 21 1 29 16 100 55 
blood 85 2 14 5 19 58 58 338 63 
blood 43 2 2 7 1 3 80 480* 74 
blood 43 32 2 7 1 3 1 520* 74 
blood 79 37 44 36 51 8 25 521* 81.2 
blood 42 2 8 22 33 3 4 484* 85 
blood 42 2 8 22 33 3 4 484* 85 
blood 4 12 36 11 4 23 1 518* 86 
blood 4 2 36 5 4 23 1 503* 86 
blood 2 6 9 13 2 14 2 502* 93 
blood 2 3 8 3 2 32 1 487* 100 
blood 2 12 8 3 2 32 1 486* 100 
blood 13 45 71 4 76 3 6 489* 102 
blood 25 37 8 7 2 3 1 353 104 
blood 2 31 2 17 4 5 1 490* 105 
blood 25 37 8 6 30 25 4 522* 110 
blood 25 4 8 6 30 25 4 493* 110 
blood 25 3 8 6 30 25 4 494* 110 
blood 4 2 2 60 21 3 81 497* 112 
blood 29 31 2 5 48 5 25 511* 118 
blood 51 49 8 25 33 3 27 544* 124 
blood 51 2 2 25 2 5 31 504* st1731 
blood 105 6 2 6 1 49 4 506* st6735 
blood 105 3 2 6 1 49 4 507* st6735 
blood 4 2 54 6 34 8 44 519* st854.1 
blood 4 31 8 5 34 3 40 517* stknb6 
*=New types, Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch 
repair protein (mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  
(Yqil)   
 
 
 Table17. Allelic profiles of Invasive – Sterile body fluids of Hospital GAS isolates(n=18) 
source gki gtr muri muts recp xpt yqil ST emm types 
CSF 48 31 41 9 2 2 36 193 60 
CSF 13 31 8 5 19 3 1 249 66 
CSF 43 2 2 7 1 3 80 480* 74 
CSF 4 59 2 5 44 33 1 237 119 
CSF 51 49 8 25 33 3 27 544* 124 
fluid(necrotising 
fascitis) 
2 28 2 17 4 5 1 151 105 
fluid bile 25 2 8 6 30 25 39 515* 110 
Peritoneal fluid 14 2 8 6 55 40 6 350 25 
Peritoneal fluid 4 36 8 7 51 3 76 473* 28 
Peritoneal fluid 85 2 14 5 19 58 58 338 63 
Peritoneal fluid 4 3 54 6 34 8 44 224 st854.1 
Peritoneal fluid 4 3 54 6 34 8 44 224 st854.1 
Peritoneal fluid 4 36 2 18 2 3 4 114 stKNB9 
Pleural fluid 47 3 2 5 10 64 12 513* 15 
Pleural fluid 40 2 9 6 41 34 12 512* 56 
synovial fluid 29 32 2 5 33 5 4 516* 58.8 
Pleural fluid 42 37 8 22 33 3 63 514* 85 
Pleural fluid 13 45 71 4 76 3 6 489* 102 
*=New types, Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA 
mismatch repair protein (mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA 
acetyl transferase  (Yqil)   
 
 
 
 
 
 
 
 
 
 
 Table.18.Comparison of STs from Community pharyngitis and Hospital pharyngitis 
emm 
Type 
STs of Community 
Pharyngitis 
STs of Hospital 
Pharyngitis 
1 469 36 
11 - 471 
12 472 28,36 
18 526 - 
28 474 - 
44 - 178,351 
49.4 534 228 
55 100 100 
63 338 338 
73 - 479 
75 - 357 
77 482 347,482 
82 320 - 
85 525 109 
92 524 485 
93 10 10 
105 151 - 
108 527 - 
110 495 - 
112 497 - 
113 499 - 
118 - 501 
st212 - 483 
stNS554 510 510 
stKNB8 509 - 
stKNB3 - 508 
Highlighted STs indicate same ST in the two groups 
 
 
 
 
 
 
 
 
 
 
 Table.19. Same ST type but different emm type 
ST emm Type 
36 1,12 
100 55,92 
357 75,108 
477 44,113 
 
Table.20.Site of isolation of GAS isolates having same ST and different emm type 
ST 36 emm 1 emm 12 
 
Hospital Pharyngitis Impetigo 
ST 357 emm 75 emm 108 
 
Hospital Pharyngitis Normal Throat 
ST 477 emm 44 emm 113 
 
Normal Throat Impetigo 
ST 100 emm 55 emm 92 
 
Community Pharyngitis Impetigo 
 
Impetigo 
 
 
Hospital Pharyngitis 
 
 
Invasive 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.21.Distribution of diverse sequence types of same emm types based on their site of isolation 
 
Highlighted STs indicate same ST among different site of isolation 
 
 
 
 
 
 
 
 
emm 
Type 
Community 
Pharyngitis 
Normal 
Throat 
Impetigo 
Normal 
Skin 
Hospital 
Pharyngitis 
blood fluid 
110 495 - - - - 493,494,522 515 
49.4 534 529 531 534 228 478 - 
1 469 530 15 - 36 - - 
18 526 120 - 535 - 523 - 
44 - 477 178 178 178,351 476 - 
105 151 491 492 491 - 490 151 
100 - 119 119 488 - 486,487 - 
85 525 109 109 - 109 484,484 514 
92 524 485 100 - 485 - - 
113 499 500 477 - - - - 
108 527 357 - 433 - - - 
12 472 - 36 - 28,36 - - 
55 100 528 100 - 100 100 - 
86 - - - - - 503,518 - 
st6735 - - - - - 506,507 - 
118 - - - - 501 511 - 
112 497 497 498 497 - 497 - 
111 - 496 532 496 - - - 
st212 - 505 - - 483 - - 
77 482 482 - - 347,482 - - 
75 - - - 481 357 - - 
28 474 474 474 - - - 473 
st854.1 - - - - - 519 224,224 
93 10 - 10 10 10 502 - 
74 - - - - - 480,520 480 
Table .22. Allelic variations in emm type 1 
Source gki gtr muri muts recp xpt yqil ST emm type 
IMP 2 6 8 5 2 3 2 15 1 
HP 5 2 2 6 6 2 2 36 1 
CP 26 2 2 5 31 3 1 469 1 
NT 4 25 4 4 4 2 4 530 1 
CP = Community Pharyngitis, HP = Hospital Pharyngitis, NT = Normal throat, IMP = impetigo, Glucose kinase (gki), 
Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS) Transketolase 
(recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
 
 
Table .23. Allelic variations in emm type 12 
Source gki gtr muri muts recp xpt yqil ST emm type 
HP 4 3 4 4 4 2 4 28 12 
HP 5 2 2 6 6 2 2 36 12 
IMP 5 2 2 6 6 2 2 36 12 
CP 4 2 2 58 6 2 2 472 12 
CP = Community Pharyngitis, HP = Hospital Pharyngitis, IMP = impetigo, Glucose kinase (gki), Glutamine 
transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS) Transketolase (recP),  
Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
 
 
Table .24. Allelic variations in emm type 18 
Source gki gtr muri muts recp xpt yqil ST emm type 
NT 43 2 2 7 1 3 1 120 18 
Blood 4 28 2 3 2 34 31 523 18 
CP 5 2 2 3 2 34 31 526 18 
NS 4 2 2 3 2 34 31 535 18 
CP = Community Pharyngitis, NS= Normal skin ,NT = Normal throat  ,Glucose kinase (gk HP = Hospital Pharyngitis, NT 
= Normal throat, IMP = impetigo i), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch 
repair protein (mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  
(Yqil)   
 
 
Table .25. Allelic variations in emm type 44 
Source gki gtr muri muts recp xpt yqil ST emm type 
HP 4 4 3 6 14 3 4 178 44 
IMP 4 4 3 6 14 3 4 178 44 
NS 4 4 3 6 14 3 4 178 44 
HP 24 4 3 6 14 3 4 351 44 
Blood 4 3 3 6 14 3 77 476 44 
NT 57 3 8 25 1 3 78 477 44 
CP = Community Pharyngitis, HP = Hospital Pharyngitis, NT = Normal throat, IMP = impetigo, NS= Normal skin 
Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein 
(mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
Table .26. Allelic variations in emm type 49.4 
Source gki gtr muri muts recp xpt yqil ST emm type 
HP 4 31 8 11 34 3 40 228 49.4 
Blood 4 2 8 11 34 3 40 478 49.4 
NT 4 6 8 3 34 3 40 529 49.4 
IMP 4 35 8 3 34 3 40 531 49.4 
CP 4 31 8 3 34 3 40 534 49.4 
NS 4 31 8 3 34 3 40 534 49.4 
CP = Community Pharyngitis, HP = Hospital Pharyngitis, NT = Normal throat, IMP = impetigo, NS= Normal skin 
Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein 
(mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
Table .27 Allelic variations in emm type 85 
Source gki gtr muri muts recp xpt yqil ST emm type 
HP 42 37 8 22 33 3 4 109 85 
NT 42 37 8 22 33 3 4 109 85 
IMP 42 37 8 22 33 3 4 109 85 
Blood 42 2 8 22 33 3 4 484 85 
Blood 42 2 8 22 33 3 4 484 85 
PF 42 37 8 22 33 3 63 514 85 
CP 4 37 8 22 33 3 4 525 85 
CP = Community Pharyngitis, HP = Hospital Pharyngitis, NT = Normal throat, IMP = impetigo, NS= Normal skin, PF= 
Plueral fluid Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch 
repair protein (mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  
(Yqil)   
 
Table .28. Allelic variations in emm type 92 
Source gki gtr muri muts recp xpt yqil ST emm type 
IMP 34 2 2 21 1 29 16 100 92 
HP 4 3 2 59 2 2 4 485 92 
NT 4 3 2 59 2 2 4 485 92 
CP 42 3 2 5 2 2 4 524 92 
CP = Community Pharyngitis, HP = Hospital Pharyngitis, NT = Normal throat, IMP = impetigo Glucose kinase (gki), 
Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS) Transketolase 
(recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
 
Table .29. Allelic variations in emm type 100  
Source gki gtr muri muts recp xpt yqil ST emm type 
NT 2 6 8 3 2 32 1 119 100 
IMP 2 6 8 3 2 32 1 119 100 
Blood 2 12 8 3 2 32 1 486 100 
Blood 2 3 8 3 2 32 1 487 100 
NS 55 6 8 3 90 32 1 488 100 
CP = Community Pharyngitis, NT = Normal throat, IMP = impetigo, NS= Normal skin, Glucose kinase (gki), Glutamine 
transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS) Transketolase (recP),  
Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
 
Table .30. Allelic variations in emm type 105 
Source gki gtr muri muts recp xpt yqil ST emm type 
NF 2 28 2 17 4 5 1 151 105 
CP 2 28 2 17 4 5 1 151 105 
Blood 2 31 2 17 4 5 1 490 105 
NT 2 28 2 17 4 76 1 491 105 
NS 2 28 2 17 4 76 1 491 105 
IMP 55 28 2 17 4 76 1 492 105 
CP = Community Pharyngitis,  NT = Normal throat, IMP = impetigo, NS= Normal skin,NF=Necrotising fascitis Glucose kinase 
(gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS) Transketolase 
(recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA acetyl transferase  (Yqil)   
 
 
Table .31. Allelic variations in emm type 108 
Source gki gtr muri muts recp xpt yqil ST emm type 
NT 75 2 44 4 66 3 1 357 108 
CP 2 6 3 22 2 2 2 527 108 
NS 2 6 8 2 2 2 2 533 108 
CP = Community Pharyngitis,NT = Normal throat,NS = Normal skin, Glucose kinase (gki), Glutamine transporter 
protein ( gtr),  Glutamate racemase (murI),  DNA mismatch repair protein (mutS), Transketolase (recP), Acetyl-
coA acetyl transferase  (Yqil) ,Xanthine phosphoribosyl transferase (xpt).  
 
 
Table .32. Allelic variations in emm type 110 
Source gki gtr muri muts recp xpt yqil ST emm type 
Blood 25 4 8 6 30 25 4 493 110 
Blood 25 3 8 6 30 25 4 494 110 
CP 25 81 8 6 30 25 39 495 110 
Bile 25 2 8 6 30 25 39 515 110 
Blood 25 37 8 6 30 25 4 522 110 
CP = Community Pharyngitis Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  
DNA mismatch repair protein (mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA 
acetyl transferase  (Yqil)   
 
 
 
Table .33. Allelic variations in emm type 113 
Source gki gtr muri muts recp xpt yqil ST emm type 
IMP 57 3 8 25 1 3 78 477 113 
CP 57 3 8 25 1 3 76 499 113 
CP 57 3 8 25 1 3 76 499 113 
NT 57 3 8 25 19 3 78 500 113 
CP = Community Pharyngitis Glucose kinase (gki), Glutamine transporter protein (gtr),  Glutamate racemase (murI),  
DNA mismatch repair protein (mutS) Transketolase (recP),  Xanthine phosphoribosyl transferase (xpt),  Acetyl-coA 
acetyl transferase  (Yqil)   
 
 
 
 
 Table.34.Score Table of maximum nucleotide identity of emm 1 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST15    3134     2    ST36    3134     99    
1    ST15    3134     3    ST469   3134     99    
1    ST15    3134     4    ST530   3134     99    
2    ST36    3134     3    ST469   3134     99    
2    ST36    3134     4    ST530   3134     99    
3    ST469   3134     4    ST530   3134     99    
================================================= 
 
 
Table.35.Score Table of maximum nucleotide identity of emm 12 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST528   3134     2    ST36    3134     99 
1    ST528   3134     3    ST472   3134     99 
2    ST36    3134     3    ST472   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 
Table.36.Score Table of maximum nucleotide identity of emm 18 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST120   3134     2    ST523   3134     99 
1    ST120   3134     3    ST526   3134     99 
1    ST120   3134     4    ST535   3134     99 
2    ST523   3134     3    ST526   3134     99 
2    ST523   3134     4    ST535   3134     99 
3    ST526   3134     4    ST535   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 
 
 
 
 Table.37.Score Table of maximum nucleotide identity of emm 44 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST178   3134     2    ST351   3134     99 
1    ST178   3134     3    ST476   3134     99 
1    ST178   3134     4    ST477   3134     99 
2    ST351   3134     3    ST476   3134     99 
2    ST351   3134     4    ST477   3134     99 
3    ST476   3134     4    ST477   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 
Table.38.Score Table of maximum nucleotide identity of emm 49.4 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST478   3134     2    ST228   3134     99 
1    ST478   3134     3    ST534   3134     99 
1    ST478   3134     4    ST531   3134     99 
1    ST478   3134     5    ST529   3134     99 
2    ST228   3134     3    ST534   3134     99 
2    ST228   3134     4    ST531   3134     99 
2    ST228   3134     5    ST529   3134     99 
3    ST534   3134     4    ST531   3134     99 
3    ST534   3134     5    ST529   3134     99 
4    ST531   3134     5    ST529   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 
Table.39.Score Table of maximum nucleotide identity of emm 85 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST109   3134     2    ST484   3134     99 
1    ST109   3134     3    ST514   3134     99 
1    ST109   3134     4    ST525   3134     99 
2    ST484   3134     3    ST514   3134     99 
2    ST484   3134     4    ST525   3134     99 
3    ST514   3134     4    ST525   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 
Table.40.Score Table of maximum nucleotide identity of emm 92 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST100   3134     2    ST485   3134     99 
1    ST100   3134     3    ST524   3134     99 
2    ST485   3134     3    ST524   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 
Table.41.Score Table of maximum nucleotide identity of emm 100 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST119   3134     2    ST486   3134     99 
1    ST119   3134     3    ST487   3134     99 
1    ST119   3134     4    ST488   3134     99 
2    ST486   3134     3    ST487   3134     99 
2    ST486   3134     4    ST488   3134     99 
3    ST487   3134     4    ST488   3134     99 
================================================= 
 
 
Table.42.Score Table of maximum nucleotide identity of emm 105 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST490   3134     2    ST491   3134     99 
1    ST490   3134     3    ST492   3134     99 
1    ST490   3134     4    ST151   3134     99 
2    ST491   3134     3    ST492   3134     99 
2    ST491   3134     4    ST151   3134     99 
3    ST492   3134     4    ST151   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
Table.43.Score Table of maximum nucleotide identity of emm 108 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST357   3134     2    ST527   3134     98 
1    ST357   3134     3    ST533   3134     98 
2    ST527   3134     3    ST533   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
 Table.44.Score Table of maximum nucleotide identity of emm 110 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST522   3134     2    ST515   3134     99 
1    ST522   3134     3    ST493   3134     99 
1    ST522   3134     4    ST494   3134     99 
2    ST515   3134     3    ST493   3134     99 
2    ST515   3134     4    ST494   3134     99 
3    ST493   3134     4    ST494   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
 
Table.45.Score Table of maximum nucleotide identity of emm 113 
SeqA Name    Len(nt)  SeqB Name    Len(nt)  Score 
================================================= 
1    ST477   3134     2    ST499   3134     99 
1    ST477   3134     3    ST500   3134     99 
2    ST499   3134     3    ST500   3134     99 
================================================= 
Seq A = Sequence A, Seq B = Sequence B, Len (nt) = Nucleotide length 
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